Quinoline derivatives as phosphodiesterase inhibitors

ABSTRACT

There are provided according to the invention novel compounds of formula (I) 
     
       
         
         
             
             
         
       
     
     or pharmaceutically acceptable salts thereof, wherein R 1 , R 2,  R 19,  R 20,  and R 34  are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed pursuant to 35 U.S.C. § 371 as a United States National Phase Application of International Application No. PCT/EP2004/005494 filed May 19, 2004, which claims priority from GB 0311688.6 filed May 21, 2003 and GB 0326187.2 filed Nov. 10, 2003.

FIELD OF THE INVENTION

The present invention relates to quinoline compounds, processes for their preparation, intermediates usable in these processes, and pharmaceutical compositions containing the compounds. The invention also relates to the use of the quinoline compounds in therapy, for example as inhibitors of phosphodiesterases and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.

BACKGROUND OF THE INVENTION

WO 02/20489 A2 (Bristol-Myers-Squibb Company) discloses 4-aminoquinoline derivatives wherein the 4-amino group NR⁴R⁵ may represent an acyclic amino group wherein R⁴ and R⁵ may each independently represent hydrogen, alkyl, cycloalkyl, aryl, heteroaryl etc.; NR⁴R⁵ may alternatively represent an aliphatic heterocyclic group. The compounds are disclosed as inhibitors of cGMP phosphodiesterase, especially type 5 (PDE5).

EP 0 480 052 (Otsuka Pharmaceutical Co. Ltd.) discloses 4-aminoquinoline-3-carboxamides wherein the 4-amino group NHR⁴ may represent an amino group wherein R⁴ represents phenyl, tetrahydronaphthyl or naphthyl, optionally substituted with alkyl, halogen, alkoxy etc.; and the 3-carboxamide group CONR²R³ represents a primary, secondary or tertiary carboxamide group. The compounds are disclosed as inhibitors of gastric acid secretion, and as cytoprotective agents; inhibition of the ATPase activated by H⁺ and K⁺at the gastric wall cells is also disclosed.

It is desirable to find new compounds which bind to, and preferably inhibit, phosphodiesterase type IV (PDE4).

SUMMARY OF THE INVENTION

According to the invention there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

R¹ is

C₁₋₆ alkyl;

C₃₋₇cycloalkyl or C₃₋₇cycloalkyl(C₁₋₄alkyl)- wherein the C₃₋₇cycloalkyl is optionally substituted by one or more substituents selected from ═O and OH;

C₄₋₇cycloalkyl fused to an aryl ring;

Aryl or aryl(C₁₋₆alkyl)- wherein the aryl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkylCONR⁶—, C₁₋₆alkylCO—, halogen, —CF₃, —(CH₂)_(m)OH, —OCF₃, C₁₋₆alkoxy-, C₁₋₆alkoxy(C₁₋₄alkyl)-, C₁₋₆alkoxyC₂₋₆alkoxy-, C₁₋₆alkoxycarbonyl, —CN, R⁴R⁵NCO, R⁷R⁶N—, R⁹R¹⁰NCONR¹¹—, HO(CH₂)₂₋₆O—, R¹²R¹³NSO₂(CH₂)_(m)-, (4-morpholinyl)C₂₋₈alkoxy, —NR¹⁴SO₂C₁₋₆alkyl, aryloxy, heteroaryl (optionally substituted by C₁₋₆alkyl), CO₂H, R²¹R²²N(C₁₋₄alkyl)-, C₁₋₆alkoxyCONR²³(CH₂)m—, aryl(optionally substituted by C₁₋₆alkyl);

Aryl fused to a C₄₋₇cycloalkyl ring, wherein the cycloalkyl ring is optionally substituted by one or more ═O;

Aryl fused to a heterocyclyl ring, wherein the heterocyclyl ring is optionally substituted by one or more substituents selected from ═O, —COC₁₋₄alkyl, C₁₋₄alkyl;

Heteroaryl or heteroaryl(C₁₋₆alkyl)- wherein the heteroaryl is optionally substituted by one or more substituents selected from: C₁₋₆alkyl, aryl(C₁₋₄alkyl), C₁₋₆alkoxy, halogen, C₁₋₆alkoxyCO; or

Heterocyclyl optionally fused to an aryl or heteroaryl ring;

R² is hydrogen or C₁₋₆alkyl;

R³⁴ is hydrogen or a group of formula:

wherein R³ is

C₁₋₆alkyl optionally substituted by one or more substituents selected from —OH, —NR¹⁶COR¹⁵, —NR¹⁷R¹⁸, —CO₂R²⁴, C₁₋₆alkoxyCONR²⁵—, —CONR²⁶R²⁷, C₁₋₆alkoxy-, C₁₋₆alkylSO₂NR³³-, or a group having one of the following formulae;

C₃₋₇cycloalkyl;

Aryl or aryl(C₁₋₆alkyl)- wherein the aryl is optionally substituted by one or more substituents selected from C₁₋₆alkyl-, halogen-, C₁₋₆alkoxy-, —CO₂R²⁸, —CH₂CO₂H, —OH, aryl(optionally substituted by a C₁₋₆ alkoxy group), heteroaryl, —CONR²⁹R³⁰, C₃₋₇cycloalkoxy, C³⁻⁷cycloalkyl(C₁₋₆alkoxy)-, —CF₃;

Heteroaryl or heteroaryl(C₁₋₆alkyl)- wherein the heteroaryl is optionally substituted by one or more C₁₋₆alkyl or —CONR²⁹R³⁰ groups; or

Heterocyclyl which is optionally substituted by one of more substituents selected from C₁₋₆alkyl-, C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO- (optionally substituted by one or more C₁₋₄alkyl- groups), C₁₋₆alkoxyCO—, arylCO—, R³¹R³²NCO—, C₁₋₆alkylSO₂—, arylSO₂, -heteroarylSO₂ (optionally substituted by one or more C₁₋₄alkyl or C₁₋₄alkylCONH— groups) The heterocyclyl is linked to the S(═O)_(n) moiety through a carbon atom.

m is 0-6

n is 0, 1 or 2;

R¹⁹ is hydrogen, C₁₋₆alkyl or a group of formula:

R²⁰ is hydrogen, C₁₋₆alkyl, halogen or C₁₋₆alkoxy;

R⁴⁻¹⁸, R²¹⁻²⁵, R²⁸ and R³¹⁻³³ all independently represent H, C₁₋₆ alkyl;

R²⁶ and R²⁷ independently represent H, C₁₋₆ alkyl, C₃₋₇cycloalkyl or heterocyclyl;

R²⁹ and R³⁰ independently represent H, C₁₋₆alkyl optionally substituted by OH;

R⁷ and R⁸ together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R⁹ and R¹⁰ together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached may form a heterocyclyl ring such as morpholine;

R²¹ and R²² together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R²⁶ and R²⁷ together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

R²⁹ and R³⁰ together with the nitrogen atom to which they are attached may form a heterocyclyl ring such as morpholine;

R³¹ and R³² together with the nitrogen atom to which they are attached may form a heterocyclyl ring;

with the proviso that R³⁴ and R¹⁹ cannot both represent R³S(═O)_(n)—.

DETAILED DESCRIPTION

As used herein, the term “alkyl” refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C₁₋₆alkyl means a straight or branched alkyl chain containing at least 1, and at most 6, carbon atoms. Examples of “alkyl” as used herein include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl and n-hexyl. A C₁₋₄alkyl group is preferred, for example methyl, ethyl or isopropyl. The said alkyl groups may be optionally substituted with one or more fluorine atoms, for example, trifluoromethyl.

As used herein, the term “alkoxy” refers to a straight or branched chain alkoxy group, for example, methoxy, ethoxy, prop-1-oxy, prop-2-oxy, but-1-oxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy or hexyloxy. A C₁₋₄alkoxy group is preferred, for example methoxy or ethoxy. The said alkoxy groups may be optionally substituted with one or more fluorine atoms, for example, trifluoromethoxy.

As used herein, the term “cycloalkyl” refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, C₃₋₇cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Examples of “cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C₃₋₆-cycloalkyl group is preferred, for example cyclopentyl or cyclohexyl.

When used herein, the term “aryl” refers to, unless otherwise defined, a mono- or bicyclic carbocyclic aromatic ring system containing up to 10 carbon atoms in the ring system, for instance phenyl or naphthyl, optionally fused to a C₄₋₇cycloalkyl or heterocyclyl ring.

As used herein, the terms “heteroaryl ring” and “heteroaryl” refer to, unless otherwise defined, a monocyclic five- to seven-membered heterocyclic aromatic ring containing one or more heteroatoms selected from oxygen, nitrogen and sulfur. In a particular aspect such a ring contains 1-3 heteroatoms. Preferably, the heteroaryl ring has five or six ring atoms. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl. The terms “heteroaryl ring” and “heteroaryl” also refer to fused bicyclic heterocyclic aromatic ring systems containing at least one heteroatom selected from oxygen, nitrogen and sulfur, preferably from 1-4 heteroatoms, more preferably from 1 to 3 heteroatoms. Preferably, the fused rings each independently have five or six ring atoms. Examples of fused aromatic rings include, but are not limited to, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyj, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and benzothiadiazolyl. The heteroaryl may attach to the rest of the molecule through any atom with a free valence.

As used herein, the term “heterocyclyl” refers to a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated ring containing at least one heteroatom selected from oxygen, nitrogen and sulfur. In a particular aspect such a ring contains 1 or 2 heteroatoms. Preferably, the heterocyclyl ring has five or six ring atoms. Examples of heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazepinyl, azepinyl, tetrahydrofuranyl, tetrahydropyranyl, and 1,4-dioxanyl.

As used herein, the terms “halogen” or “halo” refer to fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. Particularly preferred halogens are fluorine and chlorine.

As used herein, the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated. Where one or more substituents are referred to, this will refer for instance to 1 to 4 substituents, and preferably to 1 or 2 substituents.

In one embodiment, R¹ is selected from:

C₃₋₇ cycloalkyl, in particular cyclohexyl;

Aryl optionally substituted by one or more substituents selected from: C₁₋₆alkyl, halogen, C₁₋₆alkoxy, C₁₋₆alkoxy(C₁₋₄alkyl)-, —CN, —(CH₂)_(m)OH, —CF₃, C₁₋₆alkoxyC₂₋₆alkoxy-, R⁴R⁵NCO, C₁₋₆alkylCONR⁸—, R⁷R⁸N—, C₁₋₆-alkoxycarbonyl, HO(CH₂)₂₋₆O—, C₁₋₆alkylCO—, heteroaryl (optionally substituted by C₁₋₆alkyl) particularly oxazolyl, pyrazolyl or 1,2,4oxadiazolyl;

Aryl(C₁₋₂alkyl) wherein the aryl is optionally substituted by —OH;

Aryl fused to a C₅₋₈ cycloalkyl ring wherein the cycloalkyl is optionally substituted by (═O);

Aryl fused to a heterocyclyl ring, wherein the heterocyclyl ring is optionally substituted by one or more substituents selected from ═O, C₁₋₄alkyl;

Heteroaryl optionally substituted by one or more C₁₋₆alkyl, halogen (in particular chlorine or fluorine) or C₁₋₆alkoxy groups in particular wherein heteroaryl represents benzothiazolyl, benzisoxazolyl, benzimidazolyl, indazolyl, pyridyl and pyrazolyl;

Heteroaryl(C₁₋₂alkyl) wherein the heteroaryl is optionally substituted by one or more C₁₋₆alkyl groups, in particular wherein heteroaryl represents pyridyl, pyrazolyl; or

Heterocyclyl, in particular tetrahydropyranyl.

Examples of suitable aryl fused to a C₅₋₆ cycloalkyl ring include:

Examples of suitable aryl fused to heterocyclyl rings include:

The following aryl fused to heterocyclyl rings are further embodiments:

In a further embodiment, R¹ is selected from:

Aryl optionally substituted by one or more substituents selected from: methyl, ethyl, fluorine, chlorine, —CN, —CH₂OH, —OMe, —OH, —NMe₂, —O(CH₂)_(2OH, —CF) ₃, —COMe, 1,2,4-oxadiazolyl substituted by methyl; particular substitued aryl groups include; 3-(methyloxy)phenyl, 3-methylphenyl, 3-cyanophenyl, 3-fluorophenyl, 3-chlorophenyl, 4-fluoro-3-(methyloxy)phenyl, 3-acetylphenyl, 4-hydroxy-3-(methyloxy)phenyl, 2-fluoro-3-chlorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl;

Aryl fused to a cyclohexane or cyclopentane ring, wherein the cyclopentane ring is optionally substituted by (═O); in particular the following fused systems:

Aryl fused to a heterocyclyl ring, optionally substituted by methyl; in particular the following heterocyclyl ring fused aryl systems:

Heteroaryl optionally substituted by one or more methyl, ethyl, flourine, chlorine or methoxy groups; in particular a pyridyl, benzimidazolyl, pyrazolyl or indazolyl group optionally substituted by one or more methyl, ethyl, flourine, chlorine, or methoxy groups;preferably 1-methyl-1H-benzimidazolyl-6-yl, 1-methyl-1H-indazol-6-yl, 5-(methyloxy)-3-pyridinyl, 3-pyridinyl, 1-ethyl-1H-pyrazol-5-yl, 5-methyl-3-pyridinyl, 1,3-benzothiazol-6-yl, 5-fluoro-3-pyridinyl, or 5-chloro-3-pyridinyl.

In one embodiment, R² is hydrogen.

In one embodiment R³ is selected from:

C₁₋₆ alkyl which is optionally substituted by one or more substituents selected from —NR¹⁶COR¹⁵; OH—, C₁₋₆alkoxyCONR²⁵—, —CONR²⁸R²⁷, —NH₂, —NR¹⁷R¹⁸, —CO₂R²⁴, C₁₋₆alkoxy; or a group having one of the following formulae:

C₃₋₇cycloalkyl;

Aryl optionally substituted by one or more substituents selected from C₁₋₆alkyl-, halogen-, C₁₋₆alkoxy-, —CO₂R²⁸, —OH, —CONR²⁹R³⁰, C₃₋₇cycloalkoxy, C₃₋₇cycloalkyl(C₁₋₆alkoxy);

Aryl(C₁alkyl) wherein the aryl is optionally substituted by one or more C₁₋₆alkoxy groups;

Heteroaryl or heteroaryl(C₁₋₆alkyl) which is optionally substituted by one or more C₁₋₆alkyl or —CONR²⁹R³⁰ groups; or

Heterocyclyl which is optionally substituted by one or more substituents selected from C₁₋₆alkyl-, C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO— (optionally substituted by one or more C₁₋₄alkyl- groups), C₁₋₆alkoxyCO—, arylCO—, C₁₋₆alkylSO₂—.

In an alternative embodiment R³ is selected from:

methyl, ethyl, n-propyl, tert-butyl, isopropyl, MeCONH(CH₂)₂—, Me₂NCO(CH₂)₂—;

Cyclopentyl;

Aryl optionally substituted by one or more methoxy, methyl, —CONH₂ or —CONMe₂ groups; in particular: 4-(methyloxy)phenyl, phenyl, 3-[(dimethylamino)carbonyl]phenyl, 4-methylphenyl, 3-[(methyloxy)carbonyl]phenyl, 3,4-bis(methyloxy)phenyl, 3,4,5-tris(methyloxy)phenyl, 3-(ethyloxy)phenyl;

Heterocyclyl which is optionally substituted by one of more substituents selected from MeCO—, cyclopropylCO, 2-furylCO—, or MeSO₂—; in particular wherein the heterocyclyl group is tetrahydropyran-4-yl; a tetrahydrofuran-3-yl; or piperidinyl substituted by one or more substituents selected from MeCO—, cyclopropylCO, 2-furylCO—, or MeSO₂—, especially 1-acetyl-4-piperidinyl, 1-(2-furanylcarbonyl)-4-piperidinyl, 1-(cyclopropylcarbonyl)-4-piperidinyl;

Heteroaryl wherein the heteroaryl represents 3-pyridyl which is optionally substituted by CONMe₂, especially 5-[(dimethylamino)carbonyl]-3-pyridinyl.

In one embodiment R⁹ and R¹⁰ together with the nitrogen to which they are attached represent 4-morpholinyl.

In one embodiment R⁴, R⁵, R^(6,) R⁷, R⁸, R¹¹⁻¹⁶, and R²¹⁻²⁵ and R²⁸⁻³³ are independently selected from hydrogen and methyl.

In one embodiment R²⁶ and R²⁷ are independently selected from hydrogen, methyl, cyclopropyl, or 4-tetrahydropyranyl; or R²⁶ and R²⁷ together with the nitrogen to which they are attached form a heterocyclyl ring, in particular pyrrolidinyl or morpholinyl.

In one embodiment R¹⁹ is hydrogen, C₁₋₆alkyl or MeSO₂—. In a further embodiment R¹⁹ is hydrogen or methyl, especially hydrogen.

In one embodiment R²⁰ is hydrogen, halogen or C₁₋₆alkyl. Alternatively R²⁰ is hydrogen, chlorine, fluorine, methyl or ethyl. In a further embodiment R²⁰ is methyl, ethyl or chlorine.

In one embodiment m is 0 or 1.

In one embodiment n is 1 or 2, especially 2.

In one embodiment R³⁴ represents a group of formula:

It is to be understood that the present invention covers all combinations of substituent groups referred to herein above.

It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts. Specific examples which may be mentioned include:

Example 7: 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 8: 4-[(3-cyanophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 20: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 27: 4-{[3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 32: 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 35: 4-[(3-chlorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 43: 4-(1,3-benzothiazol-6-ylamino)-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 45: 4-[(1-methyl-1H-benzimidazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 52: 4-[(3-cyanophenyl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 66: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 74: 4-{[3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 89: 6-(cyclopentylsulfonyl)-4-[(3-fluorophenyl)amino]-3-quinolinecarboxamide,

Example 128: 4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide,

Example 129: 6-[(1,1-dimethylethyl)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 130: 6-{[2-(acetylamino)ethyl]sulfonyl}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide.

Example 133: 6-[(1,1-dimethylethyl)thio]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 135: 6-{[2-(acetylamino)ethyl]thio}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 163: 4-[(1-methyl-1H-indazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 167: 4-{[4-hydroxy-3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 174: 4-[(3-acetylphenyl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 184: 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 185: 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(phenylsulfonyl)-3-quinolinecarboxamide,

Example 186: 7-methyl-4-{[3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide,

Example 265: 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide,

Example 266: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide,

Example 267: 4-[(3-acetylphenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 268: 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 269: 4-(2,3-dihydro-1,4-benzodioxin-5-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 270: 4-[(3-chlorophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 271: 4-[(3-cyanophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 272: 4-(1,3-benzothiazol-6-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 273: 4-[(3-fluorophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide

Example 285: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide

Example 287: 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide

Example 292: 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide

Example 294: 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 303: 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide

Example 307: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 308: 8-methyl-6-(methylsulfonyl)-4-(3-pyridinylamino)-3-quinolinecarboxamide

Example 309: 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 311: 4-[(3-fluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 312: 4-[(3-cyanophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 315: 4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 316: 8-methyl-4-{[5-(methyloxy)-3-pyridinyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 317: 8-methyl-4-[(5-methyl-3-pyridinyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 369: 8-chloro-4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 370: 8-chloro-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 371: 8-chloro-4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 372: 8-chloro-4-[(3-cyanophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 373: 8-chloro-4-[(3-fluorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 374: 8-chloro-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 379: methyl 3-[(3-(aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)sulfonyl]benzoate

Example 380: 6-{[3,4-bis(methyloxy)phenyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 381: 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[3,4,5-tris(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide hydrochloride

Example 382: 6-{[3,4-bis(methyloxy)phenyl]sulfonyl}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 383: 6-{[3-(ethyloxy)phenyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 392: 6-{[2-(acetylamino)ethyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 399: 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 400: 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

Example 408: 4-[(3-cyanophenyl)amino]-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide,

Example 409: 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-[(1-methyl-1H-benzimidazol-6-yl)amino]-3-quinolinecarboxamide

Example 414: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide

Example 426: 6-[(1-acetyl-4-piperidinyl)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 442: 6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 443: 4-[(3-cyanophenyl)amino]-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide

Example 445: 6-{[1-(cyclopropylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 446: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide

Example 447: 6-{[1-(cyclopropylcarbonyl)-4-piperidinyl]sulfonyl}-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide

Example 451: 6-[1-acetyl-4-piperidinyl)sulfonyl]-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide

Example 457: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-({2-[(methylsulfonyl)amino]ethyl}sulfonyl)-3-quinolinecarboxamide

Example 459: 6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-[(1-methyl-1H-benzimidazol-6-yl)amino]-3-quinolinecarboxamide

Example 475: 6-{[3-(dimethylamino)-3-oxopropyl]sulfonyl}-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide

Example 500: 4-[(2,3-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 501: 4-[(3-chloro-2-fluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 502: 4-[(3,5-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 539: 4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 540: 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 546: 6-({5-[(dimethylamino)carbonyl]-3-pyridinyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}3-quinolinecarboxamide hydrochloride

Example 579: 8-methyl-6-[(1-methylethyl)sulfonyl]-4-(3-pyridinylamino)-3-quinolinecarboxamide

Example 580; 6-[(1,1-dimethylethyl)sulfonyl]-8-methyl-4-(3-pyridinylamino)-3-quinolinecarboxamide

Example 584: 4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

Example 585: 6-[(1,1-dimethylethyl)sulfonyl]-4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-3-quinolinecarboxamide

Example 588: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfinyl)-3-quinolinecarboxamide

Example 590: 4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-3-quinolinecarboxamide

Example 591: 8-ethyl-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 592: 8-ethyl-4-[(3-fluorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 593: 4-[(3-cyanophenyl)amino]-8-ethyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 598: 8-ethyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 599: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-ethyl-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 600: 8-ethyl-6-(methylsulfonyl)-4-(3-pyridinylamino)-3-quinolinecarboxamide

Example 624: 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-fluoro-6-(methylsulfonyl)-3-quinolinecarboxamide

Example 666: 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-(ethylsulfonyl)-3-quinolinecarboxamide

Example 667: 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-(propylsulfonyl)-3-quinolinecarboxamide

Example 668: 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

Example 669: 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-3-quinolinecarboxamide

Example 670: 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

Example 671: 6-(ethylsulfonyl)-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide

Example 674: 6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide

Example 676: 8-chloro-4-[(5-fluoro-3-pyridinyl)amino]-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

Example 677: 8-chloro-6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-3-quinolinecarboxamide

Example 678: 4-[(5-chloro-3-pyridinyl)amino]-6-(ethylsulfonyl)-8-methyl-3-quinolinecarboxamide

Example 679: 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-(propylsulfonyl)-3-quinolinecarboxamide

Example 680: 4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-8-methyl-3-quinolinecarboxamide

and pharmaceutically acceptable salts thereof.

Preferred compounds include:

8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide,

4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide,

4-[(3-cyanophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide,

8-methyl-4-[(5-methyl-3-pyridinyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide,

4-[(3-cyanophenyl)amino]-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide,

4(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide

4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-({2-[(methylsulfonyl) amino]ethyl}sulfonyl)-3-quinolinecarboxamide

4-[(3,5-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide

6-({5-[(dimethylamino)carbonyl]-3-pyridinyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide

8-chloro-6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-3-quinolinecarboxamide

and pharmaceutically acceptable salts thereof.

Salts of the compounds of the present invention are also encompassed within the scope of the invention. Because of their potential use in medicine, the salts of the compounds of formula (I) are preferably pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts can include acid or base addition salts. A pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, ρ-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration. A pharmaceutically acceptable acid addition salt of a compound of formula (I) can be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate, fumarate, citrate, tartrate, benzoate, ρ-toluenesulfonate, methanesulfonate or naphthalenesulfonate salt. A pharmaceutically acceptable base addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic base, optionally in a suitable solvent such as an organic solvent, to give the base addition salt which is usually isolated for example by crystallisation and filtration. Other non-pharmaceutically acceptable salts, eg. oxalates or trifluoroacetates, may be used, for example in the isolation of compounds of the invention, and are included within the scope of this invention. The invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the salts of the compounds of formula (I).

Also included within the scope of the invention are all solvates, hydrates and complexes of compounds and salts of the invention.

Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.

The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.

Process a

Compounds of formula (I), wherein R³⁴, R¹⁹, R²⁰, R¹ and R² are as defined above, may be prepared from compounds of formula II;

wherein R³⁴, R¹⁹, and R²⁰ are as defined above, and X represents a halogen atom, by treatment with an amine of formula R¹R²NH, wherein R¹ and R² are as defined above.

Suitable conditions for process a) include stirring in a suitable solvent such as acetonitrile, N,N-dimethylformamide or ethanol, at a suitable temperature, such as between room temperature and the reflux temperature of the solvent, for example at 80° C., optionally in the presence of a suitable base such as N,N-diisopropylethylamine, or in the presence of an acid catalyst such as the salt of an amine base, such as pyridine hydrochloride. Alternatively, process a) may be carried out under microwave irradiation, at a suitable power such as 100-30 W, for example at 150 W, in a suitable solvent such as N-methyl-2-pyrrolidinone or N,N-dimethylformamide, at a suitable temperature such as 60-200° C., for example at 150° C.

Compounds of formula (II), wherein R³⁴, R¹⁹, R²⁰ and X are as defined above, may be prepared from compounds of formula (IV);

wherein R³⁴, R¹⁹, and R²⁰ are as defined above, by treatment with a suitable chlorinating agent, such as thionyl chloride, in the presence of a suitable catalyst such as N,N-dimethylformamide, followed by treatment with ammonia under suitable conditions, such as 880 ammonia at room temperature.

Compounds of formula (IV), wherein R³⁴, R¹⁹, and R²⁰ are as defined above, may be prepared from compounds of formula (V);

wherein R³⁴, R¹⁹, and R²⁰ are as defined above, by hydrolysis with a suitable base, such as aqueous sodium hydroxide, in a suitable solvent, such as ethanol, at a suitable temperature such as room temperature.

Compounds of formula (V), wherein R³⁴, R¹⁹, and R²⁰ are as defined above, may be prepared from compounds of formula (VI);

wherein R³⁴, R¹⁹, and R²⁰ are as defined above, by heating in a suitable solvent, such as diphenyl ether, at a suitable temperature such as 200-300° C., for example at 250° C. The preparation of compounds of formulae (IV), (V), and (VI) wherein R³⁴ represents MeSO₂—, R¹⁹ represents H and R²⁰ represents H have been previously described in patent application WO 02/068394 A1 (Glaxo Group Limited).

Compounds of formula (VI), wherein R³⁴, R¹⁹, and R²⁰ are as defined above, may be prepared from compounds of formula (VII), wherein R³⁴, R¹⁹, and R²⁰ are as defined above, and the compound of formula (VIII);

Suitable conditions include heating together compounds of formulae (VII) and (VIII) in a suitable solvent such as ethanol or in the absence of solvent, at a suitable temperature, such as 60-100° C., for example at 80° C.

Compounds of formula (VII) wherein R³⁴, R¹⁹, and R²⁰ are as defined above may be prepared by reduction of compounds of formula (XIV), wherein R³⁴, R¹⁹, and R²⁰ are as defined above;

suitable conditions where n=1 or 2 include catalytic hydrogenation with hydrogen and a suitable catalyst, such as palladium on carbon, in a suitable solvent such as acetic acid. Suitable conditions where n=0 include reduction with a reducing agent such as iron in dilute acetic acid, at a suitable temperature such as 85-90° C.

Compounds of formula (XIV), wherein R³⁴ represents R³S(═O)_(n)—, R¹⁹ represents hydrogen or C₁₋₆alkyl, n is 0 or 2, and R²⁰ is as defined above, may be prepared from compounds of formula (XV), wherein R¹⁹ represents hydrogen or C₁₋₆alkyl and R²⁰ is as defined above and compounds of formula (XVI) wherein R³ is defined above and n=0 or 2;

Suitable conditions where n=0 include treatment of the compound of formula (XV) with a thiol of formula (XVI) (n=0) in the presence of a suitable base such as potassium carbonate, in a suitable solvent such as acetonitrile, at a suitable temperature such as room temperature. Where n=2, suitable conditions include treatment of the compound of formula (XV) with the sodium salt of a sulphinic acid of formula (XVI) (n=2), in a suitable solvent such as dimethylacetamide, at a suitable temperature such as 30-100° C., for example at 50° C.

Alternatively, compounds of formula (XIV) where n represents 2 may be prepared from compounds of formula (XIV) where n represents 0 by oxidation with a suitable oxidising agent, such as oxone, in a suitable solvent such as a mixture of methanol and water, at a suitable temperature such as room temperature. Compounds of formula (XIV) where n represents 1 may be prepared from compounds of formula (XIV) where n represents 0 by oxidation with a suitable oxidising agent, such as ceric ammonium nitrate, in the presence of a suitable solid support such as hydrated silica gel, in a suitable solvent such as methylene chloride, at a suitable temperature such as 20-40° C., for example at room temperature.

Compounds of formula R¹R²NH may contain amine or acid groups which are suitably protected. Examples of suitable protecting groups and the means for their removal are well known in the art, see for instance T. W. Greene and P. G. M. Wuts ‘Protective Groups in Organic Synthesis’ (3^(rd) Ed., J. Wiley and Sons, 1999). Addition or removal of such protecting groups may be accomplished at any suitable stage in the synthesis of compounds of formula (I).

Compounds of formula (II) wherein R³⁴ represents R³S(═O)_(n)—, n represents 0, R¹⁹ represents hydrogen or C₁₋₆alkyl, X represents chlorine and R²⁰ is as defined above may alternatively be prepared from compounds of formula (IX), wherein X represents chlorine, Y represents iodine, Z represents hydrogen or C₁₋₆alkyl, and R²⁰ is as defined above, by treatment with a trialkylstannane of formula R³SSnW₃, wherein W represents a C₁₋₆alkyl group such as an n-butyl group. Suitable conditions include heating in the presence of a suitable catalyst, such as a palladium catalyst, for example tetrakistriphenylphosphine palladium (0), in a suitable solvent such as toluene, at a suitable temperature such as between 80° C. and 150° C., for example at 110° C.

Process b

Compounds of formula (I), wherein R¹, R², R³⁴, R¹⁹, and R²⁰ are as defined above, and n=0, may alternatively be prepared from compounds of formula (III);

wherein R¹, R² and R²⁰ are as defined above, and Z represents hydrogen, C₁₋₆alkyl or halogen for example chlorine and Y represents hydrogen, chlorine, bromine or iodine, by treatment with a thiol of formula R³SH, or the sodium salt thereof, R³SNa, wherein R³ is as defined above, with the proviso that at least one of Y and Z represent halogen.

Suitable conditions for process b) include heating in a suitable solvent such as toluene or N,N-dimethylformamide, at a suitable temperature such as 60-150° C., for example at 110° C., in the presence of a suitable catalyst, such as a palladium catalyst, for example tris(dibenzylideneacetone) palladium (II), and a suitable ligand, such as a phosphine ligand, for example (oxydi-2,1-phenylene)bis(diphenylphosphine), and in the presence of a suitable base such as potassium tert-butoxide.

Alternatively, conditions for process b) include heating in a suitable solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or dimethoxyethane, at a suitable temperature such as 60-150° C., for example at 85° C., optionally in the presence of a suitable catalyst, such as a copper catalyst, for example copper (I) iodide, and in the presence of a suitable base such as potassium phosphate or potassium carbonate and optionally in the presence of a suitable ligand for example N,N-diethylsalicylamide.

Compounds of formula (III), wherein R¹, R², R²⁰, Y and Z are as defined above, may be prepared from compounds of formula (IX), wherein R²⁰, X, Y and Z are as defined above, by treatment with an amine of formula R¹R²NH, wherein R¹ and R² are as defined above;

suitable conditions include stirring in a suitable solvent such as acetonitrile, at a suitable temperature, such as between room temperature and the reflux temperature of the solvent, for example at 80° C., optionally in the presence of a base such a N,N-diisopropylethylamine, or in the presence of an acid catalyst such as pyridine hydrochloride. Alternatively, preparation of compounds of formula (III) from compounds of formula (IX) may be carried out under microwave irradiation, at a suitable power such as 100-300 W, for example at 150 W, in a suitable solvent such as N-methyl-2-pyrrolidinone, at a suitable temperature such as 60-200° C. for example at 150° C.

The compounds of formula (IX) may be prepared according to the following synthetic scheme, Scheme 1, wherein R¹⁹, R²⁰, Y and Z are as defined above:

Suitable conditions for the reactions of Scheme 1 are: (A) heating together compounds of formulae (X) and (VIII) in the absence of solvent, at a suitable temperature, such as 60-100° C., for example at 80° C.; (B) heating compounds of formula (XI) in a suitable solvent, such as diphenyl ether, at a suitable temperature such as 200-300° C., for example at 250° C.; (C) hydrolysis of compounds of formula (XII) with a suitable base, such as aqueous sodium hydroxide, in a suitable solvent, such as ethanol, at a suitable temperature such as room temperature; (D) treatment of compounds of formula (XIII) with a suitable halogenating agent, such as a chlorinating agent, for example thionyl chloride, in the presence of a suitable catalyst such as N,N-dimethylformamide, followed by treatment with ammonia under suitable conditions, such as 880 ammonia at room temperature.

Preparation of the compounds of formulae (XI) and (XII) wherein Y represents iodine and Z and R²⁰ both represent hydrogen have been previously described in: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 2002, 41B(3), 650-652. Preparation of the compound of formula (XIII) wherein Y represents iodine and Z and R²⁰ both represent hydrogen has been previously described in: PCT Int. Appl. (1999), WO9932450 A1.

Compounds of formula (X) are either known compounds (for example available from commercial suppliers such as Aldrich) or may be prepared by conventional means.

Compounds of formula (V), wherein R³⁴ represents R³S(═O)_(n)—, R¹⁹ represents hydrogen or C₁₋₆alkyl, R²⁰ is as defined above and n=0, may be prepared by treatment of compounds of formula (XII), wherein Y and R²⁰ are as defined above and Z represents hydrogen or C₁₋₆alkyl with a thiol of formula R³SH, wherein R³ is as defined above, according to the following scheme:

Suitable conditions for preparation of compounds of formula (V) from compounds of formula (XII) and a thiol of formula R³SH include heating in a suitable solvent such as toluene, at a suitable temperature such as 60-120° C., for example at 110° C., in the presence of a suitable catalyst, such as a palladium catalyst, for example tris(dibenzylideneacetone) palladium (II), and a suitable ligand, such as a phosphine ligand, for example (oxydi-2,1-phenylene)bis(diphenylphosphine), and in the presence of a suitable base such as potassium tert-butoxide.

Compounds of formulae R¹R²NH and R³SH are either known compounds (for example available from commercial suppliers such as Aldrich) or may be prepared by conventional means.

Certain compounds of formula R³SH may be prepared from compounds of formula R³SSR³. Suitable conditions include treatment with a suitable reducing agent such as a phosphine, for example triphenylphosphine, in the presence of an acid such as concentrated hydrochloric acid, in a suitable solvent such as a mixture of water and 1,4-dioxane, at a suitable temperature such as between 20° C. and 100° C., for example at 40° C. Alternatively certain compounds of formula R³SH may be prepared from compounds of formula R³SO₂Cl. Suitable conditions include treatment with a suitable reducing agent such as a phosphine, for example triphenylphosphine, in a suitable solvent such as 1,4-dioxane, at a suitable temperature such as between 0° C. and 50° C., for example at 20° C.

Compounds of formula R¹R²NH may be used in the free base form, or in the form of a suitable salt, such as a hydrochloride salt. Where the free base form is commercially available, suitable salt forms may be prepared by conventional means. Similarly, where a salt form is commercially available, the free base form may be prepared by conventional means.

Compounds of formula R³SH may contain amine or acid groups which are suitably protected. Examples of suitable protecting groups and the means for their removal are well known in the art,see for instance T. W. Greene and P. G. M. Wuts ‘Protective Groups in Organic Synthesis’ (3^(rd) Ed., J. Wiley and Sons, 1999). Addition or removal of such protecting groups may be accomplished at any suitable stage in the synthesis of compounds of formula (I).

Process c

Compounds of formula (I) may also be prepared by a process of interconversion between compounds of formula (I). For example, compounds of formula (I) where n=2 may be prepared from compounds of formula (i) wherein n=0 or 1, by treatment with a suitable oxidising agent, such as oxone, in a suitable solvent such N,N-dimethylformamide or a mixture of N,N-dimethylformamide and anisole, at a suitable temperature such as room temperature. Compounds of formula (I) where n=1 may be prepared from compounds of formula (I) where n=0 by oxidation with a suitable oxidising agent, such as oxone or ceric ammonium nitrate, in the presence of a suitable solid support such as hydrated silica gel, in a suitable solvent such as methylene chloride, at a suitable temperature such as 20-40° C., for example at room temperature.

Alternative processes of interconversion between compounds of formula (I) may include, for example oxidation, reduction, hydrolysis, alkylation, dealkylation, amide bond formation, protection, deprotection, sulphonamide formation or substitution, using methods for functional group interconversion well known to those skilled in the art.

Process d

As a particular example of a process of interconversion, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)—, R³ represents an aryl group substituted by —CONR²⁹R³⁰, R¹⁹ represents hydrogen or C₁₋₆alkyl, and wherein R¹, R², R²⁰, R²⁹, R³⁰ and n are as defined above, may alternatively be prepared from corresponding compounds of formula (I) in which R³ represents an aryl group substituted by —COOH, namely compounds of formula (XVII);

wherein R¹⁹ represents hydrogen or C₁₋₆alkyl, and R¹, R², R²⁰ and n are as defined above, by coupling with a primary or secondary amine, in a suitable solvent, such as N,N-dimethylformamide, in the presence of a suitable amide coupling reagent, such as O-(7-azabenzotriazol-1-yl)-N,N,N′N′-tetramethyluronium hexafluorophosphate, optionally in the presence of a suitable base, such as N,N-diisopropylethylamine, at a suitable temperature, such as room temperature. (Step (I))

Compounds of formula (XVII), wherein R¹⁹ represents hydrogen or C₁₋₆alkyl, and R¹, R², R²⁰ and n are as defined above, may be prepared from compounds of formula XVIII;

wherein R¹⁹ represents hydrogen or C₁₋₆alkyl, and R¹, R², R²⁰ and n are as defined above, by hydrolysis with a suitable base, such as aqueous sodium hydroxide, in a suitable solvent, such as ethanol, at a suitable temperature such as 75° C.( Step (II))

Compounds of formula (XVIII) wherein n=2 may be prepared from compounds of formula (XVIII) wherein n=0, by treatment with a suitable oxidising agent, such as oxone, in a suitable solvent such as N,N-dimethylformamide, at a suitable temperature such as room temperature. (Step (III))

Compounds of formula (XVIII), wherein R¹⁹ represents hydrogen or C₁₋₆alkyl, R¹, R² and R²⁰ are as defined above, and n=0, may be prepared from compounds of formula (III) wherein Z represents hydrogen or C₁₋₆alkyl by treatment with a suitable thiol such as methyl 3-mercaptobenzoate or methyl 4-mercaptobenzoate (both commercially available from Toronto). Suitable conditions for this include heating in a suitable solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, at a suitable temperature such as 60-150° C., for example at 85° C., in the presence of a suitable catalyst, such as a copper catalyst, for example copper (I) iodide, and in the presence of a suitable base such as potassium phosphate or potassium carbonate, optionally in the presence of a suitable ligand for example N,N-diethylsalicylamide. (Step (IV))

The order of the steps comprising this process may be arranged in a number of different ways. For example the order of steps (II) and (III) may be reversed so that compounds of formula (I) may be prepared by step (IV) followed by step (II) followed by step (III) followed by step (I).

By a similar process, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and R³ represents a C₁₋₆ alkyl group substituted by —CONR²⁶R²⁷ and wherein R¹⁹ represents hydrogen or C₁₋₆alkyl, and R¹, R², R²⁰, R²⁶, R²⁷ and n are as defined above, may alternatively be prepared from compounds of formula (III) where Z represents hydrogen or C₁₋₆alkyl and a suitable thiol such as ethyl 3-mercaptopropionate (commercially available from Aldrich) as shown in the scheme below:

Steps (I) to (IV) of Scheme 2 use conditions as described in process d above.

The order of the steps comprising this process may be arranged in a number of different ways. For example the order of steps may be changed so that compounds of formula (I) may be prepared from compounds of formula (III) by step (IV) followed by step (II) followed by step (III) followed by step (I).

Alternatively the order of steps may be changed so that compounds of formula (I) may be prepared by step (IV) followed by step (II) followed by step (I) followed by step (III).

wherein R³ is R²⁸R²⁷NCO(CH₂)₂—. Process e

As a particular example of a process of interconversion, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and R³ represents a piperidinyl group which is substituted by a substituent selected from C₁₋₆alkyl-, C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO— (optionally substituted by one or more C₁₋₄alkyl- groups), C₁₋₆alkoxyCO—, arylCO—, R³¹R³²NCO—, C₁₋₆alkylSO₂—, arylSO₂— or heteroarylSO₂— (optionally substituted by one or more C₁₋₄alkyl or C₁₋₄alkylCONH— groups) and wherein R¹, R², R²⁰, R³¹, R³² and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, may alternatively be prepared from compounds of formula (XIX);

wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, by treatment with an electrophile, such as an acylating agent, such as an acid chloride, in a suitable solvent, such as 1,4-dioxane, in the presence of a suitable base, such as an amine base, for example triethylamine, at a suitable temperature, such as room temperature. Alternative electrophiles that may be used for this process include sulphonyl chlorides, alkyl chloroformates, alkyl halides and acid anhydrides.

Alternatively, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and R³ represents a piperidinyl which is substituted by a substituent selected from C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO— (optionally substituted by one or more C₁₋₄alkyl- groups), or arylCO—, and wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, may alternatively be prepared from compounds of formula (XIX), by coupling with a carboxylic acid, in a suitable solvent, such as N,N-dimethylformamide, in the presence of a suitable amide coupling reagent, such as O-(7-azabenzotriazol-1-yl)-N,N,N′, N′-tetramethyluronium hexafluorophosphate, optionally in the presence of a suitable base, such as N,N-diisopropylethylamine, at a suitable temperature, such as room temperature. (Step (I))

Compounds of formula (XIX), wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, may be prepared from compounds of formula (XX);

wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, by treatment with a suitable reagent, such as a strong acid, for example trifluoroacetic acid, at a suitable temperature, such as room temperature (Step (II)).

Compounds of formula (XX) wherein R¹, R², and R²⁰ are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and n=2, may be prepared from compounds of formula (XX) wherein n=0, by treatment with a suitable oxidising agent, such as oxone, in a suitable solvent such as N,N-dimethylformamide, at a suitable temperature such as room temperature (Step (III)).

Compounds of formula (XX) wherein R¹, R², and R²⁰ are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and n=0, may be prepared from compounds of formula (III) wherein R¹, R², Y and R²⁰ are as defined above and Z represents hydrogen or C₁₋₆alkyl, by treatment with 1,1-dimethylethyl 4-mercapto-1-piperidinecarboxylate (prepared as described in U.S. Pat. No. 5,317,025A) (Step (IV)).

Suitable conditions for this process include heating in a suitable solvent such as dimethylformamide, at a suitable temperature such as 60-150° C., for example at 110° C., in the presence of a suitable catalyst, such as a palladium catalyst, for example tris(dibenzylideneacetone) palladium (II), and a suitable ligand, such as a phosphine ligand, for example (oxydi-2,1-phenylene)bis(diphenylphosphine), and in the presence of a suitable base such as potassium tert-butoxide.

The order of the steps comprising this process may be arranged in a number of different ways. For example the order of steps may be changed so that compounds of formula (I) may be prepared by step (IV) followed by step (II) followed by step (I) followed by step (III).

Similarly, compounds of formula (I) wherein R³⁴ represents R³S(═O)_(n)— and R³ represents a C₁₋₆alkyl which is substituted by —NR¹⁷R¹⁸, —NR¹⁶COR¹⁵, C₁₋₆alkoxyCONR²⁵— or C₁₋₆alkylSO₂NR³³— and wherein R¹, R², R²⁰ , R¹⁵, R¹⁷, R¹⁸ and n are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and R¹⁶, R²⁵ and R³³ represent hydrogen may alternatively be prepared from compounds of formula (III), wherein R¹, R², Y and R²⁰ are as defined above and Z represents hydrogen or C₁₋₆alkyl, and a thiol such as tert-butyl-N-(2-mercaptoethyl)carbamate (Aldrich), as is illustrated in the following Scheme (Scheme 3):

Steps (I) to (IV) of Scheme 3 use conditions as described in process e above.

wherein R³⁴ represents C₁₋₆alky)SO2-, wherein the C₁₋₆alkyl group is substituted by R¹⁵CONR¹⁶—, C₁₋₆alkoxyCONR²⁵—, C₁₋₆alkylSO₂NR³³— or R¹⁷R¹⁸N—. Process f

As a particular example of a process of interconversion compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and R³ represents an aryl group substituted by a C₁₋₆alkoxy-, C₃₋₇cycloalkoxy- or C₃₋₇cycloalkyl(C₁₋₆alkoxy)- group, R¹, R², R²⁰ and n are as defined above, and R¹⁹ represents hydrogen or C₁₋₆alkyl, may alternatively be prepared from compounds of formula (XXI);

wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, by coupling with a suitable alkylating agent, in a suitable solvent, such as acetonitrile, in the presence of a suitable base, such as potassium carbonate, at a suitable temperature, such as 0 to 100° C., for example the reflux temperature of the solvent.

Alternatively compounds of formula (I) wherein R³⁴ represents R³S(═O)_(n)— and R³ represents an aryl group substituted by a C₁₋₆alkoxy-, C₃₋₇cycloalkoxy- or C₃₋₇cycloalkyl(C₁₋₆alkoxy)- group, R¹, R², R²⁰ and n are as defined above, and R¹⁹ represents hydrogen or C₁₋₆alkyl, may be prepared from compounds of formula (XXI) by coupling with a suitable alcohol in a suitable solvent such as tetrahydrofuran, at a suitable temperature such as room temperature in the presence of a suitable coupling agent such as di-tert butylazodicarboxylate.

Compounds of formula (XXI) wherein n=2 may be prepared from compounds of formula (XXI) wherein n=0, by treatment with a suitable oxidising agent, such as oxone, in a suitable solvent such as N,N-dimethylformamide, at a suitable temperature such as room temperature.

Compounds of formula (XXI) wherein R¹, R², and R²⁰ are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and n=0, may be prepared from compounds of formula (III) wherein R¹, R², R²⁰ and Y are as defined above, and wherein Z represents hydrogen or C₁₋₆alkyl, by treatment with 4{[tert-butyl(dimethyl)silyl]oxy}benzenethiol (prepared according to EP 465802 A1). Suitable conditions for this process include heating in a suitable solvent such as dimethylformamide, at a suitable temperature such as 60-150° C., for example at 110° C., in the presence of a suitable catalyst, such as a palladium catalyst, for example tris(dibenzylideneacetone) palladium (II), and a suitable ligand, such as a phosphine ligand, for example (oxydi-2,1-phenylene)bis(diphenylphosphine), and in the presence of a suitable base such as potassium tert-butoxide, followed by deprotection with a suitable fluoride source such as tetrabutylammonium fluoride in a suitable solvent such as tetrahydrofuran at a suitable temperature such as room temperature.

The order of the steps comprising this process may be arranged in a number of different ways.

Process g

Compounds of formula (I) may also be prepared by a process of deprotection of protected derivatives of compounds of formula (I). Examples of suitable protecting groups and the means for their removal are well known in the art, see for instance T. W. Greene and P. G. M. Wuts ‘Protective Groups in Organic Synthesis’ (3^(rd) Ed., J. Wiley and Sons, 1999).

As an example of this, compounds of formula (I) containing a primary or secondary amine group may be prepared from compounds of formula (I) where that amine group is protected, such as a carbamate group, for example as a tert-butyl carbamate, by deprotecting under appropriate conditions, such as treating with a strong acid, for example trifluoroacetic acid.

Process h

As a particular example of a process of interconversion, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and R³ represents C₁₋₆alkoxyethyl-, R¹, R², R²⁰ and n are as defined above, and R¹⁹ represents hydrogen or C₁₋₆alkyl may be prepared from compounds of formula (XXVIII);

wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, by alkylation with a suitable alkylating agent, in a suitable solvent, such as N,N-dimethylformamide, in the presence of a suitable base, such as sodium hydride, at a suitable temperature, such as 0 to 30° C., for example at room temperature.

Alternatively compounds of formula (I) wherein R³⁴ represents R³S(═O)_(n)— and R³ represents C₁₋₆alkoxyethyl-, R¹, R², R²⁰ and n are as defined above, and R¹⁹ represents hydrogen or C₁₋₆alkyl may be prepared from compounds of formula (XXVIII) wherein R¹, R², R²⁰ and n are as defined above and R¹⁹ represents hydrogen or C₁₋₆alkyl, by coupling with a suitable alcohol in a suitable solvent such as tetrahydrofuran, at a suitable temperature such as room temperature in the presence of a suitable coupling agent such as di-tert butylazodicarboxylate.

Compounds of formula (XXVIII) wherein R¹, R², and R²⁰ are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and n=2 may be prepared from compounds of formula (XXVIII) wherein n=0, by treatment with a suitable oxidising agent, such as oxone, in a suitable solvent such as N,N-dimethylformamide, at a suitable temperature such as room temperature.

Compounds of formula (XXVIII) wherein R¹, R² and R²⁰ are as defined above, R¹⁹ represents hydrogen or C₁₋₆alkyl, and n is 0, may be prepared from compounds of formula (III) wherein R¹, R², R²⁰ and Y are as defined above and Z represents hydrogen or C₁₋₆alkyl, by treatment with 2-mercaptoethanol (available from Aldrich). Suitable conditions for this process include heating in a suitable solvent such as N,N-dimethylformamide, at a suitable temperature such as 60-150° C., for example at 110° C., in the presence of a suitable catalyst, such as a palladium catalyst, for example tris(dibenzylideneacetone) palladium (II), and a suitable ligand, such as a phosphine ligand, for example (oxydi-2,1-phenylene)bis(diphenylphosphine), and in the presence of a suitable base such as potassium tert-butoxide.

The order of the steps comprising this process may be arranged in a number of different ways.

Process i

Compounds of formula (I) wherein R³⁴ represents hydrogen, R¹⁹ represents R³S(═O)_(n)—, and R¹, R², R²⁰ and n are as defined above, may be prepared from compounds of formula (XXIX) wherein Y represents chlorine, bromine or iodine, in particular iodine, n=1 or 2, and R¹, R², R³ and R²⁰ are as defined above, by hydrogenation using a suitable hydrogenation process such as palladium on carbon in a suitable solvent such as ethanol.

Compounds of formula (XXIX) wherein Y represents chlorine, bromine or iodine, in particular iodine, n=1 or 2, and R¹, R², R³ and R²⁰ are as defined above, may be prepared from compounds of formula (XXIX) wherein n=0 by treatment with a suitable oxidising agent such as oxone in a suitable solvent such as N,N-dimethylformamide of a mixture of N,N-dimethylformamide and anisole at a suitable temperature such as room temperature.

Compounds of formula (XXIX) wherein Y represents chlorine, bromine or iodine, in particular iodine, R¹, R², R³ and R²⁰ are as defined above, and n=0 may be prepared from compounds of formula (III) wherein R¹, R² and R²⁰ are as defined above, Y represents chlorine, bromine or iodine, especially iodine, and Z represents chlorine, bromine or iodine, especially chlorine, and a thiol of formula R³SH by heating in a suitable solvent such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, at a suitable temperature such as 60-150° C. for example at 100° C. in the presence of a suitable base such as potassium carbonate.

Process j

As a particular example of a process of interconversion, compounds of formula (I), wherein R³⁴ represents R³S(═O)_(n)— and wherein R³ represents:

and wherein R¹, R², R²⁰, and n are as defined above, and R¹⁹ represents hydrogen or C₁₋₆alkyl, may be prepared from compounds of formula (XXVII) in scheme 3, wherein R¹, R², and R²⁰ are as defined above and Z represents hydrogen or C₁₋₆alkyl, by treatment with a suitable alkylating agent such as ethyl 4-bromobutyrate in a suitable solvent such as 1,4-dioxane at a suitable temperature such as 120° C.

The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance in a mammal such as a human. The compound or salt can be for use in the treatment and/or prophylaxis of any of the conditions described herein and/or for use as a phosphodiesterase inhibitor, for example for use as a phosphodiesterase 4 (PDE4) inhibitor. “Therapy” may include treatment and/or prophylaxis.

Also provided is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament (e.g. pharmaceutical composition) for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human.

Also provided is a method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal (e.g. human) in need thereof, which comprises administering to the mammal (e.g. human) a therapeutically effective amount of a compound of formula (I) as herein defined or a pharmaceutically acceptable salt thereof.

Phosphodiesterase 4 inhibitors are believed to be useful in the treatment and/or prophylaxis of a variety of diseases, especially inflammatory and/or allergic diseases, in mammals such as humans, for example: asthma, chronic bronchitis, emphysema, atopic dermatitis, urticaria, allergic rhinitis (seasonal or perennial), vasomotor rhinitis, nasal polyps, allergic conjunctivitis, vernal conjunctivitis, occupational conjunctivitis, infective conjunctivitis, eosinophilic syndromes, eosinophilic granuloma, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, multiple sclerosis or memory impairment (including Alzheimer's disease).

In the treatment and/or prophylaxis, the inflammatory and/or allergic disease is preferably chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema, asthma, rheumatoid arthritis, psoriasis or allergic rhinitis in a mammal (e.g. human). More preferably, the treatment and/or prophylaxis is of COPD including chronic bronchitis and emphysema or asthma in a mammal (e.g. human). PDE4 inhibitors are thought to be effective in the treatment of asthma (e.g. see M. A. Giembycz, Drugs, February 2000, 59(2), 193-212; Z. Huang et al., Current Opinion in Chemical Biology, 2001, 5, 432-438; and refs cited therein) and COPD (e.g. see S. L. Wolda, Emerging Drugs, 2000, 5(3), 309-319; Z. Huang et al., Current Opinion in Chemical Biology, 2001, 5, 432-438; and refs cited therein). COPD is often characterised by the presence of airflow obstruction due to chronic bronchitis and/or emphysema (S. L. Wolda, Emerging Drugs, 2000, 5(3), 309-319).

For use in medicine, the compounds of the present invention are usually administered as a pharmaceutical composition.

The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or excipients.

The pharmaceutical composition can be for use in the treatment and/or prophylaxis of any of the conditions described herein.

The compounds of formula (I) and/or the pharmaceutical composition may be administered, for example, by oral, parenteral (e.g. intravenous, subcutaneous, or intramuscular), inhaled, nasal, transdermal or rectal administration, or as topical treatments (e.g. ointments or gels). Accordingly, the pharmaceutical composition is preferably suitable for oral, parenteral (e.g. intravenous, subcutaneous or intramuscular), inhaled or nasal administration. More preferably, the pharmaceutical composition is suitable for inhaled or oral administration, e.g. to a mammal such as a human. Inhaled administration involves topical administration to the lung, e.g. by aerosol or dry powder composition.

A pharmaceutical composition suitable for oral administration can be liquid or solid; for example it can be a solution, a syrup, a suspension or emulsion, a tablet, a capsule or a lozenge.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable pharmaceutically acceptable liquid carrier(s), for example an aqueous solvent such as water, ethanol or glycerine, or an oil, or a non-aqueous solvent, such as a surfactant, such as polyethylene glycol. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

A pharmaceutical composition suitable for oral administration being a tablet can comprise one or more pharmaceutically acceptable carriers and/or excipients suitable for preparing tablet formulations. Examples of such carriers include lactose and cellulose. The tablet can also or instead contain one or more pharmaceutically acceptable excipients, for example binding agents, lubricants such as magnesium stearate, and/or tablet disintegrants.

A pharmaceutical composition suitable for oral administration being a capsule can be prepared using encapsulation procedures. For example, pellets containing the active ingredient can be prepared using a suitable pharmaceutically acceptable carrier and then filled into a hard gelatin capsule. Alternatively, a dispersion, suspension or solution can be prepared using any suitable pharmaceutically acceptable carrier, for example an aqueous solution, aqueous gum or an oil and the dispersion, suspension or solution then filled into a hard or soft gelatin capsule.

The compounds of formula (I) and/or the pharmaceutical composition may be administered by a controlled or sustained release formulation as described in WO 00/50011.

A parenteral composition can comprise a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil. Alternatively, the solution can be lyophilised; the lyophilised parenteral pharmaceutical composition can be reconstituted with a suitable solvent just prior to administration.

Compositions for nasal or inhaled administration may conveniently be formulated as aerosols, solutions, suspensions, drops, gels or dry powders.

For compositions suitable and/or adapted for inhaled administration, it is preferred that the compound or salt of formula (I) is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation. The preferable particle size of the size-reduced (e.g. micronised) compound or salt is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).

Aerosol formulations, e.g. for inhaled administration, can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.

Where the dosage form comprises an aerosol dispenser, it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC). Suitable CFC propellants include dichlorodifluoromethane, trichlorofluoromethane and dichlorotetrafluoroethane. Suitable HFC propellants include 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage forms can also take the form of a pump-atomiser.

Optionally, in particular for dry powder inhalable compositions, a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (e.g. containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device. The container is rupturable or peel-openable on demand and the dose of e.g. the dry powder composition can be administered by inhalation via the device such as the DISKUS™ device, marketed by GlaxoSmithKline. The DISKUS™ inhalation device is for example described in GB 2242134 A, and in such a device at least one container for the pharmaceutical composition in powder form (the container or containers preferably being a plurality of sealed dose containers mounted longitudinally in a strip or ribbon) is defined between two members peelably secured to one another; the device comprises: a means of defining an opening station for the said container or containers; a means for peeling the members apart at the opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale the pharmaceutical composition in powder form from the opened container.

In the pharmaceutical composition, each dosage unit for oral or parenteral administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base. Each dosage unit for nasal or inhaled administration preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

The pharmaceutically acceptable compounds or salts of the invention can be administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0.01 mg to 3000 mg per day or 0.5 to 1000 mg per day, or a nasal or inhaled dose of 0.001 to 50 mg per day or 0.01 to 5 mg per day, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

The compounds, salts and/or pharmaceutical compositions according to the invention may also be used in combination with one or more other therapeutically active agents, for example, a β₂ adrenoreceptor agonist, an anti-histamine, an anti-allergic agent, an anti-inflammatory agent (including a steroid), an anticholinergic agent or an antiinfective agent (e.g. antibiotics or antivirals).

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof with one or more other therapeutically active agents, for example, a β₂-adrenoreceptor agonist, an anti-histamine, an anti-allergic agent, an anti-inflammatory agent (including a steroid), an anticholinergic agent or an antiinfective agent (e.g. antibiotics or antivirals).

Examples of β₂-adrenoreceptor agonists include salmeterol (e.g. as racemate or a single enantiomer such as the R-enantiomer), salbutamol, formoterol, salmefamol, fenoterol or terbutaline and salts thereof, for example the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the fumarate salt of formoterol. Long-acting β₂-adrenoreceptor agonists are preferred, especially those having a therapeutic effect over a 24 hour period, such as salmeterol or formoterol.

Examples of anti-histamines include methapyrilene or loratadine.

Examples of anti-inflammatory steroids include fluticasone propionate and budesonide.

Examples of anticholinergic compounds which may be used in combination with a compound of formula (I) or a pharmaceutically acceptable salt thereof are described in WO 03/011274 A2 and WO 02/069945 A2/US 2002/0193393 A1 and US 2002/052312 A1. For example, anticholinergic agents include muscarinic M3 antagonists, such as ipratropium bromide, oxitropium bromide or tiotropium bromide.

Other suitable combinations include, for example, combinations comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with other anti-inflammatory agents such as an anti-inflammatory corticosteroid; or a non-steroidal anti-inflammatory drug (NSAID) such as a leukotriene antagonist (e.g. montelukast), an iNOS inhibitor, a tryptase inhibitor, an elastase inhibitor, a beta-2 integrin antagonist, an adenosine a2a agonist, a chemokine antagonist such as a CCR3 antagonist, or a 5-lipoxygenase inhibitor; or an antiinfective agent (e.g. an antibiotic or an antiviral). An iNOS inhibitor is preferably for oral administration. Suitable iNOS inhibitors (inducible nitric oxide synthase inhibitors) incluse those disclosed in WO 93/13055, WO 98/30537, WO 02/50021, WO 95/34534 and WO 99/62875. Suitable CCR3 inhibitors include those disclosed in WO 02/26722.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus a pharmaceutical composition comprising a combination as defined above together with one or more pharmaceutically acceptable carriers and/or excipients represent a further aspect of the invention.

The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or in combined pharmaceutical compositions.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The various aspects of the invention will now be described by reference to the following Biological Test Methods and Examples. These Examples are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

Biological Test Methods

PDE3, PDE4B, PDE4D, PDE5 and PDE6 Primary Assay Methods

The activity of the compounds can be measured as described below. Preferred compounds of the invention are selective PDE4 inhibitors, i.e. they inhibit PDE4 (e.g. PDE4B and/or PDE4D) more strongly than they inhibit other PDE's such as PDE3 and/or PDE5.

1. PDE Enzyme Sources and Literature References.

Human recombinant PDE4B, in particular the 2B splice variant thereof (HSPDE4B2B), is disclosed in WO 94/20079 and also in M. M. McLaughlin et al., “A low Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA”, J. Biol. Chem., 1993, 268, 6470-6476. For example, in Example 1 of WO 94/20079, human recombinant PDE4B is described as being expressed in the PDE-deficient yeast Saccharomyces cerevisiae strain GL62, e.g. after induction by addition of 150 μM CuSO₄, and 100,000×g supernatant fractions of yeast cell lysates are described for use in the harvesting of PDE4B enzyme.

Human recombinant PDE4D (HSPDE4D3A) is disclosed in P. A. Baecker et al., “Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phoshodiesterase (PDE IV_(D))”, Gene, 1994,138, 253-256.

Human recombinant PDE5 is disclosed in K. Loughney et al., “Isolation and characterisation of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase”, Gene, 1998, 216, 139-147.

PDE3 was purified from bovine aorta. Its presence in the tissue was reported by H. Coste and P. Grondin in “Characterisation of a novel potent and specific inhibitor of type V phosphodiesterase”, Biochem. Pharmacol., 1995, 50,1577-1585.

PDE6 was purified from bovine retina. Its presence in this tissue was reported by: P. Catty and P. Deterre in “Activation and solubilization of the retinal cGMP-specific phosphodiesterase by limited proteolysis”, Eur. J. Biochem., 1991, 199, 263-269; A. Tar et al. in “Purification of bovine retinal cGMP phosphodiesterase”, Methods in Enzymology, 1994, 238, 3-12; and/or D. Srivastava et al. in “Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase”, Biochem. J., 1995, 308, 653-658.

2. Inhibition of PDE3, PDE4B, PDE4D, PDE5 or PDE6 Activity: Radioactive Scintillation Proximity Assay (SPA)

The ability of compounds to inhibit catalytic activity at PDE4B or 4D (human recombinant), PDE3 (from bovine aorta), PDE5 (human recombinant) or PDE 6 (from bovine retina) was determined by Scintillation Proximity Assay (SPA) in 96-well format. Test compounds (preferably as a solution in DMSO, e.g. 2 microlitre (μl) volume) were preincubated at ambient temperature in Wallac Isoplates (code 1450-514) with PDE enzyme in 50 mM Tris-HCl buffer pH 7.5, 8.3 mM MgCl₂, 1.7 mM EGTA, 0.05% (w/v) bovine serum albumin for 10-30 minutes. The enzyme concentration was adjusted so that no more than 20% hydrolysis of the substrate occurred in control wells without compound, during the incubation. For the PDE3, PDE4B and PDE4D assays [5′,8-³H]adenosine 3′,5′-cyclic phosphate (Amersham Pharmacia Biotech, code TRK.559 or Amersham Biosciences UK Ltd, Pollards Wood, Chalfont St Giles, Buckinghamshire HP8 4SP, UK) was added to give 0.05 μCi per well and ˜10 nM final concentration. For the PDE5 and PDE6 assays [8-³H]guanosine 3′,5′-cyclic phosphate (Amersham Pharmacia Biotech , code TRK.392) was added to give 0.05 μCi per well and ˜36 nM final concentration. Plates e.g. containing approx. 100 μl volume of assay mixture were mixed on an orbital shaker for 5 minutes and incubated at ambient temperature for 1 hour. Phosphodiesterase SPA beads (Amersham Pharmacia Biotech, code RPNQ 0150) suspended in buffer were added (˜1 mg per well) to terminate the assay. Plates were sealed and shaken and allowed to stand at ambient temperature for 35 minutes to 1 hour to allow the beads to settle. Bound radioactive product was measured using a WALLAC TRILUX 1450 Microbeta scintillation counter. For inhibition curves, 10 concentrations (e.g. 1.5 nM-30 μM) of each compound were assayed; more potent compounds were assayed over lower concentration ranges (assay concentrations were generally between 30 μM and 50 fM). Curves were analysed using

ActivityBase and XLfit (ID Business Solutions Limited, 2 Ocean Court, Surrey Research Park, Guildford, Surrey GU2 7QB, United Kingdom). Results were expressed as pIC₅₀ values.

Alternatively, the activity of the compounds can be measured in the following Fluorescence Polarisation (FP) assay:

3. Inhibition of PDE4B or PDE4D Activity: Fluorescence Polarisation (FP) Assay

The ability of compounds to inhibit catalytic activity at PDE4B (human recombinant) and PDE4D (human recombinant) was determined by IMAP Fluorescence Polarisation (FP) assay (Molecular Devices code: R8062) in 384-well format. Test compounds (small volume, e.g. 0.5 μl, of solution in DMSO) were preincubated at ambient temperature in black 384-well microtitre plates (supplier: NUNC, code 262260) with PDE enzyme in 10 mM Tris-HCl buffer pH 7.2, 10 mM MgCl₂, 0.1% (w/v) bovine serum albumin. 0.05% NaN₃ for 10-30 minutes. The enzyme level was set so that reaction was linear throughout the incubation.

Fluorescein adenosine 3′,5′-cyclic phosphate (Molecular Devices code: R7091) was added to give ˜40 nM final concentration. Plates were mixed on an orbital shaker for 10 seconds and incubated at ambient temperature for 40 minutes. IMAP binding reagent (Molecular Devices code: R7207) was added (60 μl of a 1 in 400 dilution in binding buffer of the kit stock suspension) to terminate the assay. Plates were allowed to stand at ambient temperature for 1 hour. The FP ratio of parallel to perpendicular light was measured using an Analyst™ plate reader (from Molecular Devices Ltd). For inhibition curves, 11 concentrations (0.5 nM-30 μM) of each compound were assayed; more potent compounds were assayed over lower concentration ranges (assay concentrations were generally between 30 μM and 50 fM). Curves were analysed using ActivityBase and XLfit (ID Business Solutions Limited). Results were expressed as pIC₅₀ values. For a given PDE4 inhibitor, the PDE4B (or PDE4D) inhibition values measured using the SPA and FP assays can differ slightly. However, in a regression analysis of 100 test compounds, the pIC₅₀ inhibition values measured using SPA and FP assays have been found generally to agree within 0.5 log units for PDE4B and PDE4D (linear regression coefficient 0.966 for PDE4B and 0.971 for PDE4D; David R. Mobbs et al, “Comparison of the IMAP Fluorescence Polarisation Assay with the Scintillation Proximity Assay for Phosphodiesterase Activity”, poster presented at 2003 Molecular Devices UK & Europe User Meeting, 2nd Oct. 2003, Down Hall, Harlow, Essex, United Kingdom).

Examples of compounds of the invention described above inhibit the catalytic activity at the PDE4B (human recombinant) enzyme with pIC₅₀ values in the range 6.0-11.7. Biological Data obtained for some of the Examples (PDE4B and PDE5 inhibitory activity) is as follows:

PDE4B PDE5 Example mean mean No. pIC₅₀ pIC₅₀ 27 8.4 4.8 70 7.3 5.0 92 7.7 <4.5 125 6.6 5.5 265 11.3 5.2 307 10.5 <4.6 309 10.1 <4.9 312 9.4 <4.5 369 9.5 5.1 380 11.4 <7.0 399 >11.6 5.6 400 11.0 <5.0 408 11.4 4.9 446 11.3 <4.5 457 11.0 <5.5 502 8.9 <5 546 10.7 4.7 4. Emesis:

Many known PDE4 inhibitors cause emesis and/or nausea to greater or lesser extents (e.g. see Z. Huang et al., Current Opinion in Chemical Biology, 2001, 5, 432-438, see especially pages 433-434 and references cited therein). Therefore, it would be preferable but not essential that a PDE4 inhibitory compound of the invention causes only limited or manageable emetic side-effects. Emetic side-effects can for example be measured by the emetogenic potential of the compound when administered to ferrets; for example one can measure the time to onset, extent, frequency and/or duration of vomiting and/or writhing in ferrets after oral or parenteral administration of the compound. See for example A. Robichaud et al., “Emesis induced by inhibitors of PDE IV in the ferret” Neuropharmacology, 1999, 38, 289-297, erratum Neuropharmacology, 2001, 40, 465465.

EXAMPLES

In this section, “intermediates” represent syntheses of intermediate compounds intended for use in the synthesis of the “Examples”.

-   -   Abbreviations used herein:     -   HPLC high performance liquid chromatography     -   NMR nuclear magnetic resonance     -   LC/MS liquid chromatography/mass spectroscopy     -   TLC thin layer chromatography     -   SPE solid phase extraction column. Unless otherwise specified         the solid phase will be silica gel. C18 SPE refers to reverse         phase SPE columns (eg Varian Bond Elut C18 columns). Aminopropyl         SPE refers to a silica SPE column with aminopropyl residues         immobilised on the solid phase (eg. IST Isolute™ columns). It is         thought that compounds isolated by SPE are free bases.     -   SCX solid phase extraction (SPE) column with benzene sulfonic         acid residues immobilised on the solid phase (eg. IST lsolute™         columns). When eluting with ammonia/methanol, it is thought that         compounds isolated by SCX are free bases.         General Experimental Details         LC/MS (Liquid Chromatography/Mass Spectroscopy)     -   Waters ZQ mass spectrometer operating in positive ion         electrospray mode, mass range 100-1000 amu.     -   UV wavelength: 215-330 nm     -   Column: 3.3 cm×4.6 mm ID, 3 μm ABZ+PLUS     -   Flow Rate: 3 ml/min     -   Injection Volume: 5 μl     -   Solvent A: 95% acetonitrile+0.05% formic acid     -   Solvent B: 0.1% formic acid+10 mM ammonium acetate     -   Gradient: Mixtures of Solvent A and Solvent B are used according         to the following gradient profiles (expressed as % Solvent A in         the mixture): 0% A/0.7 min, 0-100% A/3.5 min, 100% A/1.1 min,         100-0% A/0.2 min         Mass Directed Automated Preparative HPLC Column, Conditions and         Eluent         Method A     -   The preparative column used was a Supelcosil ABZplus (10 cm×2.12         cm internal diameter; particle size 5 μm)     -   UV detection wavelength : 200-320 nm     -   Flow rate: 20 ml/min     -   Injection Volume: 0.5 ml     -   Solvent A: 0.1 % formic acid     -   Solvent B: 95% acetonitrile+0.05% formic acid     -   Gradient systems: mixtures of Solvent A and Solvent B are used         according to a choice of 5 generic gradient profiles (expressed         as % Solvent B in the mixture), ranging from a start of 0 to 50%         Solvent B, with all finishing at 100% Solvent B to ensure total         elution. It is thought that compounds isolated by this method         are free bases, unless the R¹ or R³ groups contain basic         moieties, in which case formate salts may be formed.         Mass Directed Automated Preparative HPLC Column, Conditions and         Eluent         Method B     -   The preparative column used was a Supelcosil ABZplus (10 cm×2.12         cm internal diameter; particle size 5 μm)     -   UV detection wavelength: 200-320 nm     -   Flow rate: 20 ml/min     -   Injection Volume: 0.5 ml     -   Solvent A: water+0.1% trifluoroacetic acid     -   Solvent B: acetonitrile+0.1% trifluoroacetic acid     -   Gradient systems: mixtures of Solvent A and Solvent B are used         according to a choice of 5 generic gradient profiles (expressed         as % Solvent B in the mixture), ranging from a start of 0 to 50%         Solvent B, with all finishing at 100% Solvent B to ensure total         elution. It is thought that compounds isolated by this method         are trifluoroacetate salts.         Mass Directed Automated Preparative HPLC Column, Conditions and         Eluent         Method C

This is identical to method A. After purification but before solvent removal an excess (between a few drops and 0.5 ml) of dilute hydrochloric acid is added to the product containing fractions.

It is thought that compounds isolated by this method are hydrochloride salts.

Product Isolation by Filtration Directly from the Reaction Mixture

It is thought that compounds isolated by this method from reactions involving displacement of a 4-chloroquinoline intermediate with an amine of formula R¹R²NH are hydrochloride salts.

‘Hydrophobic Frit’

This refers to a Whatman PTFE filter medium (frit), pore size 5.0 μm, housed in a polypropylene tube.

Oasis Cartridge

This refers to a Waters Oasis™ HLB Liquid Phase Extraction Cartridge

Evaporation of Product Fractions After Purification

Reference to column chromatography, SPE and preparative HPLC purification includes evaporation of the product containing fractions to dryness by an appropriate method.

Aqueous Ammonia Solutions

‘880 Ammonia’ or ‘0.880 ammonia’ refers to concentrated aqueous ammonia (specific gravity 0.880).

INTERMEDIATES AND EXAMPLES

All reagents not detailed in the text below are commercially available from established suppliers such as Sigma-Aldrich.

Intermediate 1. 1-(Cyclopentylthio)-4-nitrobenzene

Cyclopentanethiol (1.0 g) (available from Aldrich) was dissolved in acetonitrile (10 ml) and potassium carbonate (1.35 g) was added. After 5 min, 1-fluoro-4-nitrobenzene (1.38 g) (available from Aldrich) was added and the mixture was stirred at room temperature overnight. The mixture was diluted with water and extracted with ether. The organic layer was washed with 1M aqueous sodium hydroxide (20 ml), water (20 ml), and 1M aqueous hydrochoric acid (20 ml). The organic layer was separated and the solvent evaporated in vacuo to give the title compound as a yellow liquid (0.7 g).

¹HNMR (CDCl₃) δ 8.12 (2H,m), 7.33 (2H,m), 3.75 (1H,m), 2.19 (2H,m), 1.87-162 (6H,m).

Intermediate 2. 1-(Cyclopentylsulfonyl)-4-nitrobenzene

Intermediate 1 (0.7 g) was dissolved in methanol (20 ml) and the solution cooled to 0° C. A solution of oxone (1.93 g) in water (20 ml) was added and the mixture was stirred under nitrogen for 2 h at room temperature. The mixture was extracted with dichloromethane, the layers were separated (hydrophobic frit), and the organic layer evaporated to give the title compound as a yellow oil which crystallised on standing (0.79 g).

LC/MS R_(t) 3.05 min, m/z 273 [MNH₄ ⁺]

Intermediate 3. 4-(Cyclopentylsulfonyl)aniline

Intermediate 2 (13.1 g) was dissolved in acetic acid (150 ml) and hydrogenated over palladium on activated carbon (1.6 g) with stirring overnight. The mixture was filtered through Celite filter aid, and the filtrate was evaporated to give a yellow/green oil. The oil was taken up in methanol and an insoluble precipitate filtered off; the filtrate was evaporated in vacuo to give a yellow solid. Trituration with ether and filtration gave the title compound as a pale yellow solid (8.1 g).

LC/MS R_(t) 2.5 min, m/z 243 [MNH₄ ⁺]

Intermediate 4. Diethyl ({[4-cyclopentylsulfonyl)phenyl]amino}methylidene)propanedioate

Intermediate 3 (10.8 g) (Helvetica Chimica Acta 1983, 66(4), 1046-52) and diethyl (ethoxymethylene)malonate (11.4 g) (available from Aldrich) were heated at 130° C. for 2 h. After cooling, the brown oil was scratched around the edge of the flask which caused the oil to solidify. Trituration with methanol gave a beige solid, which was filtered off to give the title compound (12.3 g). The filtrate was evaporated in vacuo to give a brown oil. Purification by chromatography on silica gel, eluting with 5% ethyl acetate/cyclohexane followed by 10% ethyl acetate/cyclohexane, gave an orange solid; trituration with methanol and filtration gave the title compound as a yellow solid (2.5 g; total yield 14.8 g).

LC/MS R_(t) 3.27 min m/z 396 [MH⁺]

Intermediate 5. Ethyl 6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylate

Intermediate 4 (14.7 g) was dissolved in diphenyl ether (150 ml) and the solution heated at 250° C. for 30 min. After cooling, the mixture was diluted with cyclohexane and the resulting precipitate filtered off and washed with further cyclohexane to give the title compound as a beige solid (10.9 g).

LC/MS R_(t) 2.46 min m/z 350 [MH³⁰ ]

Intermediate 6. 6-(Cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

Intermediate 5 (10.9 g) was dissolved in ethanol (100 ml) and 2M sodium hydroxide (100 ml), and the mixture was heated under reflux for 3 h. After cooling, the solvent was evaporated in vacuo and the residue was dissolved in water and washed with ethyl acetate. The aqueous layer was acidified with 2M hydrochloric acid to between pH 5 and pH 6 which caused a precipitate to form. The precipitate was filtered off, washed with water, and dried in vacuo overnight to give the title compound as a beige solid (9.47 g).

LC/MS R_(t) 2.65 min m/z 322 [MH⁺]

Intermediate 7. 4-Chloro-6-(cyclopentylsulfonyl)-3-quinolinecarboxamide

Intermediate 6 (1.43 g) was suspended in thionyl chloride (20 ml) and N,N-dimethylformamide (5 drops) was added. The mixture was heated under reflux for 2 h. After cooling, the thionyl chloride was evaporated in vacuo and the resulting residue was azeotroped with toluene. 0.880 Ammonia (25 ml) was added dropwise to the yellow solid (caution: exotherm), and the suspension was stirred at room temperature for 16 h. The resulting precipitate was filtered off, washed with water, and dried in vacuo to give the title compound (0.71 g).

LC/MS R_(t) 2.47 min m/z 339 [MH⁺]

Similarly prepared were the following:

Intermediate LCMS LCMS No. R³— R¹⁹— R²⁰— Starting material/source MH⁺ R_(t) (min) Intermediate 8 Ph— H— H— 4-(phenylsulfonyl)aniline/ 347 2.58 Maybridge Intermediate 9 Me— H— H— 4-(methylsulphonyl)aniline/ 285 2.00 Salor Intermediate 16 Ph— H— Me— Intermediate 15 361 2.78 Intermediate 17 Me— Me— H— 1-fluoro-2-methyl-4- 299 2.19 nitrobenzene/ Aldrich Intermediate 95 ^(t)Bu— H— H— 4-[(1,1- 327 2.40 dimethylethyl)sulphonyl]aniline/ Helvetica Chimica Ada (1983), 66(4), 1046-52

Intermediate 30. 4-Chloro-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide

This was made in the same manner as Intermediate 7 starting from 4-[(1-methylethyl)sulfonyl]aniline (Helvetica Chimica Acta (1983), 66(4), 1046-52).

LC/MS R_(t) 2.27 min n/z 313 [MH⁺]

The following were also made in the same manner as Intermediate 7, with the proviso that the intermediates of formula

were prepared from the appropriate 4-fluoronitrobenzene in a similar manner to Intermediate 15:

Starting Nitroaryl LCMS Intermediate Compound/ Starting Sulfinic LCMS R_(t) Number R³SO₂— R²⁰— Supplier Acid/Supplier MH⁺ (min) Intermediate 31

H— 4- fluoro nitrobenzene/ Aldrich Sodium 4- (methyloxy) benzenesulfinate/ WO 9830566 A1 379 2.72 Intermediate 32

Me— 5-fluoro-2- nitrotoluene/ Aldrich Sodium 4- (methyloxy) benzenesulfinate/ WO 9830566 A1 391 2.91 Intermediate 34

Me— 5-fluoro-2- nitrotoluene/ Aldrich Sodium 4- methylbenzene sulfinate/Aldrich 375 2.93 Intermediate 33 MeSO₂— Me— 5-fluoro-2- Methanesulfinic 299 2.12 nitrotoluene/ acid sodium salt/ Aldrich Lancaster Intermediate 50 MeSO₂— MeO— 4-fluoro-2- Methanesulfinic 315 1.99 (methyloxy)-1- acid sodium salt/ nitrobenzene/ Lancaster Maybridge

Intermediate 10. Diethyl {[(4-iodophenyl)amino]methylidene}propanedioate

A mixture of 4-iodoaniline (208 g) (available from Aldrich) and diethyl (ethoxymethylene)malonate (210 ml) (available from Aldrich) was heated to ca. 60° C., whereupon the mixture set solid. Heating was continued to 100° C., and then the mixture was removed from heating and broken up. Heating was continued at 100° C. for 1 h, and the solid was collected, washed with cyclohexane (1 L) and ethanol (2×500 ml), and dried in vacuo at 40° C. overnight to give the title compound as a white solid (356 g).

LC/MS R_(t) 3.57 min m/z 390 [MH⁺]

Intermediate 11. Ethyl 6-iodo-4-oxo-1,4-dihydro-3-quinolinecarboxylate

Diphenyl ether (175 ml) was heated to reflux temperature, and Intermediate 10 was gradually added down an air condenser. Once all the reagent had been added the mixture was heated under reflux for a further 30 min. The mixture was then cooled and 2-methylpentane (200 ml) was added. The solid formed was collected by filtration to give the title compound (24.6 g).

¹HNMR (DMSO) δ 8.58 (1H,s), 8.42(1H,d), 7.99 (1H,dd), 7.44(1H,d), 4.21(2H,q), 1.28 (3H,t)

Intermediate 12. 6-Iodo-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

Sodium hydroxide (9.8 g) was dissolved in water (61 ml) and ethanol (30 ml) was added. The resultant solution was added to Intermediate 11, and the mixture was heated under reflux for 60 min with stirring under nitrogen. Concentrated hydrochloric acid was added, giving a white precipitate. After stirring for 16 h, the precipitate was filtered off, washed with water and dried in vacuo to give the title compound as a white solid (8.15 g).

LC/MS R_(t) 3.01min m/z 316 [MH⁺]

Intermediate 13. 4-Chloro-6-iodo-3-quinolinecarboxamide

Intermediate 12 (8.1 g) was added portionwise to stirred thionyl chloride (60 ml). N,N-dimethylformamide (3 drops) was added and the mixture was heated under reflux with stirring under nitrogen for 1.75 h. The excess thionyl chloride was evaporated in vacuo and the residue was azeotroped with toluene (2×50 ml). The resulting pale yellow solid was added portionwise to stirred 0.880 ammonia (250 ml), and the mixture stirred at room temperature for 1.5 h. The solid was filtered off, washed with water and dried in vacuo at 60° C. for 16 h to give the title compound as a white solid (7.94 g).

LC/MS R_(t) 2.72min m/z 332 [MH⁺]

The following were made in the same manner as Intermediate 13:

Intermediate Starting LCMS LCMS Number R¹⁹— R²⁰— Material MH⁺ R_(t) (min) Intermediate 48 H— Me— 4-iodo-2- 347 3.06 methylaniline/ Aldrich Intermediate 49 H— Cl— 2-chloro-4- 367 2.99 iodoaniline/ Avocado Intermediate 72 H— Et— Intermediate 73 361 3.22 Intermediate 87 H— F— 2-Fluoro-4-iodo 352 2.65 aniline/Aldrich Intermediate 67 Cl— H— from 3-chloro-4- 367 3.07 iodoaniline/ Aldrich

Intermediate 68. 4.7-Dichloro-8-methyl-3-quinolinecarboxamide

Intermediate 68 was prepared from 2-methyl-3-chloroaniline (Aldrich) in a similar manner to Intermediate 13.

LC/MS R_(t) 3.00 min m/z 255 [MH⁺]

Intermediate 14. 6-Iodo-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

Intermediate 13 (5.0 g) was dissolved in ethanol (60 ml), 3-methoxyaniline (3.37 ml) (available from Aldrich) was added, and the mixture was heated under reflux for 2.5 h. The resulting precipitate was filtered off and washed with ether to give the title compound.

LC/MS R_(t) 2.59 min m/z 420 [MH⁺]

The following were made in the same manner as Intermediate 14, using acetonitrile as solvent:

Intermediate Number Starting LCMS LCMS (a) R¹NH— R²⁰— Material Amine/Source MH⁺ R_(t) (min) Intermediate 38 HCl

Cl— Intermediate 49 3-methylaniline/ Aldrich 438 3.56 Intermediate 35 HCl

Me— Intermediate 48 4-fluoro-3- methoxyaniline/ Apollo-Chem 452 2.78 Intermediate 36 HCl

Me— Intermediate 48 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Journal of Heterocyclic Chemistry, (1980), 17(6), 1333-5. 446 2.81 Intermediate 39 HCl

Cl— Intermediate 49 4-fluoro-3- methoxyaniline/ Apollo-Chem 472 3.29 Intermediate 40 HCl

Cl— Intermediate 49 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Journal of Heterocyclic Chemistry (1980), 17(6), 1333-5. 466 3.35 Intermediate 41 HCl

Cl— Intermediate 49 3- aminobenzonitrile/ Aldrich 449 3.19 Intermediate 42 HCl

Cl— Intermediate 49 3-fluoroaniline/ Aldrich 442 3.40 Intermediate 43 HCl

Cl— Intermediate 49 1-methyl-1H- indazol-6-amine hydrochloride/ Synthetic Communications (1996), 26(13), 2443-2447. 477 3.05 Intermediate 44 HCl

Me— Intermediate 48 1-methyl-1H- benzimidazol-6- amine/ Heterocycles (1991), 32(5), 1003-12. 458 2.03 Intermediate 45 HCl

Me— Intermediate 48 3-methoxyaniline/ Aldrich 434 2.75 Intermediate 46 HCl

Me— Intermediate 48 3- aminobenzonitrile/ Aldrich 429 2.93 Intermediate 61 HCl

Me— Intermediate 48 3-fluoroaniline/ Aldrich 422 3.02 Intermediate 74 HCl

Et— Intermediate 72 4-fluoro-3- methoxyaniline/ Apollo-Chem 466 2.92 Intermediate 75 HCl

Et— Intermediate 72 3-fluoroaniline/ Aldrich 436 3.24 Intermediate 76 HCl

Et— Intermediate 72 3-chloroaniline/ Aldrich 452 3.44 Intermediate 77 HCl

Et— Intermediate 72 3- aminobenzonitrile/ Aldrich 443 3.12 Intermediate 78 HCl

Et— Intermediate 72 3-methylaniline/ Aldrich 432 3.15 Intermediate 79 HCl

Et— Intermediate 72 1-methyl-1H- indazol-6-amine hydrochloride/ Synthetic Communications (1996), 26(13). 2443-2447 472 2.8 Intermediate 80 HCl

Et— Intermediate 72 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Joumal of Heterocyclic Chemistry (1980), 17(6), 1333-5. 460 2.97 Intermediate 88 HCl

F— Intermediate 87 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Journal of Heterocyclic Chemistry (1980), 17(6), 1333-5. 450 3.06 Intermediate 89 HCl

F— Intermediate 87 3-fluoroaniline/ Aldrich 426 3.11 Intermediate 90 HCl

F— Intermediate 87 3-chloroaniline/ Aldrich 442 3.19 Intermediate 91 HCl

F— Intermediate 87 3-methylaniline/ Aldrich 422 3.15 Intermediate 92 HCl

F— Intermediate 87 3- aminobenzonitrile/ Aldrich 433 2.88 Intermediate 93 HCl

F— Intermediate 87 1-methyl-1H- indazol-6-amine hydrochloride/ Synthetic Communications (1996), 26(13), 2443-2447 462 2.87 Intermediate 94 HCl

F— Intermediate 87 4-fluoro-3- methoxyaniline/ Apollo-Chem 456 3.11 (a) Salt form: HCl = hydrochloride

Intermediate 63. 7-Chloro-6-iodo-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

Intermediate 63 was prepared from Intermediate 67 in a similar manner to Intermediate 14, using acetonitrile as solvent.

LC/MS R_(t) 3.15 min m/z 452 [MH⁺]

Intermediate 66. 7-Chloro-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

Intermediate 66 was prepared from Intermediate 68 using 3-methoxyaniline in a similar manner to Intermediate 14.

LC/MS R_(t) 2.80 min m/z 342 [MH⁺]

Intermediate 104. 7-Chloro-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide hydrochloride

Intermediate 104 was prepared from Intermediate 68 using 2,3-dihydro-1-benzofuran-4-amine in a similar manner to Intermediate 14, using acetonitrile as solvent.

LC/MS R_(t) 2.80 min m/z 354 [MH⁺]

Intermediate 15. 3-Methyl-4-nitrophenyl phenyl sulphone

4-Fluoro-2-methyl-1-nitrobenzene (2.6 g) (available from Aldrich) and sodium benzenesulfinate (3.0 g) (available from Aldrich) were heated in N,N-dimethylacetamide (40 ml) at 50° C. for 16 h. After cooling the mixture was filtered, the filtrate collected and the solvent removed in vacuo. The residue was triturated with cyclohexane and the resultant precipitate collected by filtration to give the title compound as a white solid (3.5 g).

LC/MS R_(t) 3.22 min m/z 295 [MNH₄ ⁺]

Intermediate 18. 3-Amino-N-hydroxybenzenecarboximidamide

To a stirred solution of 3-aminobenzonitrile (4.0 g) (available from Aldrich) in ethanol (100 ml) was added hydroxylamine hydrochloride (4.7 g) and potassium carbonate (14.0 g) and the mixture heated under reflux for 22 h. After cooling to room temperature the mixture was filtered through ‘hyflo’ filter aid, the residue washed with ethanol, and the filtrates concentrated in vacuo to give the title compound as a viscous oil (5.3 g).

TLC SiO₂ (ethyl acetate) R_(f)=0.34

Intermediate 19. 3-(5-Methyl-1,2,4-oxadiazol-3-yl)aniline

To a stirred solution of Intermediate 18 (5.3 g) in dry tetrahydrofuran (50 ml) was added 4 Å molecular sieves, followed by sodium hydride (60% dispersion in mineral oil; 1.5 g) and the mixture heated at 65° C. for 30 min. After cooling to room temperature methyl acetate (2.8 ml) was added and the mixture heated under reflux for 16 h. After cooling to 20° C. the mixture was added to water (100 ml) and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulphate and concentrated in vacuo. The residue was purified by chromatography on silica gel, eluting with dichloromethane to give the title compound as a white solid (4.0 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.22

Intermediate 20. 1-[2-Amino-3-chloro-6-(methyloxy)phenyl]-2-chloroethanone

Boron trichloride (25 g) was added to dry dichloromethane (250 ml) at 0° C. and the resulting solution stirred for 10 min. A solution of 2-chloro-5-(methyloxy)aniline (30.6 g) (available from Pfaltz Bauer) in dichloromethane (100 ml) was added dropwise over 15 min to give a dark red/black mixture which was stirred for 20 min at 0° C. Chloroacetonitrile (29.5 ml) was added, followed by the portionwise addition of aluminum chloride (28.4 g). The mixture was stirred at room temperature for 1 h and then heated under reflux for 3 h. The mixture was cooled in an ice/water bath and 2M hydrochloric acid added, followed by 5M hydrochloric acid (200 ml). The resulting biphasic mixture was stirred at room temperature for 15 h and then heated at 80° C. for 30 min. After cooling to room temperature the organic layer was collected and the aqueous layer extracted with dichloromethane. The combined organic layers were washed with water, dried over sodium sulphate and concentrated in vacuo to give the title compound as a dark khaki solid (57.8 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.52

Intermediate 21. 4-Amino-5-chloro-1-benzofuran-3(2H)-one

To a stirred suspension of aluminum chloride (77.6 g) in dry dichloromethane (300 ml) was added dropwise a solution of Intermediate 20 (45 g) in dichloromethane (250 ml). The mixture was heated under reflux for 6 h and then cooled to room temperature. The mixture was decomposed by the dropwise addition of 2M hydrochloric acid, then methanol and dichloromethane were added and the organic layer collected. The aqueous layer was extracted with dichloromethane and the combined organic layers dried over sodium sulphate and concentrated in vacuo. The residue was dissolved in boiling methanol and an excess of triethylamine added. The solvent was removed in vacuo and the residue absorbed onto silica gel. Purification by chromatography on silica gel eluting with a gradient of 20% to 50% ethyl acetate in cyclohexane gave the title compound as an orange/brown solid (46.9 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.66

Intermediate 22. N-(5-Chloro-3-oxo-2,3-dihydro-1-benzofuran-4-yl)-2,2,2-trifluoroacetamide

To a stirred solution of Intermediate 21 (2 g) in dichloromethane (35 ml) at 0° C. was added triethylamine (2.1 ml) and trifluoroacetic anhydride (2.1 ml) and the mixture stirred at 0° C. for 30 min, then at room temperature for 30 min. The mixture was quenched by the dropwise addition of water, the organic layer washed with water and the combined aqueous layers re-extracted with dichloromethane. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. Purification by chromatography on silica gel, eluting with 10% ethyl acetate in cyclohexane, gave the title compound as a bright yellow/orange solid (1.0 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.69

Intermediate 23. N-(5-Chloro-3-methylidene-2,3-dihydro-1-benzofuran-4-yl)-2,2,2-trifluoroacetamide

To a mixture of potassium tert-butoxide (2.0) and methyltriphenylphosphonium iodide (7.1 g) was added dry toluene (70 ml) and the mixture stirred at room temperature for 30 min, then heated under reflux for 30 min. The mixture was cooled to room temperature, a solution of Intermediate 22 (1.0 g) in toluene (30 ml) added dropwise and the mixture heated under reflux for 30 min. The mixture was cooled and quenched by the dropwise addition of saturated ammonium chloride solution. The mixture was partitioned between ethyl acetate and water and the organic phase washed with water. The combined aqueous layers were re-extracted with ethyl acetate and the combined organic layers dried over sodium sulphate and concentrated in vacuo to give a dark brown oil. Purification by column chromatography on silica gel, eluting with 10% ethyl acetate in cyclohexane, gave the title compound as a rose coloured solid (0.5 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.50

Intermediate 24. 2,2,2-Trifluoro-N-(3-methyl-2,3-dihydro-1-benzofuran-4-yl)acetamide

A solution of Intermediate 23 (0.10 g) in ethanol (20 ml) was added to 10% palladium on carbon (0.20 g) and the mixture stirred under an atmosphere of hydrogen for 20 h. The mixture was filtered through ‘hyflo’ filter aid, washed with ethanol and the solvent removed in vacuo to give the title compound as a white solid (0.092 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.53

Intermediate 25. 3-Methyl-2,3-dihydro-1-benzofuran-4-amine

To a stirred solution of Intermediate 24 (0.087 g) in 2:2:1 tetrahydrofuran:methanol:water (5 ml) was added lithium hyroxide (0.149 g) and the mixture stirred at room temperature for 47 h, then at 60° C. for 2.5 h. The solvent was removed in vacuo and the residue partitioned between ethyl acetate and water. The aqueous layer was re-extracted with dichloromethane and the combined organic layers dried over sodium sulphate and concentrated in vacuo to give the title compound as a colourless oil (0.049 g).

TLC SiO₂ (30% ethyl acetate in cyclohexane) R_(f)=0.69

Intermediate 26. 3-(1-Methyl-1H-pyrazol-3-yl)aniline

A solution of 3-(4-bromo-1-methyl-1H-pyrazol-3-yl)aniline (1.0 g) (available from Maybridge) in ethanol (20 ml) was added to a pre-hydrogenated suspension of 5% palladium on charcoal (0.5 g) in ethanol (40 ml). The resulting suspension was stirred under an atmosphere of hydrogen for 3 h. The mixture was filtered through ‘hyflo’ filter aid and the filter pad washed with ethanol (50 ml). The combined filtrate was evaporated in vacuo to give a brown gum. This gum was treated with 2M sodium carbonate solution (100 ml) and extracted with ethyl acetate (2×100 ml); the organic layer was dried over magnesium sulphate and the solvent removed in vacuo. Purification by chromatography on silica gel, eluting with diethyl ether, gave the title compound as a white crystalline solid (0.5 g).

TLC SiO₂ (diethyl ether) R_(f)=0.28

Intermediate 27. 1.2-Dimethyl-1H-benzimidazol-6-amine

To a stirred solution of tin (II) chloride dihydrate (4.7 g) in concentrated hydrochloric acid (15 ml) was added 1,2-dimethyl-6-nitro-1H-benzimidazole (1 g) (J. Chem. Soc.,1931, 1143-1153), and the mixture was stirred at room temperature for 6 h. The mixture was poured onto ice and chloroform, and basified to pH 10 by the addition of 10M sodium hydroxide solution. The mixture was extracted several times with chloroform and the combined organic extracts dried and concentrated in vacuo to give a brown solid. This was crystallised from ethanol to give the title compound.

TLC SiO₂ (dichloromethane:methanol:880 ammonia 90:10:1) Rf 0.75.

Intermediate 28. 3-Mercapto-N,N-dimethylbenzamide

Iodine (1 g) was added to a stirred solution of 3-[(dimethylamino)carbonylbenzenesulfonyl chloride (2 g) (Borthwick et al, J. Med. Chem 2002, 45(1), 1-18) and triphenylphosphine (8.4 g) in 1,4-dioxane at 0° C. The mixture was stirred for 0.5 h at ambient temperature. The mixture was poured into a sodium sulphite solution (50 ml), extracted into ethyl acetate (2×30 ml) and washed with 2N sodium hydroxide solution (2×40 ml). The alkaline extracts were acidified and re-extracted into dichloromethane (3×50 ml). The extracts were washed with water (100 ml), dried (Na₂SO₄) and evaporated to give the title compound as a colourless solid (1.1 g).

LC/MS R_(t) 2.32 min, m/z 182 [MH⁺]

Intermediate 28. 3-Mercapto-N,N-dimethylbenzamide (alternative synthesis)

A solution of 3,3′-dithiobis(N,N-dimethylbenzamide) (Ger. Offen. (1978), DE 2821410) (54.2 g) in 1,4-dioxane (400 ml) and water (100 ml) was warmed to 35° C. and concentrated hydrochloric acid (3 ml) was added. Triphenylphosphine (55 g) was added portionwise over 25 min maintaining the temperature below 42° C., then the mixture was stirred at 40° C. for 2.5 h. After cooling to ambient temperature the mixture was concentrated to ca. 200 ml, and partitioned between 2N aqueous sodium hydroxide solution (250 ml) and ethyl acetate (500 ml). The aqueous phase was separated and washed with ethyl acetate (2×300 ml). The aqueous phase was acidified with 5N hydrochloric acid and extracted with ethyl acetate (3×400 ml). The organic extracts of the acidic aqueous phase were combined, dried over sodium sulphate, and the solvent evaporated to leave a solid. The solid was dissolved in hot ethyl acetate (100 ml) and 40-60 petrol (160 ml) was added to the hot solution. The solution was left to cool and the resulting solid filtered off, washed and dried to give the title compound (28.4 g)

LC/MS R_(t) 2.24min m/z 182 [MH⁺].

Intermediate 29. 6-({3-[(Dimethylamino)carbonyl]phenyl}thio)-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide

A stirred mixture of Intermediate 45 (0.5 g), Intermediate 28 (0.392 g), cuprous iodide (0.03 g) and potassium carbonate (0.38 g) in 1,3-dimethyltetrahydropyrimidin-2(1H)-one (7 ml) was heated at 100° C. for 16 h. The mixture was cooled, poured into water (100 ml) and extracted into ethyl acetate (3×40 ml). The extracts were washed with water (100 ml), dried (Na₂SO₄) and evaporated. The residual oil was triturated with ethyl acetate (10 ml) to give the title compound as a fawn coloured solid (0.263 g).

LC/MS R_(t) 2.67 min, m/z 487 [MH⁺]

Intermediate 37. 1,1-Dimethylethyl [(6-iodo-4-{[3-(methyloxy)phenyl]amino}-3-quinolinyl)carbonyl]carbamate

To a stirred suspension of Intermediate 14 (6.93 g) in dichloromethane (170 ml) was added N,N-dimethyl-4-aminopyridine (2.42 g) followed by di-tert-butyldicarbonate (18 g) (Aldrich). The solution was stirred at room temperature for 25 min, then quenched by addition of aqueous citric acid (200 ml) and stirred vigorously for 30 min. The organic layer was separated and the aqueous layer washed with dichloromethane (50 ml). The combined organic extracts were washed with brine (100 ml), dried over magnesium sulphate and concentrated in vacuo. The residue was trituated in diethyl ether to give a yellow solid which was collected by filtration, washed with diethyl ether (3×15 ml) and dried in vacuo to give the title compound as a yellow solid (6.6 g).

LC/MS R_(t) 3.59 min m/z 520 [MH⁺]

Intermediate 47. 6-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)thio]-4-[(3-methoxyphenyl)amino]quinoline-3-carboxamide

A stirred mixture of Intermediate 37 (0.8 g) and 4-{[tert-butyl(dimethyl)silyl]oxy} benzenethiol (0.74 g, EP465802A1), with (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.05 g), potassium tert-butoxide (0.26 g) and tris(dibenzylideneacetone) dipalladium(0) (0.08 g) in toluene (30 ml) was heated at 106° C. for 18 h. The mixture was cooled, diluted with ethyl acetate (25 ml) and washed with a sodium carbonate solution (30 ml). The organic extracts were washed with water (30 ml) , dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by chromatography on silica gel using ethyl acetate/diethyl ether (7:3) as the eluent. The appropriate fractions were concentrated in vacuo to give the title compound as a yellow foam (0.38 g).

LC/MS R_(t) 3.9 min, m/z 532 [MH⁺]

Intermediate 51. 1.1-Dimethylethyl-4-amino-1H-indazole-1-carboxylate

To a solution of 4-nitro-1H-indazole (1.57 g, Journal of Heterocyclic Chemistry 1979, 16(8), 1599-603) and di-tert-butyidicarbonate (2.33 g) in acetonitrile (30 ml) was added N,N-dimethyl-4-aminopyridine (0.059 g). The reaction mixture was stirred at room temperature for 30 min, then concentrated in vacuo to leave a brown solid which was purified by silica SPE, eluting sequentially with dichloromethane and diethyl ether to give 1,1-dimethylethyl 4-nitro-1H-indazole-1-carboxylate as a yellow solid (1.9 g).

LC/MS R_(t) 3.26 min, m/z 263 [MH⁺]

1,1-Dimethylethyl 4-nitro-1H-indazole-1-carboxylate (1.2 g) was dissolved in ethanol (150 ml) and stirred with 10% palladium on carbon (0.24 g) under an atmosphere of hydrogen (1 atmosphere pressure) for 18 h. The solution was filtered through a pad of celite and the filtrate concentrated in vacuo to give the title compound as a yellow-orange solid (1.03 g).

LC/MS R_(t) 2.36 min, m/z 234 [MH⁺]

Intermediate 52: Ethyl 3-[(3-(aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-quinolinyl)thio]propanoate

A mixture containing Intermediate 35 (1.4 g), ethyl 3-mercaptopropionate (0.74 g, available from Aldrich), potassium tert-butoxide (0.64 g), tris(dibenzylideneacetone)dipalladium(0) (0.26 g) and (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.15 g) was dissolved in N,N-dimethylformamide (20 ml) and stirred under an atmosphere of nitrogen at 100° C. for 18 h. The solvents were concentrated in vacuo and the residue dissolved in methanol. This was purified by chromatography on an SPE column eluting with methanol and a solution of ammonia in methanol, to give the title compound as a brown foam (1.06 g).

LC/MS R_(t) 2.69 min, m/z458 [MH⁺]

Similarly prepared were the following:

Intermediate Starting LCMS LCMS Number R¹NH— Material MH⁺ R_(t) (min) Intermediate 57

Intermediate 36 452 2.67 Intermediate 58

Intermediate 62 411 2.36 Intermediate 103

Intermediate 61 428 2.86

Intermediate 53: 3-[(3-(Aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-quinolinyl)thio]propanoic acid

A solution of Intermediate 52 (0.95 g) in ethanol (10 ml) was treated with 2M sodium hydroxide (10 ml) and the resulting solution was left standing at room temperature overnight. The solvent was evaporated in vacuo. The residue was dissolved in water and acidified with 2M hydrochloric acid to pH 4. The resulting precipitate was filtered off, washed with water and dried in vacuo to give the title compound as an orange solid (0.8 g).

LC/MS R_(t) 2.3 min, m/z 430 [MH⁺]

Similarly prepared were the following:

Intermediate Starting LCMS LCMS Number R¹NH— Material MH⁺ R_(t) (min) Intermediate 59

Intermediate 103 400 2.39 Intermediate 60

Intermediate 58 383 2.10

Intermediate 54. 4-{[3-(Methyloxy)phenyl]amino}6-(4-piperidinylsulfonyl)-3-quinolinecarboxamide trifluoroacetate

To a mixture containing Example 377 (0.64 g) in anisole (9 ml) was added a solution of 95% trifluoroacetic acid in water (16 ml). The mixture was stirred for 1.5 h at room temperature and was then concentrated in vacuo. The residue was co-evaporated with toluene (2×20 ml), triturated with ethyl acetate and filtered to give a yellow solid. This residue was again triturated with ethyl acetate and filtered to give the title compound as a yellow solid (0.570 g).

LC/MS R_(t) 1.94 min, m/z 455 [MH⁺]

Intermediate 55. 1,1-Dimethylethyl 4-[(3-(aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}8-methyl-6-quinolinyl)sulfonyl]-1-piperidinecarboxylate

To a solution of Intermediate 35 (1.0 g) in N,N-dimethylformamide (30 ml) under an atmosphere of nitrogen was added 1,1-dimethylethyl 4-mercapto-1-piperidinecarboxylate (0.89 g, U.S. Pat. No. 5,317,025A), potassium tert-butoxide (0.46 g), tris(dibenzylideneacetone) dipalladium(0) (0.19 g) and (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.11 g). The mixture was heated to 100° C. for 3 h, cooled and the solvent removed under reduced pressure. The residue was partitioned between ethyl acetate (100 ml) and water (100 ml) then dried over magnesium sulphate, filtered and concentrated in vacuo. The residue was purified by SPE (eluting with a gradient of 0 to 5% methanol in chloroform) to give intermediate 1,1-dimethylethyl 4-[(3-(aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-quinolinyl)thio]-1-piperidinecarboxylate as a yellow solid (1.1 g). This sulphide was dissolved in N,N-dimethylformamide (50 ml) and oxone (5.15 g) was added portionwise. The mixture was stirred at room temperature for 3 h, then quenched by addition of 1M sodium sulphite solution (500 ml). The mixture was extracted with chloroform (2×200 ml), and the organic layers were washed with 10% lithium chloride solution, dried over magnesium sulphate, filtered and concentrated to give the title compound as a pale yellow solid (0.71 g) after trituration with ether.

LC/MS R_(t) 3.04 min, m/z 573 [MH⁺]

Similarly prepared from Intermediate 35 and 1,1-dimethylethyl (2-mercaptoethyl) carbamate (available from Aldrich) was:

Intermediate 56. 1,1-Dimethylethyl {2-[(3-(aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-quinolinyl)sulfonyl]ethyl}carbamate

LC/MS R_(t) 2.79 min, m/z 533 [MH⁺]

Intermediate 62. 6-Iodo-8-methyl-4-(3-pyridinylamino)-3-quinolinecarboxamide hydrochloride

To a solution of Intermediate 48 (1.1 g) in N,N-dimethylformamide (20 ml) was added 3-aminopyridine (0.8 g, available from Aldrich) and pyridine hydrochloride (0.7 g, available from Aldrich). The mixture was heated at 80° C. under nitrogen for 2 days. The solvent was evaporated in vacuo. The residue was triturated with methanol and the precipitate filtered off to give the title compound as a brown solid (0.9 g).

LC/MS R_(t) 2.32 min m/z 405 [MH⁺].

Similarly prepared were the following:

Intermediate Number Starting Amine/ LCMS LCMS (a) (b) R¹NH— R²⁰— Material Supplier MH⁺ R_(t) (min) Intermediate 81 HCl

Et— Intermediate 72 3-pyridinamine/ Aldrich 419 2.52 Intermediate 82 HCl

Et— Intermediate 72 5-chloro-3- pyridinamine/ Synchem OHG 453 3.19 Intermediate 83 HCl

Et— Intermediate 72 5-fluoro-3- pyridinamine/ Synchem OHG 437 2.93 Intermediate 84 HCl

F— Intermediate 87 5-fluoro-3- pyridinamine/ Synchem OHG 427 2.6 Intermediate 85 HCl

F— Intermediate 87 5-chloro-3- pyridinamine/ Synchem OHG 443 2.88 Intermediate 86 HCl

F— Intermediate 87 3-pyridinamine/ Aldrich 409 2.27 96 HCl

Cl— Intermediate 49 3-pyridinamine/ Aldrich 425 2.52 97 HCl

Me— Intermediate 48 5-chloro-3- pyridinamine/ Synchem OHG 439 2.95 98 HCl

Me— Intermediate 48 5-fluoro-3- pyridinamine/ Synchem OHG 423 2.65 99 HCl

Cl— Intermediate 49 5-fluoro-3- pyridinamine/ Synchem OHG 443 2.91 100 HCl

Cl— Intermediate 49 5-chloro-3- pyridinamine/ Synchem OHG 459 2.94 101 HCl

Me— Intermediate 48 1-ethyl-1H- pyrazol-5-amine/ Aldrich 422 2.58 102 HCl

Cl— Intermediate 49 1-ethyl-1H- pyrazol-5-amine/ Aldrich 442 2.86 (a) Salt form HCl = hydrochloride (b) All products isolated by trituration with acetonitrile and filtration.

Intermediate 73. 2-Ethyl-4-iodoaniline

To a stirred solution of 2-ethylaniline (1.88 g, available from Aldrich) and sodium acetate (1.27 g) in acetic acid (20 ml) was added iodine monochloride (1 ml, available from Aldrich). The mixture was stirred at 20° C. for 90 min and then the solvent was removed in vacuo. The residue was partitioned between ethyl acetate (25 ml) and saturated aqueous sodium carbonate solution (25 ml). The organic layer was dried using a hydrophobic frit and the solvent was removed in vacuo. Purification by C18 SPE eluting with 20% acetonitrile in water gave the title compound as a purple solid (0.402 g).

LC/MS R_(t) 3.23 min, m/z 248 [MH⁺]

Intermediate 64. 7-({3-[(Dimethylamino)carbonyl]phenyl}thio)-6-iodo-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

A stirred mixture of Intermediate 63 (0.4 g), Intermediate 28 (0.16 g) and potassium carbonate (0.38 g) in 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (10 ml) was heated at 100° C. under nitrogen for 3 h. A further portion of Intermediate 28 (0.07 g) was added and the mixture stirred at 60° C. for 23 h. The cooled mixture was diluted with water (100 ml) and extracted with ethyl acetate (3×100 ml). The combined organic extracts were washed with water (2×70 ml) and brine (70 ml), dried over magnesium sulphate and concentrated in vacuo. The residue was purified by chromatography on silica gel eluting with methanol followed by mass directed preparative HPLC (Method A) to give the title compound as a yellow foam (0.12 g).

LC/MS R_(t) 2.94 min, m/z 599 [MH⁺]

Intermediate 65. 7-({3-[(Dimethylamino)carbonyl]phenyl}sulfinyl)-6-iodo-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Oxone (0.5 g) was added portionwise to a stirred solution of Intermediate 64 (0.12 g) in N,N-dimethylformamide (5 ml). The solution was stirred at room temperature under nitrogen for 21 h. More oxone (0.5 g) was added and the mixture was stirred for a further 3 h, quenched with a solution of sodium sulphite (1.5 g) in water (15 ml), diluted with water (50 ml) and extracted with ethyl acetate (3×50 ml). The combined organic extracts were dried over magnesium sulphate and concentrated in vacuo to give the title compound as a yellow solid (0.15 g).

LC/MS R_(t) 2.70 min, m/z 615 [MH⁺]

Intermediate 69. 5-Mercapto-N,N-dimethyl-3-pyridinecarboxamide

Sodium thiomethoxide (3 g) was added to a stirred solution of 5-bromo-N,N-dimethyl-3-pyridinecarboxamide (2.5g, WO2000055168) in N,N-dimethylformamide (40 ml) and the suspension stirred at 100° C. for 4 h. The solvent was concentrated in vacuo, the residue dissolved in 2M sodium hydroxide (35 ml) and water (50 ml), and the solution washed with chloroform (4×75 ml). The aqueous layer was acidified with 2M hydrochloric acid to pH 4 and extracted with chloroform (5×80 ml), and the combined organic layers were washed with brine (20 ml), dried over magnesium sulphate and concentrated in vacuo to give the title compound as an orange oil (1.8 g).

LC/MS R_(t) 0.96 min, m/z 183 [MH⁺]

Intermediate 70. 1-Methyl-4-nitro-2,3-dihydro-1H-indole

To a stirred solution of 1-methyl-4-nitro-1H-indole (3.8 g, Organic Process Research and Development 2001 5 (6) 604) and borane-tetrahydrofuran complex (1M in tetrahydrofuran, 86.3 ml) at 0° C. under an atmosphere of nitrogen was added, dropwise, trifluoroacetic acid (88 ml). The resulting mixture was allowed to warm to room temperature and stirred at room temperature for 90 min. The mixture was cautiously added to 2M sodium carbonate solution (750 ml) over 20 min and then stirred for 30 min. The mixture was extracted with ethyl acetate (2×300 ml), the combined organic extracts were dried over sodium sulphate and the solvent was removed in vacuo. Purification by column chromatography on silica gel, eluting with hexane : ethyl acetate (9:1) gave the title compound as a red solid (1.97 g).

TLC SiO₂ (hexane:ethyl acetate (4:1)) R_(f)=0.61

Intermediate 71. 1-Methyl-2,3-dihydro-1H-indol-4-amine

A solution of Intermediate 70 (0.50 g) in ethanol (30 ml) was added to 10% palladium on carbon (0.050 g) and the mixture was stirred under an atmosphere of hydrogen for 20 min. The mixture was filtered through ‘hyflo’ filter aid and the solvent removed in vacuo to give the title compound as a brown oil (0.405 g).

TLC SiO₂ (hexane:ethyl acetate (4:1)) R_(f)=0.25

EXAMPLES

Experimental details for the preparation of representative Examples are given in full below. Summary details for further Examples prepared by analagous methods are give in the accompanying tables,

Example 10 4-[(3-Fluorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Intermediate 9 (0.014 g) was suspended in acetonitrile (3 ml), 3-fluoroaniline (0.0056 g, available from Aldrich) was added, and the mixture was heated under reflux for 16 h. After cooling to room temperature, the mixture was cooled in a refrigerator for 2 h, filtered, and the residue purified by mass directed preparative HPLC (Method A) to give the title compound (0.011 g).

LC/MS R_(t) 1.95 min m/z 359 [MH⁺]

Similarly prepared were the following:

Ex. Isolation LCMS No. Starting Amine/Reagent Method LCMS R_(t) (a) R¹NH— R³SO₂— Material Source (b) MH⁺ (min) 1 HCl

MeSO₂— Intermediate 9 6-aminobenzo thiazole/ Lancaster (I) 399 1.9 2 HCl

MeSO₂— Intermediate 9 3-amino-N- methyl acetanilide/ Merlin synthesis (I) 413 1.89 3 HCl

MeSO₂— Intermediate 9 N,N-dimethyl benzene-1,3- diamine hydrochloride/ Aldrich (I) 385 1.83 4 HCl

MeSO₂— Intermediate 9 3,5- dimethoxyaniline/ Aldrich (I) 402 2.05 5 HCl

MeSO₂— Intermediate 9 1,2- benzoisoxazol- 5-amine/ Key organics Ltd (8W-0024) (I) 383 1.84 6 HCl

MeSO₂— Intermediate 9 methyl 3- amino benzoate hydrochloride/ Fluka (I) 400 1.99 7 HCl

MeSO₂— Intermediate 9 3-methylaniline hydrochloride/ TCI-JP (I) 356 2 8 HCl

MeSO₂— Intermediate 9 3-aminobenzo nitrile/ Aldrich (I) 367 2.26 9

MeSO₂— Intermediate 9 3-aminobenzyl alcohol/ Aldrich (II) 372 1.82 11

MeSO₂— Intermediate 9 1-methyl-1H- benzimidazol- 6-amine/ Heterocycles, 1991, 32(5), 1003-12. (II) 396 1.65 12

MeSO₂— Intermediate 9 3-chloro-4- fluoroaniline/ ABCR (II) 394 2.37 13 HCl

MeSO₂— Intermediate 9 aniline/ Aldrich (I) 342 2.07 15 HCl

MeSO₂— Intermediate 9 6- aminobenzoxa- zolinone/ WO 9845268 A1 (I) 399 1.99 16 HCl

MeSO₂— Intermediate 9 2,3-dihydro- 1H-inden-5- ylamine hydrochloride/ Aldrich (I) 382 2.48 17 HCl

MeSO₂— Intermediate 9 2,3-dihydro- benzodioxin-6- amine hydrochloride/ Aldrich (I) 400 2.18 18 HCl

MeSO₂— Intermediate 9 2,3-dihydro- 1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (I) 400 2.2 19 HCl

MeSO₂— Intermediate 9 1-amino- 5,6,7,8- tetrahydro napthalene/ Aldrich (I) 396 2.57 20 HCl

MeSO₂— Intermediate 9 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Journal of Heterocyclic Chemistry, 1980, 17(6), 1333-5. (I) 384 2.23 21

MeSO₂— Intermediate 9 7-amino-1,3- benzoxazol- 2(3H)-one/ Annales Universitatis Mariae Curie- Sklodowska, Sectio D: Medicine, 1980, Volume Date 1979, 35 121-8. (II) 399 1.93 22 HCl

MeSO₂— Intermediate 9 3-ethylaniline/ Aldrich (I) 370 2.33 23 HCl

MeSO₂— Intermediate 9 3- isopropylaniline/ APIN (I) 384 2.5 24 HCl

MeSO₂— Intermediate 9 3-chloro-4- methoxyaniline/ Aldrich (I) 406/408 2.2 25

MeSO₂— Intermediate 9 3- (methoxymethyl) aniline/ WO 0018721 A1 (II) 386 2.01 26 HCl

MeSO₂— Intermediate 9 2,5-dimethoxy aniline/ Aldrich (I) 402 2.37 27 HCl

MeSO₂— Intermediate 9 3- methoxyaniline/ Aldrich (I) 372 2.33 28 HCl

MeSO₂— Intermediate 9 3-hydroxy-4- methoxyaniline/ Aldrich (I) 388 2.0 29 HCl

MeSO₂— Intermediate 9 3- phenoxyaniline/ Aldrich (I) 434 2.97 30 HCl

MeSO₂— Intermediate 9 3-amino-2- methylphenol/ Aldrich (I) 372 2.2 31 HCl

MeSO₂— Intermediate 9 3-aminophenol hydrochloride/ TCI-US (I) 358 2.04 32 HCl

MeSO₂— Intermediate 9 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 390 1.92 33 HCl

MeSO₂— Intermediate 9 2-(3-amino phenoxy) ethanol hydrochloride/ J. Amer. Chem. Soc.; 1937, 59; 1716 (I) 402 1.8 34 HCl

MeSO₂— Intermediate 9 3- ethoxyaniline/ Aldrich (I) 386 2.04 35 HCl

MeSO₂— Intermediate 9 3- chloroaniline/ Aldrich (I) 376 2.09 36 HCl

MeSO₂— Intermediate 9 [3-(2-methoxy ethoxy)phenyl] amine hydrochloride/ EP 388165 A2 (I) 416 1.94 37 HCl

MeSO₂— Intermediate 9 4- methoxyaniline/ Aldrich (I) 372 1.88 38 HCl

MeSO₂— Intermediate 9 3,4-dimethoxy aniline/ Aldrich (I) 402 1.84 39

PhSO₂— Intermediate 8 3- ethoxyaniline/ Aldrich (II) 448 2.55 40

PhSO₂— Intermediate 8 [3-(2-methoxy ethoxy)phenyl] amine hydrochloride/ EP 388165 A2 (II) 478 1.42 41

PhSO₂— Intermediate 8 3-amino-N- methyl benzamide/ TCI-US (II) 461 2.37 42

PhSO₂— Intermediate 8 4-aminophenol hydrochloride/ Aldrich (II) 420 2.46 43 HCl

PhSO₂— Intermediate 8 6- aminobenzothia- zole/ Lancaster (I) 461 2.67 44 HCl

PhSO₂— Intermediate 8 N-(3- aminophenyl)- N-methyl acetamide/ Merlin Synthesis (I) 475 2.58 45 HCl

PhSO₂— Intermediate 8 1-methyl-1H- benzimidazol- 6-amine/ Gwyn Ellis Heterocycles, 1991, 32(5), 1003- 12. (I) 458 2.24 46 HCl

PhSO₂— Intermediate 8 3,5-dimethoxy aniline/ Aldrich (I) 464 2.89 47 HCl

PhSO₂— Intermediate 8 methyl 3- amino benzoate hydrochloride/ Fluka (I) 462 2.86 48 HCl

PhSO₂— Intermediate 8 4-(2- morphalin-4- ylethoxy) aniline EP 410358 A1 (I) 533 2.1 49 HCl

PhSO₂— Intermediate 8 3-fluoroaniline/ Aldrich (I) 422 2.96 50 HCl

PhSO₂— Intermediate 8 3-chloro-4- fluoroaniline/ Aldrich (I) 456 3.12 51 HCl

PhSO₂— Intermediate 8 3-methylaniline hydrochloride/ TCI-US (I) 418 2.87 52 HCl

PhSO₂— Intermediate 8 3-amino benzonitrile/ Aldrich (I) 429 2.91 53

PhSO₂— Intermediate 8 N-(4- aminophenyl) morpholine-4- carboxamide/ Peakdale Molecular Ltd (II) 532 2.34 54

PhSO₂— Intermediate 8 N,N-dimethyl benzene-1,3- diamine hydrochloride/ Aldrich (II) 447 2.75 55

PhSO₂— Intermediate 8 N-(3- aminophenyl) acetamide hydrochloride/ Acros Chimica (II) 461 2.4 56

PhSO₂— Intermediate 8 3-aminobenzyl alcohol/ Aldrich (II) 434 2.34 57 HCl

PhSO₂— Intermediate 8 aniline/ Aldrich (I) 404 2.73 58 HCl

PhSO₂— Intermediate 8 1-acetylindolin- 5-amine/ Maybridge (I) 487 2.52 59 HCl

PhSO₂— Intermediate 8 6-amino-1,3- benzoxazol- 2(3H)-one/ WO 9845268 A1 (I) 461 2.48 60 HCl

PhSO₂— Intermediate 8 1-acetyl-6- aminoindoline/ SIGMA (I) 487 2.55 61 HCl

PhSO₂— Intermediate 8 6-amino-2,3- dihydro-1H inden-1-one/ J. Med. Chem. 2003, 46(3), 399-408. (I) 458 2.67 62 HCl

PhSO₂— Intermediate 8 6-amino- 1,2,3,4- tetrahydro naphthalen-1- one/ Maybridge (I) 472 2.93 63 HCl

PhSO₂— Intermediate 8 2,3-dihydro- 1,4- benzodioxin-6- amine hydrochloride/ Aldrich (I) 462 2.69 64 HCl

PhSO₂— Intermediate 8 1-amino- 5,6,7,8- tetrahydro napthalene/ Aldrich (I) 458 3.07 65 HCl

PhSO₂— Intermediate 8 7-amino-1,3- benzoxazol- 2(3H)-one/ Medicine 1980, Volume Date 1979, 35, 121-8. (I) 461 2.64 66 HCl

PhSO₂— Intermediate 8 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ Journal of Heterocyclic Chemistry 1980, 17(6), 1333-5. (I) 446 2.84 67

PhSO₂— Intermediate 8 2,3-dihydro- 1H-inden-5- amine hydrochloride/ Aldrich (II) 444 2.95 68

PhSO₂— Intermediate 8 2,3-dihydro- 1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (II) 462 2.69 69 HCl

PhSO₂— Intermediate 8 3-ethylaniline/ Aldrich (I) 432 2.92 70 HCl

PhSO₂— Intermediate 8 3-isopropyl aniline/ APIN (I) 446 3.04 71 HCl

PhSO₂— Intermediate 8 3-chloro-4- methoxyaniline/ Aldrich (I) 468 2.76 72 HCl

PhSO₂— Intermediate 8 8-amino-3,4- dihydro-1(2H)- naphthalenone/ WO 0160826 A2 (I) 472 2.86 73

PhSO₂— Intermediate 8 3- [(methyloxy) methyl]aniline/ WO 0018721 A1 (II) 448 2.60 74 HCl

PhSO₂— Intermediate 8 3-(methyloxy) aniline/ Aldrich (I) 434 2.77 75 HCl

PhSO₂— Intermediate 8 2-[(3- aminophenyl) oxy]ethanol hydrochloride/ J. Amer. Chem. Soc.; 1937, 59, 1716 (I) 464 2.21 76 HCl

PhSO₂— Intermediate 8 4-amino-N- methyl benzamide/ Buttpark (I) 461 2.2 77

PhSO₂— Intermediate 8 3-amino-2- methylphenol/ Aldrich (II) 434 2.57 78 HCl

PhSO₂— Intermediate 8 4- methoxyaniline hydrochloride/ Acros (I) 434 2.32 79 HCl

PhSO₂— Intermediate 8 3-[(trifluoro methyl)oxy] aniline/ Aldrich (I) 487 2.8 80

PhSO₂— Intermediate 8 3-(4- morpholinyl) aniline/ Journal of Organic Chemistry 2002, 67(9), 3029-3036. (II) 489 2.72 81

PhSO₂— Intermediate 8 3-aminophenol hydrochloride/ TCI-US (II) 420 2.6 82

PhSO₂— Intermediate 8 [3,4- bis(methyloxy) phenyl]amine hydrochloride/ Aldrich (II) 463 2.58 83 HCl

Intermediate 7 6-aminobenzo thiazole/ Lancaster (I) 453 2.3 84 HCl

Intermediate 7 N-(3- aminophenyl)- N-methyl acetamide/ Merlin synthesis (I) 467 2.29 85 HCl

Intermediate 7 N-(4- aminophenyl)- 4-morpholine carboxamide/ Peakdale molecular Ltd (I) 524 2.21 86 HCl

Intermediate 7 3,5-dimethoxy aniline/ Aldrich (I) 456 2.51 87 HCl

Intermediate 7 methyl 3- amino benzoate hydrochloride/ Fluka (I) 454 2.48 88 HCl

Intermediate 7 3-amino-N- methyl benzamide/ TCI-US (I) 453 2.17 89 HCl

Intermediate 7 3-fluoroanillne/ Aldrich (I) 414 2.53 90 HCl

Intermediate 7 3-chloro-4- fluoroaniline/ Aldrich (I) 448 2.72 91 HCl

Intermediate 7 (3- methylphenyl) amine hydrochloride/ TCI-US (I) 410 2.49 92

Intermediate 7 N,N-dimethyl- 1,3-benzene diamine hydrochloride/ Aldrich (II) 439 2.62 93

Intermediate 7 N-(3- aminophenyl) acetamide hydrochloride/ Acros (II) 453 2.25 94

Intermediate 7 2- chloroaniline/ Aldrich (II) 430 2.69 95 HCl

Intermediate 7 aniline/Aldrich (I) 396 2.58 96 HCl

Intermediate 7 1-methyl-1H- benzlmidazol- 6-amine/ Heterocycles 1991, 32(5), 1003- 12. (I) 450 2.04 97 HCl

Intermediate 7 3-ethylaniline/ Aldrich (I) 424 2.81 98 HCl

Intermediate 7 3-isopropyl aniline/ TCI-US (I) 438 3.0 99 HCl

Intermediate 7 3-methoxy aniline/ Aldrich (I) 426 2.58 100

PhSO₂— Intermediate 8 3- aminopyridine/ Aldrich (II) 405 2.41 145 HCl

MeSO₂— Intermediate 9 4-fluoro-3- methylaniline/ Aldrich (I) 396 1.77 146 TFA

MeSO₂— Intermediate 9 5-amino-2- methyl benzofuran hydrochloride/ Aldrich (III) 396 2.43 147 TFA

MeSO₂— Intermediate 9 1-methyl-1H- indazol-6- amine hydrochloride/ Synthetic Communications, 1996, 26(13), 2443- 2447. (III) 396 2.15 148 TFA

MeSO₂— Intermediate 9 1-methyl-1H- indazole-5- amine/ Bionet Research Ltd (III) 396 2.06 149 TFA

MeSO₂— Intermediate 9 1- (phenylmethyl)- 1H-indazol-5- amine/ WO 0283654 A1 (III) 472 2.56 150 HCl

MeSO₂— Intermediate 9 3-(trifluoro methyl)aniline/ Aldrich (I) 410 2.05 151 HCl

MeSO₂— Intermediate 9 1-(3- aminophenyl) ethanone/ Aldrich (I) 384 1.71 152 HCl

MeSO₂— Intermediate 9 3-(5-methyl- 1,2,4- oxadiazol-3- yl)aniline/ Intermediate 19 (I) 424 1.88 153 HCl

MeSO₂— Intermediate 9 1-(3- aminophenyl)- N,N-dimethyl methane sulfonamide/ Peakdale molecular Ltd (I) 463 1.78 154 HCl

MeSO₂— Intermediate 9 3-(3- thienyl)aniline/ U.S. Pat. No. 6,211,220 B1 (I) 424 2.15 155 HCl

MeSO₂— Intermediate 9 3-methyl-2,3- dihydro-1- benzofuran-4- amine/ Intermediate 25 (I) 398 1.91 156

MeSO₂— Intermediate 9 4-amino-2- methyl-1H- isoindole- 1,3(2H)-dione/ Archiv der Pharmazie (Weinheim, Germany) 1989, 322(7), 419-26. (II) 425 2.35 157 TFA

PhSO₂— Intermediate 8 1,2- benzisoxazol- 5-amine/ Key organics Ltd (III) 445 2.61 158 TFA

PhSO₂— Intermediate 8 1,2-dimethyl- 1H- benzimidazol- 6-amine/ Intermediate 27 (III) 472 2.15 159 TFA

PhSO₂— Intermediate 8 3,5- dichloroaniline/ Aldrich (III) 472 3.35 160 TFA

PhSO₂— Intermediate 8 2-methyl-1,3- benzoxazol-5- amine/ Collection of Czechoslovak Chemical Communications 1996, 61(3), 371-380. (III) 459 2.33 161 TFA

PhSO₂— Intermediate 8 4-chloro-3- methoxyaniline/ Wychem (III) 468 3.08 162 TFA

PhSO₂— Intermediate 8 5-amino-2- methyl benzofuran hydrochloride/ Sigma Aldrich (III) 458 2.92 163 TFA

PhSO₂— Intermediate 8 1-methyl-1H- indazol-6- amine hydrochloride/ Heterocycles, 1995, 41(3), 487-96. (III) 458 2.67 164 TFA

PhSO₂— Intermediate 8 5-fluoro-2- methoxyaniline/ Wychem (III) 452 2.92 165 TFA

PhSO₂— Intermediate 8 1-methyl-1H- indazol-5- amine/ Bionet Research Ltd (III) 458 2.51 166 TFA

PhSO₂— Intermediate 8 1- (phenylmethyl)- 1H-indazol-5- amine/ WO 0283654 A1 (III) 534 2.97 167 TFA

PhSO₂— Intermediate 8 4-amino-2- (methyloxy) phenol hydrochloride/ Journal of Chemical Research, Synopses 1988, (9), 284-5. (III) 450 2.42 168 TFA

PhSO₂— Intermediate 8 3-fluoro-4- methylaniline/ Aldrich (III) 436 3.04 169 TFA

PhSO₂— Intermediate 8 2-methyl-1,3- benzothiazol- 6-amine/ AsInEx Compound Collection (III) 475 2.73 170 TFA

PhSO₂— Intermediate 8 1H-indol-6- amine/ Lancaster Synthesis (III) 443 2.7 171 TFA

PhSO₂— Intermediate 8 3-chloro-5- (methyloxy) aniline/ J. Chem. Soc. Perkin 2, 1977, 14. (III) 468 3.17 172 HCl

PhSO₂— Intermediate 8 3-(2-methyl-4- pyrimidinyl) aniline/ Fluorochem (I) 496 2.23 173 HCl

PhSO₂— Intermediate 8 3-(trifluoro methyl)aniline/ Aldrich (I) 472 2.62 174 HCl

PhSO₂— Intermediate 8 1-(3- aminophenyl) ethanone/ Aldrich (I) 446 2.2 175 HCl

PhSO₂— Intermediate 8 3-(1,3-oxazol- 5-yl)aniline/ Fluorochem (I) 471 2.24 176 HCl

PhSO₂— Intermediate 8 3-(1-methyl- 1H-pyrazol-3- yl)aniline/ Intermediate 26 (I) 484 2.27 177 HCl

PhSO₂— Intermediate 8 3-(5-methyl- 1,2,4- oxadiazol-3- yl)aniline/ Intermediate 19 (I) 486 2.34 178 HCl

PhSO₂— Intermediate 8 1-(3- aminophenyl)- N,N-dimethyl methane sulfonamide/ Peakdale molecular Ltd (I) 525 2.23 179 HCl

PhSO₂— Intermediate 8 3-(3- thienyl)aniline/ U.S. Pat. No. 6,211,220 B1 (I) 486 2.55 180 HCl

PhSO₂— Intermediate 8 3-methyl-2,3- dihydro-1- benzofuran-4- amine/ Intermediate 25 (I) 460 2.36 181 HCl

PhSO₂— Intermediate 8 2,2-dimethyl- 2,3-dihydro-1- benzofuran-7- amine/ DE 3526510 A1 (I) 474 2.34 182

PhSO₂— Intermediate 8 4-amino-2- methyl-1H- isoindole- 1,3(2H)-dione/ Archiv der Pharmazie (Weinheim, Germany) 1989, 322(7), 419-26. (II) 487 2.85 183

PhSO₂— Intermediate 8 [4-(methyloxy)- 2- naphthalenyl] amine 4- methyl benzene sulfonate/ Sigma (I) 484 3.19 590 HCl

Intermediate 95 5-chloro-3- pyridinamine/ Synchem OHG (I) 419 2.44 589 HCl

Intermediate 95 3-pyridinamine Aldrich (I) 385 1.96 (a) Salt forms: HCl = hydrochloride TFA = trifluoroacetate (b) Isolation Method: (I) Filtered off directly from the reaction mixture. (II) Mass Directed preparative HPLC Method A. (III) Mass Directed preparative HPLC Method B.

The following compounds were prepared by a similar method to Example 10:

Ex. Isolation LCMS No. Starting Amine Reagent/ Method LCMS R_(t) (a) R¹NH— R³SO₂— R²⁰— Material Source (b) MH⁺ (min) 187 HCl

MeSO₂— H— Intermediate 9 1,1-dimethylethyl (3-aminophenyl) carbamate/ J. Med. Chem. 2003, 46(9) 1661- 1669 (I) 457 2.47 188 HCl

MeSO₂— H— Intermediate 9 1,1-dimethylethyl [(3-aminophenyl) methyl]carbamate/ J. Med. Chem. 2003, 46(9) 1661- 1669 (I) 471 2.39 189

MeSO₂— H— Intermediate 9 1,3-benzodioxol- 5-amine/ Aldrich (II) 386 1.98 190 HCl

MeSO₂— H— Intermediate 9 3-(1,3-oxazol-5- yl)aniline/ Maybridge (I) 409 1.82 191 HCl

MeSO₂— H— Intermediate 9 3-(3- aminophenyl)-1- methyl-1H- pyrazole/ Buttpark (I) 422 1.88 192 HCl

MeSO₂— H— Intermediate 9 3-chloro-2- fluoroaniline/ Aldrich (I) 394 2.46 193 HCl

MeSO₂— H— Intermediate 9 2,3-difluoroaniline/ Aldrich (I) 378 2.3 194 HCl

MeSO₂— H— Intermediate 9 3- aminobenzonitrile/ Aldrich (I) 367 2.07 195 HCl

MeSO₂— H— Intermediate 9 5-amino-2- fluorobenzonitrile/ Maybridge (I) 385 2.15 196 HCl

MeSO₂— H— Intermediate 9 3- isopropoxyaniline/ Maybridge (I) 400 2.35 197 HCl

MeSO₂— H— Intermediate 9 2-amino-5- fluorotoluene/ Aldrich (I) 374 2.2 198 HCl

MeSO₂— H— Intermediate 9 3,4-difluoroaniline/ Aldrich (I) 378 2.26 199 HCl

MeSO₂— H— Intermediate 9 4-fluoro-3- (trifluoromethyl) aniline/Avocado (I) 428 2.61 200 HCl

MeSO₂— H— Intermediate 9 2-fluoroaniline/ Aldrich (I) 360 2.04 201 HCl

MeSO₂— H— Intermediate 9 2,4-difluoroaniline/ Aldrich (I) 378 2.22 202 HCl

MeSO₂— H— Intermediate 9 2-chloro-4- fluoroaniline/ Aldrich (I) 394 2.43 203 HCl

MeSO₂— H— Intermediate 9 3-aminopyridine/ Aldrich (IV) 343 1.69 204 HCl

MeSO₂— H— Intermediate 9 4-aminobenzoic acid/Aldrich (I) 386 2 205 TFA

MeSO₂— H— Intermediate 9 4-chloro-3- methoxyaniline/ Wychem (III) 406 2.49 206 TFA

MeSO₂— H— Intermediate 9 1-methyl-1H- benzimidazol-6- amine/ Heterocycles. 1991, 32(5), 1003-12. (III) 396 1.77 207 TFA

MeSO₂— H— Intermediate 9 6-(methyloxy)- 1,3-benzothiazol- 4-amine J. Am. Chem. Soc, 1939, 61(8), 2013-2017. (III) 429 2.35 208 TFA

MeSO₂— H— Intermediate 9 3-fluoro-5-(3- pyridinyl)aniline J. Med. Chem. 2000, 43(6), 1123-1134. (III) 437 2.34 209 TFA

MeSO₂— H— Intermediate 9 5-fluoro-2- methoxyaniline/ Wychem (III) 390 2.3 210 TFA

MeSO₂— H— Intermediate 9 1-methyl-1H- 1,2,3- benzotriazol-5- amine/US 2003060453 A1 (III) 397 1.98 211 TFA

MeSO₂— H— Intermediate 9 3,5-dlfluoroaniline/ Aldrich (III) 378 2.51 212 TFA

MeSO₂— H— Intermediate 9 3-fluoro-4- methylaniline/ Aldrich (III) 374 2.43 213 TFA

MeSO₂— H— Intermediate 9 4-amino-2- fluorophenol/ Apollo (III) 376 2.01 214 TFA

MeSO₂— H— Intermediate 9 4-(methyloxy)-2- naphthalenamine/ Sigma (III) 422 2.73 215 TFA

MeSO₂— H— Intermediate 9 6-aminoindole/ Lancaster (III) 381 2.25 216 TFA

MeSO₂— H— Intermediate 9 methyl 4-amino- 2-methoxy benzoate/ Avocado (III) 430 2.36 217 HCl

MeSO₂— H— Intermediate 9 1,3-benzodioxol- 4-amine J. Med. Chem. 1979, 22(11), 1354-7. (I) 386 2.06 218 HCl

PhSO₂— H— Intermediate 8 3- aminobenzonitrile/ Aldrich (I) 429 2.80 219

PhSO₂— H— Intermediate 8 1,3-benzodioxol- 5-amine/Aldrich (II) 448 2.63 220

PhSO₂— H— Intermediate 8 3-amino-N,N- dimethylbenzene sulfonamide/WO 9737646 A1 (II) 511 2.94 221

PhSO₂— H— Intermediate 8 3-aminobenzene sulfonamide/ Fluka (II) 483 2.6 222

PhSO₂— H— Intermediate 8 4-amino-N- methylbenzene- sulfonamide/ Zelinsky BB (II) 497 2.51 223 TFA

PhSO₂— H— Intermediate 8 6-(methyloxy)- 1,3-benzothiazol- 4-amine J. Am. Chem. Soc., 1939, 61(8), 2013- 2017. (III) 491 2.92 224 TFA

PhSO₂— H— Intermediate 8 3-fluoro-5-(3- pyridinyl)aniline/ J. Med. Chem., 2000, 43(6), 1123-1134. (III) 499 2.89 225 TFA

PhSO₂— H— Intermediate 8 Intermediate 51 (III) 444 3.21 226 TFA

PhSO₂— H— Intermediate 8 3,5-difluoroaniline/ Aldrich (III) 440 3.12 227 TFA

PhSO₂— H— Intermediate 8 4-amino-2- fluorophenol/ Apollo (III) 438 2.56 228 TFA

PhSO₂— H— Intermediate 8 3,4-difluoroaniline/ Aldrich (III) 440 3.03 229 TFA

PhSO₂— H— Intermediate 8 methyl 4-amino- 2-methoxy benzoate/ Avocado (III) 492 2.89 230 HCl

PhSO₂— Me— Intermediate 16 2-(3- aminophenoxy) ethanol/Key Organics Ltd. (I) 478 2.22 231 HCl

PhSO₂— Me— Intermediate 16 3- aminothiophene- 2-carboxylic acid methyl ester/ Avocado (I) 482 2.79 232 HCl

PhSO₂— Me— Intermediate 16 5-amino-2- methoxyphenol/ Aldrich (I) 464 2.1 233 HCl

PhSO₂— Me— Intermediate 16 5-aminotetralin/ Aldrich (I) 472 2.64 234 HCl

PhSO₂— Me— Intermediate 16 ethyl 3- aminobenzoate/ Aldrich (I) 490 2.66 235 HCl

PhSO₂— Me— Intermediate 16 5-amino-2- methylphenol/ TCI America (I) 448 2.31 236 HCl

PhSO₂— Me— Intermediate 16 1-dimethylethyl [(3-aminophenyl) methyl]carbamate/ J. Med. Chem., 2003, 46(9), 1661-1669. (I) 547 2.64 237 HCl

PhSO₂— Me— Intermediate 16 4-amino-N- methylbenzamide/ Buttpark (I) 475 2.27 238 HCl

PhSO₂— Me— Intermediate 16 3-aminobenzyl alcohol/Aldrich (I) 448 2.13 239 TFA

PhSO₂— Me— Intermediate 16 3-aminobenzoyl methylamide/ Buttpark (III) 475 2.55 240 TFA

PhSO₂— Me— Intermediate 16 3-aminophenol/ Aldrich (III) 434 2.64 241 TFA

PhSO₂— Me— Intermediate 16 5-amino-1- ethylpyrazole/ Aldrich (III) 436 2.75 242 TFA

PhSO₂— Me— Intermediate 16 3-cyano-4- fluoroaniline hydrochloride/ Combiblocks (III) 461 3.04 243 TFA

PhSO₂— Me— Intermediate 16 1-acetyl-6- aminoindoline/ Sigma (III) 501 2.59 244 HCl

iPrSO₂— H— Intermediate 30 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ J. Heterocyclic Chem., 1980, 17(6), 1333-5. (I) 412 2.36 245 HCl

iPrSO₂— H— Intermediate 30 3-amino- acetophenone/ Aldrich (I) 412 2.33 246 HCl

iPrSO₂— H— Intermediate 30 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996. 26(13), 2443-2447. (I) 424 2.22 247 HCl

iPrSO₂— H— Intermediate 30 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 418 2.38 248 HCl

iPrSO₂— H— Intermediate 30 2,3-dihydro-1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (I) 428 2.30 249 HCl

iPrSO₂— H— Intermediate 30 3-chloroaniline/ Aldrich (I) 404 2.64 250 HCl

iPrSO₂— H— Intermediate 30 3- aminobenzonitrile/ Aldrich (I) 395 2.40 251 HCl

iPrSO₂— H— Intermediate 30 3-methylaniline hydrochloride/ TCI-US (I) 384 2.41 252 HCl

iPrSO₂— H— Intermediate 30 3-aminopyridine/ Aldrich (I) 371 1.92 253 HCl

iPrSO₂— H— Intermediate 30 6-aminobenzo thiazole/ Lancaster (I) 427 2.20 254 HCl

H— Intermediate 31 3-iodoaniline/ Aldrich (I) 560 3.06 255 HCl

H— Intermediate 31 3-amino- acetophenone/ Aldrich (I) 476 2.68 256 HCl

H— Intermediate 31 1-methyl-1H- benzimidazol-6- amine/ Heterocycles, 1991, 32(5), 1003-12. (I) 488 2.17 257 HCl

H— Intermediate 31 2,3-dihydro-1- benzofuran-4- amine hydmbromide/ J. Heterocyclic Chem., 1980, 17(6), 1333-5. (I) 476 2.76 258 HCl

H— Intermediate 31 3-fluoroaniline/ Aldrich (I) 452 2.89 259 HCl

H— Intermediate 31 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 482 2.78 260 HCl

H— Intermediate 31 6-aminobenzo thiazole/ Lancaster (I) 491 2.61 261 HCl

H— Intermediate 31 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996, 26(13), 2443-2447. (I) 488 2.62 262 HCl

H— Intermediate 31 3- aminobenzonitrile/ Aldrich (I) 459 2.86 263 HCl

H— Intermediate 31 3-chloroaniline/ Aldrich (I) 468 3.02 264 HCl

H— Intermediate 31 3-methylaniline hydrochlorlde/ TCI-US (I) 448 2.78 265

Me— Intermediate 32 3-methoxyaniline/ Aldrich (II) 478 3.04 266 TFA

Me— Intermediate 32 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ J. Heterocyclic Chem., 1980, 17(6). 1333-5. (III) 490 2.45 267 TFA

Me— Intermediate 32 3-amino- acetophenone/ Aldrich (III) 490 2.41 268 TFA

Me— Intermediate 32 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996, 26(13), 2443-2447. (III) 502 2.36 269 TFA

Me— Intermediate 32 2,3-dihydro-1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (III) 506 2.36 270 TFA

Me— Intermediate 32 3-chloroaniline/ Aldrich (III) 482 2.72 271 TFA

Me— Intermediate 32 3- aminobenzonitrile/ Aldrich (III) 473 2.62 272 TFA

Me— Intermediate 32 6-aminobenzo thiazole/ Lancaster (III) 505 2.36 273 TFA

Me— Intermediate 32 3-fluoroaniline/ Aldrich (III) 466 2.6 274 HCl

H— Intermediate 31 2-(3- aminophenoxy) ethanol hydrochloride/ J. Am. Chem. Soc., 1937, 59; 1716 (I) 494 2.15 275 HCl

H— Intermediate 31 3-aminophenol/ Aldrich (I) 450 2.15 276 HCl

H— Intermediate 31 ethyl 3- aminobenzoate/ Aldrich (I) 506 2.51 277 HCl

H— Intermediate 31 5-amino-2- methylphenol/ TCI America (I) 464 2.27 278 HCl

H— Intermediate 31 4-amino-N- methylbenzamide/ Buttpark (I) 491 2.16 279 HCl

H— Intermediate 31 3-aminobenzyl- alcohol/Aldrich (I) 464 2.07 280 TFA

H— Intermediate 31 methyl 3- aminothiophene- 2-carboxylate/ Avocado (III) 498 2.95 281 TFA

H— Intermediate 31 5-amino-2- methoxyphenol/ Aldrich (III) 480 2.37 282 TFA

H— Intermediate 31 3-amino-N- methylbenzamide/ Buttpark (III) 491 2.43 283 TFA

H— Intermediate 31 1-amino-5,6,7,8- tetrahydro napthalene/ Aldrich (III) 488 2.96 284 TFA

H— Intermediate 31 4-amino-2- methoxyphenol/ WO 2003049702 A2 (III) 480 2.34 285 TFA

Me— Intermediate 34 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ J. Heterocyclic Chem., 1980, 17(6), 1333-5. (III) 474 2.53 286 TFA

Me— Intermediate 34 3-amino- acetophenone/ Aldrich (III) 474 2.49 287 TFA

Me— Intermediate 34 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996, 26(13), 2443-2447. (III) 486 2.41 288 TFA

Me— Intermediate 34 2,3-dihydro-1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (III) 490 2.43 289 TFA

Me— Intermediate 34 3-chloroaniline/ Aldrich (III) 466 2.82 290 TFA

Me— Intermediate 34 3-fluoroaniline/ Aldrich (III) 450 2.70 291 TFA

Me— Intermediate 34 3- aminobenzonitrile/ Aldrich (III) 457 2.71 292 TFA

Me— Intermediate 34 3-methoxyaniline/ Aldrich (III) 462 2.51 293 HCl

MeSO₂— Me— Intermediate 33 3-methoxyaniline/ Aldrich (I) 386 2.20 294 HCl

MeSO₂— Me— Intermediate 33 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 404 2.23 295 HCl

MeSO₂— MeO— Intermediate 50 3-methoxyaniline/ Aldrich (I) 402 2.09 296 HCl

MeSO₂— MeO— Intermediate 50 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 420 2.12 297 HCl

PhSO₂— Me— Intermediate 16 3-amino- acetophenone/ Aldrich (I) 460 2.82 298 HCl

PhSO₂— Me— Intermediate 16 1-methyl-1H- benzimidazol-6- amine/ Heterocycles, 1991, 32(5), 1003-12. (I) 472 2.24 299 HCl

PhSO₂— Me— Intermediate 16 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ J. Heterocyclic Chem., 1980, 17(6), 1333-5. (I) 460 2.90 300 HCl

PhSO₂— Me— Intermediate 16 3-fluoroaniline/ Aldrich (I) 436 3.07 301 TFA

PhSO₂— Me— Intermediate 16 2,3-dihydro-1,4- benzodioxin-5- amine hydrochloride/ WO 9703067 A1 (III) 476 2.77 302 HCl

PhSO₂— Me— Intermediate 16 6-aminobenzo thiazole/ Lancaster (I) 475 2.75 303 HCl

PhSO₂— Me— Intermediate 16 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996, 26(13), 2443-2447. (I) 472 2.74 304 HCl

PhSO₂— Me— Intermediate 16 3- aminobenzonitrile/ Aldrich (I) 443 3.01 305 HCl

PhSO₂— Me— Intermediate 16 3-chloroaniline/ Aldrich (I) 452 3.21 306 HCl

PhSO₂— Me— Intermediate 16 3-methylaniline/ Aldrich (I) 432 2.93 307 HCl

MeSO₂— Me— Intermediate 33 2,3-dihydro-1- benzofuran-4- amine hydrobromide/ J. Heterocyclic Chem., 1980, 17(6), 1333-5. (I) 398 2.38 308 TFA

MeSO₂— Me— Intermediate 33 3-aminopyridine/ Aldrich (III) 357 1.95 309 HCl

MeSO₂— Me— Intermediate 33 1-methyl-1H- indazol-6-amine hydrochloride/ Synth. Comm., 1996, 26(13), 2443-2447. (I) 410 2.28 310 HCl

MeSO₂— Me— Intermediate 33 3-chloroaniline/ Aldrich (I) 390 2.68 311 HCl

MeSO₂— Me— Intermediate 33 3-fluoroaniline/ Aldrich (I) 374 2.49 312 HCl

MeSO₂— Me— Intermediate 33 3- aminobenzonitrile/ Aldrich (I) 381 2.44 313 HCl

MeSO₂— Me— Intermediate 33 1-methyl-1H- benzimidazol-6- amine/ Heterocycles, 1991, 32(5), 1003-12. (I) 410 1.87 314 HCl

MeSO₂— Me— Intermediate 33 3-methylaniline/ Aldrich (I) 370 2.40 315 HCl

MeSO₂— Me— Intermediate 33 1-ethyl-1H- pyrazol-5-amine/ Aldrich (I) 374 2.22 316 HCl

MeSO₂— Me— Intermediate 33 5-(methyloxy)-3- pyridinamine/ Australian J. Chem., 1981, 34(4). 927-32 (I) 387 2.08 317 HCl

MeSO₂— Me— Intermediate 33 5-methyl-3- pyridinamine/ Synchem (I) 371 1.90 318 HCl

MeSO₂— Me— Intermediate 33 5-amino-2- fluorobenzonitrile/ Matrix Scientific (I) 399 2.38 329 HCl

PhSO₂— Me— Intermediate 16 2-methoxybenzyl amine/Aldrich (I) 462 2.26 479 HCl

MeSO₂— Me— Intermediate 33 1-methyl-1H- pyrazol-5-amine/ Apollo Chem (IV) 360 2.09 496 HCl

MeSO₂— Me— Intermediate 33 1,3-benzodioxol- 4-amine/J. Med. Chem., 2002, 45(19), 4128- 4139 (I) 400 2.22 497 HCl

MeSO₂— Me— Intermediate 33 4-fluoro-3- methylaniline/ Fluoro Chem (I) 388 2.35 498 HCl

MeSO₂— Me— Intermediate 33 3-chloro-4- fluoroaniline/ Aldrich (IV) 408 2.59 499 HCl

MeSO₂— Me— Intermediate 33 5,6,7,8- tetrahydro-1- naphthalenamine/ Fluka (I) 410 2.57 500 HCl

MeSO₂— Me— Intermediate 33 2,3-difluoroaniline/ Aldrich (IV) 392 2.52 501 HCl

MeSO₂— Me— Intermediate 33 3-chloro-2- fluoroaniline/ Aldrich (I) 408 2.67 502 HCl

MeSO₂— Me— Intermediate 33 3,5-difluoroaniline Aldrich (I) 392 2.60 503 HCl

MeSO₂— Me— Intermediate 33 1,3-benzothiazol- 6-amine/ Maybridge (I) 413 2.13 504 HCl

MeSO₂— Me— Intermediate 33 3,4-difluoroaniline/ Aldrich (I) 392 2.43 505 HCl

MeSO₂— Me— Intermediate 33 2,4-difluoroaniline/ Aldrich (I) 392 2.33 508 HCl

MeSO₂— Me— Intermediate 33 1-methyl-2,3- dihydro-1H-indol- 4-amine/ Intermediate 71 (IV) 411 2.2 509 HCl

MeSO₂— Me— Intermediate 33 1-methyl-1H- indazol-4-amine/ J. Med. Chem., 2002, 45(3), 740-743 (I) 410 2.21 510 HCl

MeSO₂— Me— Intermediate 33 2,3-dihydro-1- benzofuran-7- amine/ WO 9517401 A1 (I) 398 2.15 511 HCl

MeSO₂— Me— Intermediate 33 2,3-dihydro-1H- inden-4-amine/ Aldrich (I) 396 2.46 512 HCl

MeSO₂— Me— Intermediate 33 4-amino-2,3- dihydro-1H-inden- 1-one/Davos (IV) 410 2.13 520 HCl

MeSO₂— Me— Intermediate 33 2-methyl-4- pyridinamine/ Asym Chem (I) 371 1.7 542 HCl

MeSO₂— Me— Intermediate 33 1,3-dihydro-2- benzofuran-4- amine/U.S. Pat. No. 4,521,241 (I) 398 2.16 587 HCl

MeSO₂— Me— Intermediate 33 3,4-dihydro-2H- chromen-5- ylamine/J. Heterocyclic Chem., 1973, 10(4), 623-9 (I) 412 2.26 (a) Salt forms: HCl = hydrochloride TFA = trifluoroacetate (b) Isolation Method: (I) Filtered off directly from the reaction mixture. (II) Mass Directed preparative HPLC Method A. (III) Mass Directed preparative HPLC Method B. (IV) Mass Directed preparative HPLC Method C.

Example 14 4-[(3-Chlorophenyl)(methyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide

Intermediate 9 (0.023 g) was dissolved in 1-methyl-2-pyrrolidinone (1 ml), and 3-chloro-N-methylaniline (available from Avocado) (0.012 ml) was added. The mixture was stirred under microwave irradiation (power 150 W) for 10 min at 180° C. and for a further 10 min (power 150 W) at 150° C. Purification by mass directed HPLC (Method A) gave the title compound (0.015 g).

LC/MS R_(t) 2.58 min m/z 390 [MH⁺]

Example 112 4-({[2-(Methyloxy)phenyl]methyl}amino)-6-(phenylsulfonyl)-3-quinolinecarboxamide

Intermediate 8 (0.017 g) was taken up in acetonitrile (1.5 ml) to give a slurry. 2-Methoxy benzylamine (available from Aldrich) (0.021 g) and N,N-diisopropylethylamine (0.050 ml) were added and the resultant mixture was heated under reflux for 16 h. The mixture was cooled, the solvent evaporated in vacuo and the residue purified by mass directed HPLC (Method A) to give the title compound (0.014 g).

LC/MS R_(t) 2.73 min m/z 448 [MH⁺]

Similarly prepared were the following:

Ex. Isolation LCMS No. Starting Amine reagent/ Method LCMS R_(t) (a) R¹NH R³SO₂ Material Source (b) MH⁺ (min) 101 (c) HCl

MeSO₂— Intermediate 9 1- phenylmethanamine/ Aldrich (I) 356 2.07 102

MeSO₂— Intermediate 9 tetrahydro-2H-pyran- 3-amine hydrochloride/ Anales de Quimica, Serie C: Quimica Organica y Bioquimica, 1988, 64(2), 148-55. (II) 350 1.78 103

PhSO₂— Intermediate 8 2- (aminomethyl)phenol/ Buttpark (I) 434 2.56 104

PhSO₂— Intermediate 8 2,3-dihydro-1H-inden- 2-amine hydrochloride/ Aldrich (I) 444 2.85 105

PhSO₂— Intermediate 8 cyclopropylamine/ Aldrich (I) 368 2.37 106

PhSO₂— Intermediate 8 [4-(aminomethyl) phenyl] dimethylamine hydrochloride/ Aldrich (I) 461 2.69 107

PhSO₂— Intermediate 8 N-[3- (aminomethyl)phenyl] methanesulfonamide trifluoroacetate/ J. Med. Chem., 1999, 42(14), 2504-2526. (I) 511 2.52 108

PhSO₂— Intermediate 8 2-aminocyclohexanol/ TCI-US (I) 426 2.49 109

PhSO₂— Intermediate 8 [(1-methyl-1H- pyrazol-4-yl) methyl]amine/ Zelinsky-BB; CA 400877-05-6 (I) 422 2.28 110

PhSO₂— Intermediate 8 (2-pyridinylmethyl) amine hydrochloride/ Aldrich (I) 419 2.35 111

PhSO₂— Intermediate 8 1,2,3,4-tetrahydro-1- naphthalenamine hydrochloride/ Aldrich (I) 458 2.92 113

PhSO₂— Intermediate 8 (cyclohexylmethyl) amine/Aldrich (I) 424 2.87 114

PhSO₂— Intermediate 8 {[4- (methyloxy)phenyl] methyl}amine hydrochloride/ Aldrich (I) 448 2.69 115

PhSO₂— Intermediate 8 (phenylmethyl)amine hydrochloride/ Aldrich (I) 418 2.67 116

PhSO₂— Intermediate 8 cyclohexylamine hydrochloride/ Acros (II) 410 2.59 117

PhSO₂— Intermediate 8 2-methyl-1- propanamine trifluoroacetate/ Aldrich (II) 384 2.43 118

PhSO₂— Intermediate 8 [2-(3-pyridinyl)ethyl] amine/Lancaster (II) 433 2.08 119

PhSO₂— Intermediate 8 [2-(4-pyridinyl)ethyl] amine/Maybridge (II) 433 2.01 120

PhSO₂— Intermediate 8 2-phenylethanamine/ Aldrich (II) 432 2.68 121

PhSO₂— Intermediate 8 (3-pyridinylmethyl) amine/Aldrich (II) 419 2.12 122

PhSO₂— Intermediate 8 {[3,5- bis(methyloxy)phenyl] methyl}amine hydrochloride/ Aldrich (II) 478 2.68 123

PhSO₂— Intermediate 8 tetrahydro-2H-pyran- 3-amine hydrochloride/ Anales de Quimica, Serie C: Quimica Organica y Bioquimica, 1988, 84(2), 148-55. (II) 412 2.20 124

PhSO₂— Intermediate 8 4-amino cyclohexanane/ Nouveau Journal de Chimie, 1984, 8(7), 459-67. (II) 424 2.15 125 (c) HCl

PhSO₂— Intermediate 8 {[3-chloro-4- (methyloxy)phenyl] methyl}amine/ Apin Chemicals (I) 482 2.56 126

Intermediate 7 cyclohexylamine/ Aldrich (II) 402 2.49 127

Intermediate 7 2-methyl-1- propanamine/ Aldrich (II) 376 2.34 (a) Salt forms: HCl = hydrochloride (b) Isolation Method: (I) Filtered off directly from the reaction mixture; it is thought that compounds isolated by this method are free bases, apart from Examples 101 and 125 which are thought to be hydrochloride salts. (II) Mass Directed preparative HPLC Method A. (c) No N,N-diisopropylethylamine was used in the preparation of Examples 101 and 125.

The following were made in a similar manner to Example 112:

Ex. Isolation LCMS No. Starting Amine Reagent/ Method LCMS R_(t) (a) R¹R²N— R³SO₂— R²⁰— Material Source (b) MH⁺ (min) 319

PhSO₂— H— Intermediate 8 N,3-dimethylaniline/ Acros (II) 432 2.97 320

PhSO₂— H— Intermediate 8 3-chloro-N- methylaniline/ Maybridge (II) 452 3.00 321 TFA

PhSO₂— H— Intermediate 8 3-aminoquinuclidine dihydrochloride/ Aldrich (III) 437 1.98 330 TFA

PhSO₂— Me— Intermediate 16 (3-pyridinylmethyl) amine/ Aldrich (III) 433 2.08 331 HCl

H— Intermediate 31 2-(aminomethyl) phenol/Buttpark (I*) 464 2.14 332 TFA

H— Intermediate 31 (3-pyridinylmethyl) amine/ Aldrich (III) 449 2.06 333 TFA

H— Intermediate 31 [2-(4-pyridinyl)ethyl] amine/ Maybridge (III) 463 1.93 334 HCl

MeSO₂— Me— Intermediate 33 2-methyl-2- propanamine/Aldrich (IV) 336 2.04 (a) Salt forms: HCl = hydrochloride TFA = trifluoroacetate (b) Isolation Method: (I) Filtered off directly from the reaction mixture; it is thought that compounds isolated by this method are free bases. (I*) No base is used in the reaction procedure. Filtered off directly from the reaction mixture; it is thought that compounds isolated by this method are hydrochloride salts. (II) Mass Directed HPLC Method A; it is thought that compounds isolated by this method are free bases unless the R¹ or R³ groups contain basic moieties, in which case formate salts may be formed. (III) Mass Directed HPLC Method B; it is thought that compounds isolated by this method are trifluoroacetate salts. (IV) Mass Directed HPLC Method C; it is thought that compounds isolated by this method are hydrochloride salts.

Example 133 6-[(1,1-Dimethylethyl)thio]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Intermediate 14 (0.050 g), potassium tert-butoxide (0.015 g) and tert-butylmercaptan (0.0135 ml) were added to a stirred solution of tris(dibenzylidineacetone)dipalladium (0) (0.007 g) and (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.005 g) in toluene (2 ml), and the mixture was heated at 100° C. for 3.5 h and left to cool. The solvent was evaporated in vacuo to leave a brown solid (0.072 g), which was purified by Mass Directed Preparative HPLC (Method A) to give the title compound (0.008 g).

LC/MS R_(t) 2.83 min m/z 382 [MH⁺].

Similarly prepared from Intermediate 14 were the following:

Isolation Ex. Thiol reagent/ Method LCMS LCMS No. R³S— Source (b) MH⁺ R_(t) (min) 132

cyclohexanethiol/ Aldrich (II) 408 2.99 135

N-(2-mercaptoethyl) acetamide/Aldrich (II) 411 2.11 136

2,6-dichlorobenzene thiol/Aldrich (II) 471 2.77 137

2-methyl-1- propanethiol/ Aldrich (II) 382 2.66 138

1,3-oxazole-2(3H)- thione/ Can. J. Chem., 1972, 50(18), 3082-3. (II) 393 2.29 139

5-methyl-1,3,4- oxadiazole-2(3H)- thione/ U.S. Pat. No. 5,670,526 A (II) 408 2.22 140

phenylmethane thiol/ Aldrich (II) 416 2.86 141

4-fluorobenzene thiol/ Aldrich (IV) 420 2.87 142

4-(methyloxy) benzenethiol/ Aldrich (II) 432 2.90 143

cyclopentanethiol/ Aldrich (I) 394 2.98 144

benzenethiol/ Aldrich (I) 402 2.96 (b) Isolation Method: (I) Filtered off directly from the reaction mixture; it is thought that compounds isolated by this method are free bases. (II) Mass Directed preparative HPLC Method A. (IV) Purified by chromatography on silica gel, eluting with dichloromethane followed by ethyl acetate. It is thought that compounds isolated by this method are free bases.

The following were prepared in a similar manner to Example 133, using N,N-dimethylformamide as the reaction solvent:

Isolation Ex. Starting Thiol Reagent/ Method LCMS LCMS No. R¹NH— R³S— R²⁰— Material Source (b) MH⁺ R_(t) (min) 337

Me— Intermediate 35 2- mercaptoethanol/ Sigma (I) 402 2.19 338

Me— Intermediate 35 1,2,4-triazole-3- thiol/Aldrich (I) 425 2.12 339

Me— Intermediate 35 1-methyl-2- mercaptoimidazole/ Aldrich (I) 438 2.15 340

Me— Intermediate 35 2- mercaptoimidazole/ Aldrich (I) 424 1.96 341

Me— Intermediate 35 2- benzimidazolethiol/ Aldrich (I) 474 2.54 342

Me— Intermediate 35 4-methyl-1,3- oxazole-2(3H)- thione J. Org. Chem., 1967, 32(7), 2079-81. (I) 439 2.67 343

Me— Intermediate 35 2-furanyl methanethiol/ Aldrich (I) 438 2.79 344

Me— Intermediate 36 1,1-dimethylethyl (2-mercaptoethyl) carbamate/Aldrich (V) 495 2.73 345

Me— Intermediate 36 1,1-dimethylethyl 4-mercapto-1- piperidine- carboxylate/ U.S. Pat. No. 5,317,025 A (V) 535 3.22 563

Me— Intermediate 62 tetrahydro-3- furanthiol/Advan. Carbohydrate Chem. (1963), 18 123-99 (I) 381 2.17 564

Me— Intermediate 61 tetrahydro-3- furanthiol/Advan. Carbohydrate Chem. (1963), 18 123-99 (I) 398 2.65 565

Me— Intermediate 61 tetrahydro-2H- pyran-4-thiol/ WO98/05635 (I) 412 2.70 566

Me— Intermediate 62 tetrahydro-2H- pyran-4-thiol/ WO98/05635 (I) 395 2.20 569

Me— Intermediate 62 1,1-dimethylethyl 4-mercapto-1- piperidine carboxylate/U.S. Pat. No. 5,317,025 A (I) 494 2.80 570

Me— Intermediate 61 N-(2- mercaptoethyl) acetamide/Aldrich (I) 413 2.20 572

Me— Intermediate 62 N-(2- mercaptoethyl)- acetamide/ Aldrich (V) 396 1.90 516

Me— Intermediate 35 1,1-dimethylethyl 4-mercapto-1- piperidine carboxylate/ U.S. Pat. No. 5,317,025A (V) 541 3.10 517

Me— Intermediate 35 1,1-dimethylethyl (2-mercaptoethyl) carbamate/Aldrich (V) 501 3.68 528

Me— Intermediate 36 2-mercaptoethanol/ Aldrich (I) 396 2.20 603

Me— Intermediate 61 1,1-dimethylethyl (2-mercaptoethyl) carbamate (I) 471 2.80 634

Me— Intermediate 62 ethanethiol/ Aldrich (I) 339 2.32 635

Me— Intermediate 62 1-propanethiol/ Aldrich (I) 353 2.71 636

Me— Intermediate 62 2-propanethiol/ Aldrich (I) 353 2.47 637

Me— Intermediate 62 2-methyl-2- propanethiol/ Aldrich (I) 367 2.58 638

Cl— Intermediate 96 ethanethiol/ Aldrich (I) 359 2.59 639

Cl— Intermediate 96 1-propanethiol/ Aldrich (I) 373 2.76 640

Cl— Intermediate 96 2-propanethiol/ Aldrich (I) 373 2.71 641

Cl— Intermediate 96 2-methyl-2- propanethiol/ Aldrich (I) 387 2.93 642

Me— Intermediate 62 ethanethiol/ Aldrich (I) 373 2.81 643

Me— Intermediate 97 1-propanethiol/ Aldrich (I) 387 3.06 644

Me— Intermediate 97 2-propanethiol/ Aldrich (I) 387 2.95 645

Me— Intermediate 97 2-methyl-2- propanethiol/ Aldrich (I) 401 3.16 646

Cl— Intermediate 100 ethanethiol/ Aldrich (I) 393 3.1 647

Cl— Intermediate 100 1-propanethiol/ Aldrich (I) 407 3.3 648

Cl— Intermediate 100 2-propanethiol/ Aldrich (I) 407 3.25 649

Cl— Intermediate 100 2-methyl-2- propanethiol/ Aldrich (I) 421 3.33 650

Me— Intermediate 98 ethanethiol/ Aldrich (I) 357 2.59 651

Me— Intermediate 98 1-propanethiol/ Aldrich (I) 371 2.84 652

Me— Intermediate 98 2-propanethiol/ Aldrich (I) 371 2.84 653

Me— Intermediate 98 2-methyl-2- propanethiol/ Aldrich (I) 385 2.94 654

Cl— Intermediate 99 ethanethiol/ Aldrich (I) 377 2.88 655

Cl— Intermediate 99 1-propanethiol/ Aldrich (I) 391 3.07 656

Cl— Intermediate 99 2-propanethiol/ Aldrich (I) 391 3.03 657

Cl— Intermediate 99 2-methyl-2- propanethiol/ Aldrich (I) 405 3.14 658

Cl— Intermediate 102 ethanethiol/ Aldrich (I) 376 2.94 659

Cl— Intermediate 102 1-propanethiol/ Aldrich (I) 390 3.08 660

Cl— Intermediate 102 2-propanethiol/ Aldrich (I) 390 3.02 661

Cl— Intermediate 102 2-methyl-2- propanethiol/ Aldrich (I) 404 3.21 662

Me— Intermediate 101 ethanethiol/ Aldrich (I) 356 2.5 663

Me— Intermediate 101 1-propanethiol/ Aldrich (I) 370 2.65 664

Me— Intermediate 101 2-propanethiol/ Aldrich (I) 370 2.61 665

Me— Intermediate 101 2-methyl-2- propanethiol/ Aldrich (I) 384 2.89 681

Me— Intermediate 101 N-(2- mercaptoethyl)-N- methylacetamide/ Tetrahedron 1986, 42 (5), 1449 (I) 427 2.30 (b) Isolation Method: (I) These were purified by SCX column, eluting with ammonia/methanol. (V) These were purified by chromatography on silica gel (eluting with ethyl acetate/cyclohexane) followed by trituration with cyclohexane to give the pure product; it is thought that compounds isolated by this method are free bases.

Example 577 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylthio)-3-quinolinecarboxamide

A stirred mixture of Intermediate 36 (0.2 g), sodium thiomethoxide (0.058 g), tris(dibenzylideneacetone)dipalladium(0) (0.076 g), (oxidi-2,1-phenylene)-bis(diphenylphosphine) (0.045 g), and potassium tert-butoxide (0.047 g) in N,N-dimethylformamide (10 ml) was heated at 100° C. under nitrogen for 18 h. The cooled reaction mixture was applied directly to an SCX cartridge (10 g) and eluted with methanol (150 ml) followed by 2M ammonia in methanol (100 ml). Evaporation of the methanol/ammonia fraction gave the title compound as a yellow solid (0.13 g).

LC/MS R_(t) 2.48 min, m/z 366 [MH⁺]

The following were prepared in a similar manner to Example 577, but without adding potassium tert-butoxide to the reaction mixture:

Ex. Starting LCMS LCMS No. R¹NH— R²⁰— Material MH⁺ R_(t) (min) 577

Me— Intermediate 36 382 2.00 604

Et— Intermediate 74 388 2.57 605

Et— Intermediate 75 356 2.76 606

Et— Intermediate 76 372 2.95 607

Et— Intermediate 77 363 2.71 608

Et— Intermediate 78 352 2.65 609

Et— Intermediate 79 392 2.44 610

Et— Intermediate 80 380 2.62 611

Et— Intermediate 81 339 2.2 612

Et— Intermediate 82 357 2.55 613

Et— Intermediate 83 373 2.73 614

F— Intermediate 85 363 2.69 615

F— Intermediate 86 329 2.16 616

F— Intermediate 84 347 2.53 617

F— Intermediate 89 346 2.87 618

F— Intermediate 90 363 3.06 619

F— Intermediate 91 342 2.91 620

F— Intermediate 92 353 2.77 621

F— Intermediate 93 382 2.56 622

F— Intermediate 94 376 2.88 623

F— Intermediate 88 370 2.81 682

Cl— Intermediate 38 358 3.27 683

Cl— Intermediate 39 392 3.06 684

Cl— Intermediate 40 386 3.10 685

Cl— Intermediate 41 369 3.01 686

Cl— Intermediate 42 362 3.20 687

Cl— Intermediate 43 398 2.82

Example 134 4-{[3-(Methyloxy)phenyl]amino}-6-({[4-(methyloxy)phenyl]methyl}thio)-3-quinolinecarboxamide

Intermediate 14 (0.020 g), potassium tert-butoxide (0.0061 g) and [4-(methyloxy) phenyl]methanethiol (available from Aldrich) (0.007 ml) were added to a stirred solution of tris(dibenzylidineacetone)dipalladium(0) (0.002 g) and (oxydi-2,1-phenylene)bis (diphenylphosphine) (0.002 g) in N,N-dimethylformamide (1.5 ml), and the mixture was heated under microwave irradiation at 60° C. for 8 min. The solvent was evaporated in vacuo, and the residue purified by Mass Directed Preparative HPLC (Method A) to give the title compound (0.0048 g).

LC/MS R_(t) 2.93 min m/z 446 [MH⁺]

Example 129 6-[(1,1-Dimethylethyl)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Example 133 (0.010 g) was dissolved in N,N-dimethylformamide (2 ml) and anisole (0.013 ml) was added. Oxone (0.075 g) was added and the mixture stirred for 16 h at room temperature. After quenching with 1M aqueous sodium sulphite, the mixture was extracted with dichloromethane; the organic layer was dried over magnesium sulphate and evaporated in vacuo to give a yellow solid. Purification by mass directed HPLC (Method A) gave the title compound (0.005 g).

LC/MS R_(t) 2.48 min m/z 414 [MH⁺].

Similarly prepared were the following:

Isolation Ex. Starting Method LCMS LCMS No. R³SO₂— Material (b) MH⁺ R_(t) (min) 128

Example 142 (II) 464.09 2.83 130 (a)

Example 135 (II) 443.1 2.11 (a) No anisole was used in the reaction mixture in this Example. (b) Isolation Method: (II) Mass Directed preparative HPLC (Method A).

The following were prepared in a similar manner to Example 129, but without the addition of anisole to the reaction mixture:

Ex. Isolation No. Starting Method LCMS LCMS (a) R¹NH— R³SO₂— R²⁰— Material (b) MH⁺ R_(t) (min) 346 HCl

Me— Example 337 (IV) 434 2.10 347 HCl

Me— Example 338 (IV) 457 2.30 348 HCl

Me— Example 339 (IV) 470 2.46 349 HCl

Me— Example 340 (IV) 456 2.27 350 HCl

Me— Example 341 (IV) 506 2.79 351 HCl

Me— Example 343 (IV) 470 2.66 352

Me— Example 345 (V) 567 3.08 353

Me— Example 344 (VI) 527.5 2.76 369 HCl

MeSO₂— Cl— Example 682 (IV) 390 2.77 370 HCl

MeSO₂— Cl— Example 683 (IV) 424 2.63 371 HCl

MeSO₂— Cl— Example 684 (IV) 418 2.77 372 HCl

MeSO₂— Cl— Example 685 (IV) 401 2.57 373 HCl

MeSO₂— Cl— Example 686 (IV) 394 2.70 374 HCl

MeSO₂— Cl— Example 687 (IV) 430 2.51 478

Me— Intermediate 29 (VI) 519 2.55 602

Me— Example 603 (VII) 503 2.90 515

Me— Example 562 (VI) 449 2.60 (a) Salt forms: HCl = hydrochloride. (b) Isolation Method: (IV) Mass Directed preparative HPLC (Method C). (V) Column chromatography on silica gel. (VI) Aqueous work-up. (VII) Trituration from acetonitrile.

The following were prepared in a similar manner to Example 129 without the addition of anisole to the reaction mixture:

Ex. Isolation No. Starting Method LCMS LCMS (a) R¹NH— R²⁰— R³SO₂— Material (b) MH⁺ R_(t) (min) 522

Me—

Example 521 (II) 448 2.33 591 HCl

Et— MeSO₂— Example 604 (IV) 418 2.39 592 HCl

Et— MeSO₂— Example 605 (IV) 388 2.51 593 HCl

Et— MeSO₂— Example 607 (IV) 395 2.46 594 HCl

Et— MeSO₂— Example 612 (IV) 389 2.32 595 HCl

Et— MeSO₂— Example 613 (IV) 405 2.47 596 HCl

Et— MeSO₂— Example 608 (IV) 384 2.41 597 HCl

Et— MeSO₂— Example 606 (IV) 404 2.70 598 HCl

Et— MeSO₂— Example 609 (IV) 424 2.34 599 HCl

Et— MeSO₂— Example 610 (IV) 412 2.44 600 HCl

Et— MeSO₂— Example 611 (IV) 370 1.99 624

F— MeSO₂— Example 623 (II) 402 2.52 625

F— MeSO₂— Example 617 (II) 378 2.54 626

F— MeSO₂— Example 618 (II) 395 2.70 627

F— MeSO₂— Example 619 (II) 374 2.61 628

F— MeSO₂— Example 620 (II) 385 2.42 629

F— MeSO₂— Example 621 (II) 414 2.27 630

F— MeSO₂— Example 622 (II) 408 2.45 631

F— MeSO₂— Example 615 (II) 361 1.91 632

F— MeSO₂— Example 614 (II) 395 2.32 633

F— MeSO₂— Example 616 (II) 379 2.09 (a) Salt forms: HCl = hydrochoride. (b) Isolation method: (II) Mass Directed preparative HPLC (Method A). (IV) Mass Directed preparative HPLC (Method C).

Example 184 8-Methyl-4-{[3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide hydrochloride

Intermediate 16 (0.036 g) was suspended in acetonitrile (2 ml), 3-methoxyaniline (available from Aldrich) (0.012 g) was added, and the mixture was heated under reflux for 16 h. After cooling to room temperature the mixture was filtered and the residue dried to give the title compound as a beige solid (0.020 g).

LC/MS R_(t) 2.86 min m/z 448 [MH⁺]

Similarly prepared was:

Ex. Isolation No. Starting Amine Reagent/ Method LCMS LCMS (a) R¹NH— R³SO₂— Material Source (b) MH⁺ R_(t) (min) 185 HCl

PhSO₂— Intermediate 16 4-fluoro-3- methoxyaniline/ Apollo-Chem (I) 466 2.89 (b) Isolation method: (I) Filtered off from the reaction mixture.

Example 186 7-Methyl-4-{[3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide hydrochloride

Intermediate 17 (0.058 g) was suspended in acetonitrile (2 ml), 3-methoxyaniline (0.024 g) (available from Aldrich) was added, and the mixture was heated under reflux for 4 h. After cooling,to room temperature the mixture was filtered and the residue dried to give the title compound as a beige solid (0.042 g).

LC/MS R_(t) 2.21 min m/z 386 [MH⁺]

Example 335 4-[(3-Aminophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide trifluoroacetate

To a stirred mixture of Example 187 (0.130 g) in dichloromethane (5 ml) was added trifluoroacetic acid (1 ml). The mixture was stirred at 20° C. for 1 h and then the solvent was removed in vacuo to give the title compound as a yellow gum (0.100 g).

LC/MS R_(t) 1.87 min m/z 357 [MH⁺]

Similarly prepared from example 188 was:

Example 336 4-{[3-(Aminomethyl)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide trifluoroacetate

Example 376 1,1-Dimethylethyl 4-({3-(aminocarbonyl)-8-methyl-4-[(1-methyl-1H-benzimidazol-6-yl)amino]-6-quinolinyl}sulfonyl)-1-piperidinecarboxylate

A mixture containing Intermediate 44 (0.500 g), 1,1-dimethylethyl 4-mercapto-1-piperidinecarboxylate (0.442 g, synthesised according to U.S. Pat. No. 5,317,025A), potassium tert-butoxide (0.248 g), tris(dibenzylideneacetone) dipalladium (0.093 g) and (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.091 g) was dissolved in N,N-dimethylformamide (20 ml) and stirred under an atmosphere of nitrogen at 100° C. for 2 h. The solvents were concentrated in vacuo and the residue partitioned between ethyl acetate (100 ml) and water (100 ml). The organic extract was washed with sodium bicarbonate solution followed by brine, dried over magnesium sulfate and concentrated in vacuo to an orange solid. This was purified by flash chromatography on silica gel eluting with a gradient of ethanol (0% to 10%) in ethyl acetate, to give the intermediate sulphide 1,1-dimethylethyl 4-({3-(aminocarbonyl)-8-methyl-4-[(1-methyl-1H-benzimidazol-6-yl)amino]-6-quinolinyl}thio)-1-piperidinecarboxylate as a yellow solid (0.375 g).

LC/MS R_(t) 2.63 min, m/z 547 [MH⁺]

Oxone (1.6 g) was added to a solution of the sulphide (0.370 g) in N,N-dimethylformamide (10 ml). The mixture was stirred at room temperature for 1 h and was quenched with a solution of sodium sulphite (4 g) in water (150 ml). The mixture was extracted with ethyl acetate (2×100 ml) and the combined organic suspension washed with water (2×100 ml) and extracted in vacuo to a pale yellow solid. This was purified by recrystallisation from boiling methanol to give the title compound as a pale yellow powder (0.265 g).

LC/MS R_(t) 2.47 min, m/z 579 [MH⁺]

Similarly prepared were the following:

Ex. No. Starting Thiol Reagent/ (a) R¹NH— R³SO₂— R²⁰— Material Source 354

H— Intermediate 37 Methyl 4- mercaptobenzoate/ Toronto Research Chemicals 355

H— Intermediate 37 Methyl 3- mercaptobenzoate/ Toronto Research Chemicals 356

H— Intermediate 37 3-methylbenzene thiol/ Aldrich 357 HCl

H— Intermediate 14 3,4-dimethylthio phenol/Aldrich 358

H— Intermediate 14 3-fluorobenzene thiol/Avocado 359 HCl

H— Intermediate 14 4-(trifluoromethyl) thiophenol/ Fluorochem 361

H— Intermediate 37 3-chlorothiophenol/ Adrich 362

H— Intermediate 37 4-tert-butylthio phenol/ Lancaster 363

H— Intermediate 37 3,5-dimethyl benzenethiol/ Aldrich 364

H— Intermediate 37 1,1-dimethylethyl (2-mercaptoethyl) carbamate/Aldrich 365 HCl

H— Intermediate 37 [4-(methyloxy) phenyl] methanethiol/ Aldrich 366

H— Intermediate 37 4-bromothiophenol/ Aldrich 367 HCl

H— Intermediate 37 2-mercaptoanisole/ Lancaster 368 HCl

H— Intermediate 37 (4-chlorophenyl) methanethiol/ Aldrich 375 HCl

H— Intermediate 37 3-methoxybenzene thiol/ Aldrich 377

H— Intermediate 45 1,1-dimethylethyl 4-mercapto-1- piperidine carboxylate/ U.S. Pat. No. 5,317,025 A 378

H— Intermediate 46 1,1-dimethylethyl 4-mercapto-1- piperidine carboxylate/ U.S. Pat. No. 5,317,025 A 472

H— Intermediate 14 1,1-dimethylethyl 4-mercapto-1- piperidine carboxylate/ U.S. Pat. No. 5,317,025 A Ex. Isolation No. Method LCMS LCMS (a) (b) Solvent MH⁺ R_(t) (min) 354 (II) Toluene 492 2.76 355 (II) Toluene 492 2.76 356 (VII) Toluene 448 2.90 357 (IV) Toluene 462 3.02 HCl 358 (V) Toluene 452 2.83 359 (IV) Toluene 502 3.16 HCl 361 (II) Toluene 468 2.96 362 (II) Toluene 490 3.26 363 (II) Toluene 462 3.05 364 (V) Toluene 469 2.59 365 (IV) Toluene 478 2.63 HCl 366 (VI) Toluene 513 3.02 367 (IV) Toluene 464 2.52 HCl 368 (IV) Toluene 482 2.91 HCl 375 (VIII) N,N-dimethyl- 464 2.76 HCl formamide 377 (V) N,N-dimethyl- 555 2.97 formamide 378 (V) N,N-dimethyl- 550 3.01 formamide 472 (V) N,N-dimethyl- 541 2.89 formamide (a) Salt forms: HCl = hydrochloride (b) Isolation Method: (II) Mass Directed preparative HPLC (Method A). (IV) Mass Directed preparative HPLC (Method C). (V) Column chromatography on silica gel. Compounds isolated by this method are free bases. (VI) Aqueous workup only with no further chromatography. Compounds isolated by this method are free bases. (VII) Recrystallised from methanol (VIII) Mass Directed preparative HPLC (Method A), followed by treatment with 2M HCl in ethanol.

Example 360 6-[(4-Hydroxyphenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]quinoline-3-carboxamide

Oxone (3.9 g) was added to a stirred solution of Intermediate 47 (1.1 g) in dry N,N-dimethylformamide (30 ml) at room temperature for 18 h. The mixture was poured into aqueous sodium sulphite solution (200 ml) and extracted with ethyl acetate (3×100 ml). The organic extracts were washed with water (2×100 ml), dried (Na₂SO₄) and concentrated. A solution of the residual oil in tetrahydrofuran (20 ml) was stirred with a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (4 ml) for 1 h. The solvent was removed in vacuo and the residue was partitioned between ethyl acetate (2×25 ml) and water (2×50 ml). The organic extracts were dried (Na₂SO₄) and concentrated to give the title compound as a yellow solid (0.67 g).

LC/MS R_(t) 2.58 min, m/z 450 [MH⁺]

Example 379 Methyl 3-[(3-(aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)sulfonyl]benzoate

To Intermediate 45 (0.47 g) in dimethoxyethane (10 ml) was added methyl 3-mercaptobenzoate (0.34 ml), potassium phosphate (0.42 g), copper (I) iodide (0.028 g) and N,N-diethylsalicylamide (0.39 g). The mixture was heated at 85° C. for 4 h before adding further methyl 3-mercaptobenzoate (0.34 ml) and copper (I) iodide (0.028 g). After a further 16 h the reaction mixture was concentrated in vacuo and partitioned between ethyl acetate (150 ml) and water (150 ml). The organic layers were washed with brine (100 ml), dried over sodium sulfate and concentrated in vacuo to yield a crude product which was triturated with diethyl ether (20 ml). The solid obtained was collected by filtration, washed with diethyl ether (2×10 ml) to give methyl 3-[(3-(aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)thio]benzoate as a beige solid (0.37 g).

LC/MS R_(t) 3.09 min m/z 474 [MH⁺]

To a solution of the methyl 3-[(3-(aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)thio]benzoate (0.367 g) in N,N-dimethylformamide (10 ml) was added oxone (1.91 g). The mixture was stirred at room temperature for 18 h before quenching with aqueous sodium sulphite solution and extracting with chloroform (3×200 ml). The organic layers were combined, washed with brine, dried over magnesium sulfate and concentrated in vacuo and purified by chromatography on silica gel, eluting with 2:1 ethyl acetate: cyclohexane, to give the title compound as a yellow solid (0.100 g).

LC/MS R_(t) 3.03 min m/z 506 [MH⁺]

The following were synthesised in the same manner as Example 379, however potassium carbonate was used as a base instead of potassium phosphate and no N′N-diethylsalicylamide was added.

Ex. Purification No. Starting Thiol Reagent/ Method LCMS LCMS (a) R³SO₂— R²⁰— Material Source (b) MH⁺ R_(t) (min) 380

Me— Intermediate 45 3,4- dimethoxythiophenol Aldrich (V) 508 2.81 381 HCl

Me— Intermediate 45 3,4,5-tris(methyloxy) benzenethiol J. Am. Chem. Soc., 2002, 124(17), 4642-4846 (IV) 538 2.92 382 HCl

H— Intermediate 14 3,4- dimethoxythiophenol/ Avocado (IV) 494 2.59 383 HCl

Me— Intermediate 45 3-ethoxythiophenol/ Aldrich (IV) 492 3.08 (a) Salt forms: HCl = hydrochloride (b) Isolation Method: (IV) Mass Directed preparative HPLC (Method C). (V) Column chromatography on silica gel; it is thought that compounds isolated by this method are free bases.

Example 386 6-(Ethylsulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

Intermediate 37 (0.100 g) was combined with (oxydi-2,1-phenylene)bis(diphenylphosphine) (0.011 g), potassium tert-butoxide (0.025 g) and tris(dibenzylideneacetone)dipalladium(o) (0.008 g) in 1,4-dioxane (1 ml). Ethanethiol (available from Aldrich, 0.023 ml) was added and the mixture was stirred under microwave irradiation (power 40 W) for 8 min at 90° C. The reaction was quenched by addition of 4M HCl in dioxane, then partitioned between ethyl acetate and sodium bicarbonate solution. The organic layer was concentrated in vacuo to give 0.090 g of crude 6-(ethylthio)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide.

The crude sulphide was dissolved in N,N-dimethylformamide (5 ml) and treated with an excess of oxone (0.375 g) and stirred at room temperature for 4 h. The reaction was quenched by the addition of 1M aqueous sodium sulphite solution, then partitioned between dichloromethane and sodium bicarbonate solution. The solvent was removed in vacuo and the residue was purified by mass directed preparative HPLC (Method C). After evaporation of solvent the title compound was obtained as a yellow solid.

LC/MS R_(t) 2.30 min, m/z 386 [MH⁺]

The following were prepared in the same manner as Example 386:

Ex. LCMS No. Starting Thiol Reagent/ LCMS R_(t) (a) R³SO₂— R²⁰— Material Source MH⁺ (min) 384 (b)

H— Intermediate 14 Isobutyl mercaptan/ Aldrich 414 2.56 387 HCl

H— Intermediate 37 1-butanethiol/ Aldrich 414 2.67 388 HCl

H— Intermediate 37 Methyl-3- mercaptopropionate/ Fluka 444 2.39 389 HCl

H— Intermediate 37 Phenethyl mercaptan/Aldrich 462 2.88 390 HCl

H— Intermediate 37 2- furanylmethanethiol/ Aldrich 438 2.46 391 HCl

H— Intermediate 37 2,2,2- trifluoroethanethiol/ Aldrich 440 2.6 392 HCl

Me— Intermediate 45 N-(2-mercaptoethyl) acetamide/Aldrich 457 2.25 (a) Salt forms: HCl = hydrochloride (b) Isolation method: Mass Directed preparative HPLC (Method A).

Example 393 3-[(3-(Aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)sulfonyl]benzoic acid

Example 379 (0.1 g) was dissolved in methanol (5 ml) and 2M aqueous sodium hydroxide (1 ml). The mixture was heated to 75° C. for 4 h before cooling and standing at ambient temperature for 18 h. The solvent was removed in vacuo and the residue partitioned between ethyl acetate (100 ml) and water (100 ml). The layers were separated and the aqueous layer was washed with diethyl ether (50 ml), acidifed to pH4 (2M hydrochloric acid) and extracted with ethyl acetate (2×150 ml). The combined ethyl acetate layers were washed with brine (100 ml), dried over magnesium sulfate and concentrated in vacuo to yield the title compound as a beige solid (0.082 g).

LC/MS R_(t) 2.82 min m/z 492 [MH⁺].

Similarly prepared were the following:

Isolation Example Starting Method LCMS LCMS Number R³SO₂— Material (b) MH⁺ R_(t) (min) 394

Example 354 (II) 478 2.67 395

Example 355 (II) 478 2.65 (b) Isolation Method: (II) Mass Directed HPLC Method A

The following were prepared from the intermediates shown in the table in a similar manner to the method by which Example 393 was prepared, via Example 379, from Intermediate 45.

Example Isolation Number Starting Method LCMS LCMS (a) R¹NH— Material (b) MH⁺ R_(t) (min) 396 HCl

Intermediate 44 (IV) 516 2.25 397 HCl

Intermediate 46 (IV) 487 2.9 398

Intermediate 36 (I) 504 2.83 (a) Salt forms: HCl = hydrochloride (b) Isolation Method: (I) filtered off and used crude. (IV) Mass Directed HPLC Method C; it is thought that compounds isolated by this method are hydrochloride salts.

Example 399 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

To a solution of Example 393 (0.082 g) in N,N-dimethylformamide (3 ml) was added N,N-diisopropylethylamine (0.12 ml) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.071 g). The mixture was stirred for 20 min before adding a solution of dimethylamine in tetrahydrofuran (2M, 0.8 ml, Aldrich). After a further 1 h more dimethylamine in tetrahydrofuran (2M, 0.8 ml) was added. After 1 h the reaction mixture was concentrated in vacuo and partitioned between ethyl acetate (200 ml) and aqueous sodium bicarbonate (100 ml). The organic layers were washed with brine (100 ml), dried over magnesium sulfate and concentrated in vacuo. Purification by mass directed HPLC (Method C) gave the title compound as a yellow solid (0.022 g).

LC/MS R_(t) 2.61 min m/z 519 [MH⁺].

Similarly prepared were the following:

Example Amine Number Starting Reagent/ LCMS LCMS (a) R¹NH— R²⁰— R²⁹R³⁰N— Material Source MH⁺ R_(t) (min) 400 HCl

H— Me₂N— Example 395 dimethylamine 2M solution in tetrahydrofuran/ Aldrich 505 2.52 401 HCl

H— H₂N— Example 395 Ammonia solution 880/Merck 477 2.42 402 HCl

H— MeNH— Example 395 methylamine 2M solution in tetrahydrofuran/ Aldrich 491 2.47 403 HCl

H—

Example 395 Pyrrolidine/ Lancaster 531 2.64 404 HCl

H—

Example 395 propylamine/ Aldrich 519 2.74 405 (b)

H—

Example 395 Isobutylamine/ Aldrich 533 2.76 406 HCl

H—

Example 395 Morpholine/ Lancaster 547 2.51 407 HCl

H—

Example 395 Ethanolamine/ Aldrich 521 2.38 408 HCl

Me— Me₂N— Example 397 dimethylamine 2M solution in tetrahydrofuran/ Aldrich 514 2.71 409 HCl

Me— Me₂N— Example 396 dimethylamine 2M solution in tetrahydrofuran/ Aldrich 543 2.19 410 HCl

Me— H₂N— Example 396 Ammonia solution 880/Merck 515 2.13 411 HCl

Me— MeNH— Example 396 methylamine 2M solution in tetrahydrofuran/ Aldrich 529 2.17 412 HCl

Me— H₂N— Example 397 dimethylamine 2M solution in tetrahydrofuran/ Aldrich 486 2.61 413 HCl

Me— MeNH— Example 397 methylamine 2M solution in tetrahydrofuran/ Aldrich 500 2.69 414 (c)

Me— Me₂N— Example 398 dimethylamine 2M solution in tetrahydrofuran/ Aldrich 531 2.65 (a) Salt form: HCl = hydrochloride (b) Example 405 was isolated by Mass Directed preparative HPLC (Method A). (c) Example 414 was isolated by aqueous work up.

Similarly prepared from Example 394 were the following:

Example Isolation Number Amine Reagent/ method LCMS LCMS (a) R²⁹R³⁰N— Source (b) MH⁺ R_(t) (min) 415 H₂N— Ammonia solution (I) 477 2.45 HCl 880/Merck 416 MeHN— methylamine 2M (I) 491 2.51 HCl solution in tetrahydrofuran/ Aldrich 417 HCl

Pyrrolidine/Lancaster (I) 531 2.66 418 HCl

propylamine/Aldrich (I) 519 2.75 419 Me₂N— dimethylamine 2M (I) 505 2.53 HCl solution in tetrahydrofuran/ Aldrich 420

Isobutylamine/Aldrich (II) 533 2.8 (a) Salt form: HCl = hydrochloride (b) Isolation Method: (I) Mass Directed preparative HPLC (Method C). (II) Mass Directed preparative HPLC (Method A).

Example 421 4-{[3-(Methyloxy)phenyl]amino}-6-(4-piperidinylsulfonyl)-3-quinolinecarboxamide

To a mixture containing Example 472 (1.3 g) in anisole (9 ml) was added a solution of 95% trifluoroacetic acid in water (45 ml). The mixture was stirred for 2 h at room temperature and was then concentrated in vacuo. The residue was co-evaporated with toluene (2×20 ml) and triturated with diethyl ether to give a yellow solid. The solid was partitioned between aqueous potassium carbonate (300 ml) and chloroform (300 ml) and the aqueous phase extracted with chloroform (3×200 ml). The combined organic extracts were washed with water (100 ml), dried and concentrated in vacuo to give the title compound as a yellow solid (1.1 g).

LC/MS R_(t) 1.94 min, m/z 441 [MH⁺]

Similarly prepared were the following:

Ex. Isolation LCMS No. Starting Method LCMS R_(t) (a) R¹NH— R²⁰— R³SO₂— Material (b) MH⁺ (min) 422 TFA

Me—

Example 353 (I) 1.98 427 423

Me—

Example 352 (II) 467 1.97 470 TFA

Me—

Example 378 (III) 450 2.03 474 TFA

Me—

Example 376 (I) 479 1.77 476

Me—

Intermediate 55 (II) 473 2.10 477

Me—

Intermediate 56 (II) 433 2.03 561

Me—

Example 602 (IV) 403 1.93 567 HCl

Me—

Example 568 (V) 426 1.80 (a) Salt forms: TFA = trifluoroacetate (b) Isolation Method: (I) Filtered off directly from the reaction mixture; it is thought that compounds isolated by this method are trifluoroacetate salts. (II) Aqueous workup of the crude reaction mixture without further purification; it is thought that compounds isolated by this method are free bases. (III) Crude product was trituated to give the desired product and no further purification was carried out; it is thought that compounds isolated by this method are trifluoroacetate salts. (IV) Product isolated by SCX ion exchange to give the free base (V) Reaction mixture evaporated to dryness; it is assumed that this method gave the hydrochloride salt.

Example 424 4-{[3-(Methyloxy)phenyl]amino}-6-{[1-(phenylcarbonyl)-4-piperidinyl]sulfonyl}-3-quinolinecarboxamide

To a mixture containing Example 421 (0.050 g) and triethylamine (0.025 ml) in dioxane (2 ml) was added benzoyl chloride (0.020 ml). The mixture was stirred under nitrogen for 18 h at room temperature and was then diluted with methanol (5 ml). The solution was applied to an aminopropyl cartridge and eluted with methanol. The eluent was evaporated and the residual gum purified by chromatography on SPE eluting with a gradient of methanol in chloroform (0% to 10%) to give the title compound as a yellow solid (0.043 g).

LC/MS R_(t) 2.63 min, m/z 545 [MH⁺]

Similarly prepared were the following:

Ex. Isolation LCMS No. Starting Electrophile/ Method LCMS R_(t) (a) R¹NH— R²⁰— R^(x)— Material Source (b) MH⁺ (min) 425

H—

Example 421 Methyl chloroformate/ Aldrich (II) 499 2.48 426

H—

Example 421 Acetyl chloride/ Aldrich (II) 483 2.27 427

H—

Example 421 Methane sulphonyl chloride/ Aldrich (V) 519 2.43 428

H—

Example 421 3-methylbutanoyl chloride/Aldrich (III) 525 2.61 429

H—

Example 421 Cyclopropane carbonyl chloride/ Aldrich (III) 509 2.42 430

H—

Example 421 2-furancarbonyl chloride/Aldrich (III) 535 2.5 431

H—

Example 421 5-methyl-3- isoxazolecarbonyl chloride/ Maybridge (III) 550 2.55 432

H—

Example 421 Benzene sulphonyl chloride/ Aldrich (IV) 581 2.9 433

H—

Example 421 3,5-dimethyl-4- isoxazolesulfonyl chloride/Avocado (IV) 600 2.88 434

H—

Example 421 2-(acetylamino)-4- methyl-1,3- thiazole-5-sulfonyl chloride/Aldrich (IV) 659 2.69 435

H—

Example 421 1-butanesulphonyl chloride/Aldrich (IV) 561 2.75 436

H—

Example 421 1-methylimidazole 4-sulphonyl chloride/ Maybridge (IV) 585 2.35 437

H—

Example 421 Isoxazole-5- carbonyl chloride/ Lancaster (III) 536 2.37 438

H—

Example 421 2-furancarbonyl chloride/ Maybridge (III) 535 2.42 439

H—

Example 421 isobutyryl chloride/ Aldrich (III) 511 2.42 440

H—

Example 421 Propionyl chloride/ Aldrich (III) 497 2.31 441

H—

Example 421 1- pyrrolidinecarbonyl chloride/Lancaster (III) 538 2.44 442

Me—

Intermediate 54 2-furancarbonyl chloride/Aldrich (I) 549 2.65 443

Me—

Example 470 2-furancarbonyl chloride/Aldrich (I) 544 2.69 444

Me—

Example 470 Cyclopropane carbonyl chloride/ Aldrich (I) 518 2.63 445

Me—

Intermediate 54 Cyclopropane carbonyl chloride/ Aldrich (I) 523 2.57 446

Me—

Example 423 2-furancarbonyl chloride/Aldrich (I) 561 2.66 447

Me—

Example 423 Cyclopropane carbonyl chloride/ Aldrich (I) 535 2.58 448 HCl

Me—

Example 423 Methyl chloroformate/ Aldrich (VI) 525 2.57 (a) Salt forms: HCl = hydrochloride (b) Isolation Method: (I) Purified by chromatography on an SPE column. (II) Aqueous workup of the crude reaction mixture without further purification. (III) Purified using an SPE cartridge (aminopropyl solid phase) followed by chromatography using a silica SPE column. (IV) Purified using an SPE cartridge (aminopropyl solid phase) followed by trituration. (V) Aqueous workup of the crude reaction followed by trituration of the crude product. (VI) Aqueous workup of the crude reaction followed by addition of dilute HCl in dioxane and evaporation; it is thought that compounds isolated by this method are hydrochloride salts.

Example 449 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-[(1-methyl-4-piperidinyl)sulfonyl]-3-quinolinecarboxamide hydrochloride

To a mixture containing Example 423 (0.050 g) and triethylamine (0.025 ml) in N,N-dimethylformamide (2 ml) was added methyl iodide (0.0075 ml). The mixture was stirred under nitrogen for 18 h at room temperature and was concentrated by blowing down under nitrogen. Purification by chromatography on silica gel, eluting with dichloromethane/methanol (95:5), gave a white solid which was dissolved in dioxane (10 ml) and treated with 4M hydrogen chloride in 1,4 dioxane (0.100 ml). After evaporation by blowing down under nitrogen the title compound was obtained as a yellow solid (0.028 g).

LC/MS R_(t) 1.99 min, m/z 481 [MH⁺]

Example 450 6-[(1-Acetyl-4-piperidinyl)sulfonyl]-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide hydrochloride

To a mixture containing Example 423 (0.050 g) in pyridine (2 ml) was added acetic anhydride (0.011 ml). The mixture was stirred under nitrogen for 18 h at room temperature, partitioned between chloroform (100 ml) and 10% sodium carbonate solution (100 ml), the layers separated by hydrophobic frit and the organic layer treated with 4M hydrogen chloride in 1,4-dioxane (0.100 ml). After evaporation by blowing down under nitrogen the title compound was obtained as a pale yellow solid (0.021 g).

LC/MS R_(t) 2.32 min, m/z 509 [MH⁺]

Similarly prepared were the following:

Ex. Isolation LCMS No. Starting Electrophile/ Method LCMS R_(t) (a) R¹NH— R²⁰— R³SO₂— Material Source (b) MH⁺ (min) 451

Me—

Example 476 Acetic anhydride/ Aldrich (II) 515 2.31 452 HCl

Me—

Example 422 Acetyl chloride/ Aldrich (V) 469 2.14 453 HCl

Me—

Example 477 Acetic anhydride/ Aldrich (I) 475 2.15 454 HCl

Me—

Example 477 Methane- sulphonyl chloride/ Aldrich (IV) 511 2.23 455 HCl

Me—

Example 477 Methyl chloroformate/ Aldrich (IV) 491 2.29 456

Me—

Example 422 Methyl chloroformate/ Aldrich (VI) 485 2.36 457

Me—

Example 422 Methane- sulphonyl chloride/ Aldrich (VI) 505 2.31 531

Me—

Example 567 Acetic anhydride/ Aldrich (III) 468 2.00 (a) Salt forms: HCl = hydrochloride. (c) Isolation Method: (I) As for Example 450 (II) Mass Directed HPLC (Method A) (III) Purified by silica SPE eluting with ethyl acetate/methanol (IV) Mass Directed preparative HPLC (Method C). (V) Aqueous work-up followed by addition of 4M HCl in 1,4-dioxane to a chloroform solution of the free base to give the hydrochloride salt. (VI) Aminopropyl SPE column.

Example 473 4-{[3-(Methyloxy)phenyl]amino}-6-({2-[(2-methylpropanoyl)amino]ethyl}sulfonyl)-3-quinolinecarboxamide

A solution of Example 364 (0.052 g) in anisole (1 ml) was treated with a solution of 95% trifluoroacetic acid in water (5 ml). The mixture was stirred for 3 h at room temperature and was then concentrated in vacuo. The residue was trituated with ethyl acetate, and the resulting solid was collected by filtration, washed with ethyl acetate and ether and dried to give a yellow solid (0.031 g). The solid was treated with dioxane (2 ml) and the suspension treated with N,N-diisopropylethylamine (0.04 ml) followed by isobutyryl chloride (0.015 ml, Aldrich) and the resulting solution stirred at room temperature under nitrogen for 2 h. The solution was diluted with methanol (5 ml) and applied to an aminopropyl SPE cartridge. Elution with methanol gave a gum after evaporation of solvent. The gum was purified by chromatography on silica gel eluting with a gradient of 0% to 6% methanol in chloroform to give the title compound as a yellow solid (0.017 g).

LC/MS R_(t) 2.22 min, mlz 471 [MH⁺]

Example 458 6-{[1-(1H-Imidazol-4-ylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

To a solution containing Intermediate 54 (0.041 g) in N,N-dimethylformamide (3 ml) were added imidazole-4-carboxylic acid (0.012 g, Aldrich), (1H-1,2,3-benzotriazol-1-yloxy)(tri-1-pyrrolidinyl)phosphonium hexafluorophosphate (PyBop) (0.053 g) and N,N-diisopropylethylamine (0.03 ml). The solution was stirred under nitrogen at room temperature for 18 h and was then concentrated in vacuo. The residual gum was purified using an aminopropyl SPE cartridge eluting with methanol followed by chromatography on silica gel (SPE cartridge), eluting with a gradient of 0% to 8% methanol in chloroform, to give the title compound as a yellow solid (0.031 g).

LC/MS R_(t) 2.32 min, m/z 549 [MH⁺]

Similarly prepared were the following:

Example Number Starting Amine Reagent/ LCMS LCMS (a) R^(x)— Material Source MH⁺ R_(t) (min) 459

Example 474 2-furoic acid/Aldrich 573 2.15 460

Example 474 Cyclopropylmethanoic acid/Aldrich 547 2.12

Example 461 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-{[1-(methylsulfonyl)-4-piperidinyl]sulfonyl}-3-quinolinecarboxamide hydrochloride

To a mixture containing Example 423 (0.050 g) in 1,4-dioxane (2 ml) was added methanesulphonyl chloride (0.009 ml). The mixture was stirred under nitrogen for 18h at room temperature, partitioned between ethyl acetate (100 ml) and 10% sodium bicarbonate solution (100 ml), separated and dried. The solid obtained was dissolved in 1,4-dioxane and treated with 4M hydrogen chloride in 1,4-dioxane (0.100 ml). After evaporation the title compound was obtained as a pale yellow solid (0.021 g).

LC/MS R_(t) 2.5 min, m/z 545 [MH⁺]

Example 462 6-{[4-(Cyclopropylmethoxy)phenyl]sulfonyl}-4-[(3-methoxyphenyl)amino]quinoline-3-carboxamide hydrochloride

Tributyl phosphine (0.05 ml) was added to a stirred mixture of Example 360 (0.052 g), cyclopropylmethanol (0.028 g) and di-tert-butylazodicarboxylate (0.06 g) in tetrahydrofuran (1.5 ml) at 20° under nitrogen, and stirring was continued at 20° for 3 h. The solvent was concentrated and the residue purified by mass directed preparative HPLC (Method C) to give the title compound as a yellow solid (0.09 g).

LC/MS R_(t) 3.4 min, m/z 504 [MH⁺]

Example 463 6-[(4-Ethoxyphenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]quinoline-3-carboxamide hydrochloride

A stirred mixture of Example 360 (0.05 g), iodoethane (0.35 ml) and potassium carbonate (0.02 g) in acetonitrile (1.5 ml) was heated under reflux temperature for 1 h. The solvent was evaporated to dryness. The resulting solid was partitioned between dichloromethane (2×15 ml ) and water (30 ml). The extracts were dried (Na₂SO₄) and concentrated. The residual solid was purified by mass directed HPLC (Method C) to give the title compound as a pale yellow solid (0.033 g).

LC/MS R_(t) 2.87 min, m/z 478 [MH⁺]

The following examples were similarly prepared:

Example Alkylating Number Starting Agent/ LCMS LCMS (a) R^(x)O— Material Source MH⁺ R_(t) (min) 464 HCl

Example 360 1-iodopropane/ Aldrich 492 3.07 465 HCl

Example 360 2-iodopropane/ Aldrich 492 3.00 466 HCl

Example 360 Iodocyclopentane/ Aldrich 518 3.24 (a) Salt form: HCl = hydrochloride.

Example 467 4-{[3-(3-Furyl)phenyl]amino}-6-[(4methoxyphenyl)sulfonyl]quinoline-3-carboxamide hydrochloride

A stirred mixture of Example 254 (0.051 g), 3-furanboronic acid (0.017 g, Aldrich), tetrakis(triphenylphosphine)palladium(0) (0.059) and 2M sodium carbonate solution (1 ml) in dimethoxyethane (2 ml) was heated at 100° C. for 1 h. The mixture was cooled and poured into 2M sodium carbonate solution and extracted into dichloromethane (2×15 ml). The extracts were dried (Na₂SO₄) and concentrated. The residue was purified by mass directed HPLC (Method C) to give the title compound as a yellow solid (0.026 g).

LC/MS R_(t) 2.93min, m/z 500 [MH⁺]

Similarly prepared were the following:

LCMS Ex. Starting Boronic Acid/ LCMS R_(t) No. R¹NH— R³SO₂— Material Source MH⁺ (min) 468 (a)

Example 366 [4-(methyloxy)phenyl] boronic acid/Aldrich 540 3.18 469 (b)

Example 366 3-furanboronic acid/ Aldrich 500 3.02 (a) Example 468 was isolated as the free base by trituration with ether. (b) Example 469 was isolated as the free base by chromatography on silica gel, eluting with ethyl acetate.

Example 475 6-{[3-(Dimethylamino)-3-oxypropyl]sulfonyl}-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide hydrochloride

A solution of Intermediate 53 (0.04 g) in N,N-dimethylformamide (3 ml) was treated with oxone (0.22 g) and the resulting solution was stirred at room temperature overnight. The reaction was quenched by the addition on 1M sodium sulphite solution (1 ml) and extracted into dichloromethane. The combined organic layers were dried using a hydrophobic frit and evaporated in vacuo, and the product was dissolved in N,N-dimethylformamide (2 ml ) and treated with O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.016 g). After 5 min, dimethylamine hydrochloride (0.065 g) and N,N-diisopropylethylamine (0.015 ml) in N,N-dimethylformamide (2 ml) were added. The resulting solution was left standing at room temperature overnight. Chromatographic purification by SCX (IST lsolute™, 10 g), eluting with methanol and 2M ammonia/methanol gave a yellow oil. Further purification by mass-directed HPLC (Method C) gave the title compound as a yellow solid (0.009 g).

LC/MS R_(t) 2.34 min, m/z 489 [MH⁺]

Example 540 4-[(5-Chloro-3-pyridinyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide hydrochloride

To a solution of Intermediate 33 (0.050 g) in N₁N-dimethylformamide was added 5-chloro-3-pyridinamine (0.032 g; Specs) and pyridine hydrochloride (0.029 g) and the mixture heated at 90° C. for 16 h. The solvent was blown off under a stream of nitrogen at 45° C. The residue was triturated with acetonitrile and the resultant precipitate collected by filtration to give the title compound as a brown solid.

LC/MS R_(t) 2.25 min m/z 391 [MH⁺]

Similarly prepared were the following:

Ex. Amine Isolation LCMS No. Starting Reagent/ Method LCMS R_(t) (a) R¹NH— R³SO₂— Material Source (b) MH⁺ (min) 539

MeSO₂— Intermediate 33 5-Fluoro-3- pyridinamine/ Synchem OHG (I) 375 2.2 541 HCl

MeSO₂— Intermediate 33 6-Methyl-3- pyridinamine/ AsymChem (IV) 371 1.79 543 HCl

MeSO₂— Intermediate 33 4-Amino-2- benzofuran- 1(3H)-one/ EP0529636A1 (II) 412 2.25 601

MeSO₂— Intermediate 33 2,6-dimethyl-3- pyridylamine/ Lancaster (III) 385 1.76 (a) Salt form: HCl = hydrochoride (b) Isolation method: (I) Trituration with acetonitrile followed by elution through an aminopropyl SPE cartridge with methanol. (II) Reaction was performed at 80° C. in acetonitrile and the product isolated by filtration of the reaction mixture. (III) Mass Directed preparative HPLC (Method A) followed by chromatography on silica gel eluting with 3% methanol in dichloromethane. (IV) Trituration with acetonitrile followed by isolation of the product by filtration.

Example 480 Ethyl 3-{[3-(aminocarbonyl)-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-quinolinyl]sulfonyl}propanoate

To a solution of Intermediate 57 (0.82 g) in N,N-dimethylformamide (25 ml) was added oxone (4.5 g). The mixture was stirred at room temperature for 2 h before quenching with aqueous sodium sulphite solution and extracting with dichloromethane (2×25 ml). The organic layers were combined, washed with water, dried using a hydrophobic frit, concentrated in vacuo and purified by chromatography on silica gel, eluting with an ethyl acetate: cyclohexane gradient, to give the title compound as a yellow solid (0.12 g).

LC/MS R_(t) 2.61 min m/z 484 [MH⁺].

Example 481 3-[(3-(Aminocarbonyl)-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-quinolinyl)sulfonyl]propanoic acid hydrochloride

To a solution of Intermediate 53 (0.8 g) in N,N-dimethylformamide (10 ml) was added oxone (4.6 g). The mixture was stirred at room temperature for 48 h before quenching with aqueous sodium sulphite solution and extracting with dichloromethane (3×25 ml). The aqueous layers were combined and applied to an Oasis cartridge, eluting with water and methanol. The methanol fractions were combined and concentrated in vacuo. The residue was applied to an SPE cartridge (Isolute, aminopropyl solid phase), eluting with methanol and 2M ammonia/methanol; evaporation of the methanol/ammonia fraction gave an orange oil. Further purification by mass directed preparative HPLC (Method C) gave the title compound as a yellow oil (0.003 g).

LC/MS R_(t) 2.23 min m/z 462 [MH⁺].

Similarly prepared were the following:

Example LCMS Number Starting LCMS R_(t) (a) R¹NH— Material MH⁺ (min) 549 HCl

Intermediate 59 432 2.38 550 HCl

Intermediate 60 415 1.92 (a) Salt forms: HCl = hydrochloride

Example 482 4-{[4-Fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-{[3-(4-morpholinyl) -3-oxopropyl]sulfonyl}-3-quinolinecarboxamide hydrochloride

To a solution of Example 481 (0.035 g) in N,N-dimethylformamide (2 ml) was added O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.029 g). After 5 min, morpholine (0.007 ml, available from Aldrich) and N,N-diisopropylethylamine (0.026 ml ) were added. The resulting solution was stirred at room temperature overnight, and applied directly to an SCX cartridge (IST Isolute™, 5 g). Elution with methanol and 2M ammonia/methanol gave an orange residue, which was further purified by mass directed preparative HPLC (Method C) to give the title compound as a yellow solid (0.006 g).

LC/MS R_(t) 2.37 min m/z 531 [MH⁺].

Similarly prepared were the following:

Example Amine Isolation LCMS Number Starting reagent/ Method LCMS R_(t) (a) R³SO₂— R¹NH— Material Source (b) MH⁺ (min) 483 HCl

Example 481 tetrahydro-2H- pyran-4-amine/ Aldrich (II) 545 2.22 484 HCl

Example 481 1-methyl piperazine/ Aldrich (II) 544 1.84 506 HCl

Example 550 1-methyl piperazine/ Aldrich (II) 497 1.75 507 HCl

Example 549 1-methyl piperazine/ Aldrich (II) 514 1.98 (a) Salt form HCl = hydrochloride (b) Isolation Method: (II) Mass Directed preparative HPLC (Method C).

Example 551 6-{[3-(Dimethylamino)-3-oxopropyl]thio}-4-[(3-fluorophenyl)amino]-8-methyl-3-quinolinecarboxamide

To a solution of Intermediate 59 (0.04 g) in N,N-dimethylformamide (1 ml) was added O-(7-azabenzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.038 g). After 5 min, dimethylamine hydrochloride (0.026 g) and N,N-diisopropylethylamine (0.07 ml) were added. The resulting solution was stirred at room temperature overnight, and applied directly to an SCX cartridge (IST Isolute™, 5 g), eluting with methanol followed by 2M ammonia in methanol to give the title compound as an orange oil (0.038 g).

LC/MS R_(t) 2.39 min m/z 427 [MH⁺].

Similarly prepared were the following:

LCMS Example Starting Amine reagent/ LCMS R_(t) Number R²⁸R²⁷N— R¹NH— Material Source MH⁺ (min) 552

Intermediate 59 tetrahydro-2H- pyran-4-amine/ Aldrich 483 2.34 553

Intermediate 59 cyclopropyl(methyl) amine/Karl Industries 453 2.56 554

Intermediate 59 Morpholine/ Aldrich 469 2.36 555

Intermediate 59 Pyrrolidine/Aldrich 453 2.49 556

Intermediate 60 Dimethylamine/ Aldrich 410 2.03 557

Intermediate 60 tetrahydro-2H- pyran-4-amine/ Aldrich 466 2.01 558

Intermediate 60 cyclopropyl(methyl) amine/Karl Industries 436 2.20 559

Intermediate 60 Morpholine/ Aldrich 452 2.03 560

Intermediate 60 Pyrrolidine/Aldrich 436 2.13

Example 485 6-{[3-(Dimethylamino)-3-oxopropyl]sulfonyl}-4-[(3-fluorophenyl)amino]-8-methyl-3-quinolinecarboxamide hydrochloride

To a solution of the Example 551 (0.038 g) in N,N-dimethylformamide (2 ml) was added oxone (0.22 g). The mixture was stirred at room temperature for 2 h before quenching with aqueous sodium sulphite solution and extracting with dichloromethane. The organic layers were combined, dried by filtration through a hydrophobic frit and concentrated in vacuo. Purification by mass directed preparative HPLC (Method C) gave the title compound as a yellow solid (0.015 g).

LC/MS R_(t) 2.31 min m/z 459 [MH⁺].

Similarly prepared were the following:

Example Isolation LCMS Number Starting Method LCMS R_(t) (a) R³SO₂— Material R²⁸— R¹NH— (b) MH⁺ (min) 486 HCl

Example 552 Me—

(II) 515 2.39 487 HCl

Example 553 Me—

(II) 485 2.62 488 HCl

Example 554 Me—

(II) 501 2.38 489 HCl

Example 555 Me—

(II) 485 2.49 490 HCl

Example 556 Me—

(II) 442 1.98 491 HCl

Example 557 Me—

(II) 498 1.95 492 HCl

Example 558 Me—

(II) 468 2.1 493 HCl

Example 559 Me—

(II) 484 1.96 494 HCl

Example 560 Me—

(II) 468 2.04 525 HCOOH

Example 563 Me—

(I) 413 2.00 526

Example 564 Me—

(I) 430 2.50 527

Example 681 Me—

(III) 459 2.30 529

Example 565 Me—

(IV) 444 2.5 530 HCl

Example 566 Me—

(II) 427 2.00 532

Example 570 Me—

(V) 445 2.20 533 HCl

Example 571 Me—

(II) 442 2.3 534 HCOOH

Example 572 Me—

(I) 428 1.8 535 HCOOH

Example 573 Me—

(I) 467 2.6 538 HCl

Example 574 Me—

(II) 520 2.83 568

Example 569 Me—

(VI) 526 2.60 578 HCl

Example 635 Me—

(II) 385 2.13 579 HCl

Example 636 Me—

(II) 385 2.08 580 HCl

Example 637 Me—

(II) 399 2.22 581 HCl

Example 634 Me—

(II) 371 1.95 582 HCl

Example 638 Cl—

(II) 391 2.07 583 HCl

Example 662 Me—

(II) 388 2.33 584 HCl

Example 664 Me—

(II) 402 2.4 585 HCl

Example 665 Me—

(II) 416 2.54 666 HCl

Example 646 Cl—

(II) 425 2.52 667 HCl

Example 647 Cl—

(II) 439 2.73 668 HCl

Example 648 Cl—

(II) 439 2.56 669 HCl

Example 649 Cl—

(II) 453 2.66 670 HCl

Example 644 Me—

(II) 419 2.47 671 HCl

Example 650 Me—

(II) 389 2.28 672 HCl

Example 651 Me—

(II) 403 2.49 673 HCl

Example 652 Me—

(II) 403 2.35 674 HCl

Example 653 Me—

(II) 417 2.47 675 HCl

Example 655 Cl—

(II) 423 2.49 676 HCl

Example 656 Cl—

(II) 423 2.43 677 HCl

Example 657 Cl—

(II) 437 2.54 678 HCl

Example 642 Me—

(II) 405 2.38 679 HCl

Example 643 Me—

(II) 419 2.53 680 HCl

Example 645 Me—

(II) 433 2.67 (a) Salt form HCl = hydrochloride HCOOH = formate (b) Isolation Method: (I) Mass Directed Preparative HPLC (Method A) (II) Mass Directed Preparative HPLC (Method C) (III) Aqueous work-up (IV) SCX ion exchange eluting with 2M ammonia in methanol (V) Trituration with methanol and collection of the product by filtration (VI) Chromatography on silica gel eluting with methanol/ethyl acetate mixtures

Example 495 4-{[4-Fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-{[2-(2-oxo-1-pyrrolidinyl)ethyl]sulfonyl}-3-quinolinecarboxamide hydrochloride

To a solution of Example 477 (0.03 g) in 1,4-dioxan (5 ml) was added ethyl 4-bromobutyrate (0.01 ml, available from Aldrich). The mixture was heated at 120° C. for 48h. The solvent was evaporated in vacuo. Purification by mass directed preparative HPLC (Method C) gave the title compound as a yellow solid (0.007 g).

LC/MS R_(t) 2.3 min m/z 501 [MH⁺].

Similarly prepared were the following:

Example LCMS Number Starting LCMS R_(t) (a) R¹NH— Material MH⁺ (min) 514 HCl

Example 561 471 2.29 (a) Salt form HCl = hydrochloride

Example 518 6-{[2-(Dimethylamino)ethyl]sulfonyl}-4-{[4-fluoro-3-(methyloxy)phenyl]amino}8-methyl-3-quinolinecarboxamide formate salt

To a stirred mixture of Example 477 (0.05 g) in dry N,N-dimethylformamide (1 ml) was added methyl iodide (0.033 g) and triethylamine (0.032 ml), and the mixture was stirred under nitrogen for 18 h. The mixture was applied directly to an SPE cartridge (1 g) and eluted with 4% methanol in chloroform; the eluent was evaporated in vacuo and the residue purified using mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.003 g).

LC/MS R_(t) 2.01 min, m/z 461 [MH⁺]

Example 519 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-6-{[2-(dimethylamino)ethyl]sulfonyl}-8-methyl-3-quinolinecarboxamide formate salt

Example 519 was prepared by a similar method to Example 518 from Example 422 to give the title compound as a yellow solid (0.005 g)

LC/MS R_(t) 1.94 min, m/z 455 [MH⁺]

Example 521 4-{[4-Fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-{[2-(methyloxy)ethyl]thio}-3-quinolinecarboxamide.

To a solution of Example 337 (0.05 g) in dry N,N-dimethylformamide (2 ml) under nitrogen was added sodium hydride (60% dispersion in mineral oil, 0.015 g). The mixture was stirred at room temperature for 10 min when methyl iodide (0.0078 ml) was added; the mixture was stirred at room temperature for 18 h and the solvent evaporated in vacuo. The residue was partitioned between chloroform and water, the layers separated by hydrophobic frit, and the organic layer evaporated. The crude product was purified using mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.025 g).

LC/MS R_(t) 2.46 min, m/z 416 [MH⁺]

Similarly prepared from Example 528 was the following:

Example 571 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-{[2-(methyloxy)ethyl]thio}-3-quinolinecarboxamide

LC/MS R_(t) 2.40 min, m/z 410 [MH⁺]

Example 523 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-6-[(2-hydroxyethyl)sulfonyl]-8-methyl-3-quinolinecarboxamide

To a solution of Example 528 (0.05 g) in N,N-dimethylformamide (2 ml) was added oxone (0.311 g). The mixture was stirred at room temperature for 3 h before quenching with aqueous sodium sulphite solution and extracting with ethyl acetate (50 ml). The organic layer was dried (Na₂SO₄) and concentrated in vacuo, and the mixture purified by mass directed preparative HPLC (Method A) to give the title compound as a white solid (0.035 g).

LC/MS R_(t) 2.1 min m/z 428 [MH⁺].

Example 524 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-{[2-(methyloxy)ethyl]sulfonyl}-3-quinolinecarboxamide

To a solution of Example 523 (0.018 g) in dry N,N-dimethylformamide (1 ml) under nitrogen was added sodium hydride (60% dispersion in mineral oil, 0.0017 g). The mixture was stirred at room temperature for 10 min when methyl iodide (0.0026 ml) was added, stirring was continued for 18 h at room temperature and the solvent evaporated in vacuo. The residue was partitioned between ethyl acetate and water and the organic layer dried (MgSO₄) and evaporated. The crude product was purified using mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.0024 g).

LC/MS R_(t) 2.3 min, m/z 442 [MH⁺]

Example 536 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfinyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

To a mixture containing Example 544 (0.10 g) in N,N-dimethylformamide (10 ml) was added oxone (0.253 g). The mixture was stirred under nitrogen for 3 h at room temperature and was then quenched with a solution of sodium sulphite (0.25 g) in water (10 ml), diluted with water (30 ml) and extracted with ethyl acetate (2×30 ml). The combined organic extracts were evaporated to dryness and the residue purified by mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.028 g).

LC/MS R_(t) 2.24 min, m/z 503 [MH⁺]

Example 537 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-4-[(3-hydroxyphenyl)amino]-8-methyl-3-quinolinecarboxamide

A solution of borontribromide in dichloromethane (1.0 M, 2.2 ml) was added dropwise to an ice-cooled mixture containing Example 478 (0.35 g) in dichloromethane (25 ml) under nitrogen. The mixture was stirred at room temperature for 20 h, and was then treated with a further portion of borontribromide in dichloromethane (1.0 M, 2.2 ml) and stirred for a further 5 h. The mixture was quenched with methanol (10 ml) and evaporated to dryness in vacuo. The residue was partitioned between ethyl acetate (30 ml) and saturated aqueous sodium bicarbonate (30 ml), the organic extract evaporated to dryness in vacuo, and the residue purified by mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.075 g).

LC/MS R_(t) 2.46 min, m/z 505 [MH⁺]

Example 575 7-({3-[(Dimethylamino)carbonyl]phenyl}sulfinyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

A mixture containing Intermediate 65 (0.15 g), 10% palladium on activated carbon (0.04 g) and triethylamine (5 ml) in ethanol (25 ml) and N,N-dimethylformamide (10 ml) was hydrogenated at room temperature for 4 h. The suspension was filtered through celite, the residue washed with ethanol/N,N-dimethylformamide (3:1, 50 ml), and the filtrate concentrated in vacuo. The residue was purified by mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.035 g).

LC/MS R_(t) 2.32 min, m/z 489 [MH⁺]

Example 545 7-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

Oxone (0.22 g) was added portionwise to a stirred solution of Example 575 (0.035 g) in N,N-dimethylformamide (4 ml). The mixture was stirred at room temperature under nitrogen for 24 h, a further portion of oxone (0.17 g) was added, and the mixture stirred for a further 5 h. The reaction was quenched with a solution of sodium sulphite (1.2 g) in water (15 ml), diluted with water (10 ml) and extracted with ethyl acetate (3×30 ml). The combined organic extracts were dried over magnesium sulphate and concentrated in vacuo to give the title compound as a buff solid (0.035 g).

LC/MS R_(t) 2.66 min, m/z 505 [MH⁺]

Example 576 6-({5-[(Dimethylamino)carbonyl]-3-pyridinyl}thio)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, formate salt

A stirred mixture of Intermediate 45 (0.47 g), Intermediate 69 (0.37 g), copper iodide (0.06 g), and potassium carbonate (0.47 g) in 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (10 m) was heated at 100° C. under nitrogen for 4 h. The mixture was diluted with water (150 ml) and extracted with ethyl acetate (3×200 ml). The combined organic extracts were washed with water (2×200 ml) and brine (200 ml), and the organic layers dried over magnesium sulphate and concentrated in vacuo. The residue was purified by mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.1 g).

LC/MS R_(t) 2.35 min, m/z 488 [MH⁺]

Example 547 6-({5-[(Dimethylamino)carbonyl]-3-pyridinyl}sulfinyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride and Example 546 6-({5-[(Dimethylamino)carbonyl]-3-pyridinyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride

Oxone (1.2 g) was added portionwise to a stirred solution of Example 576 (0.1 g) in N,N-dimethylformamide (6 ml). The solution was stirred at room temperature under nitrogen for 2 h and then quenched with a solution of sodium sulphite (3 g) in water (30 ml). The mixture was diluted with water (25 ml) and extracted with ethyl acetate (4×50 ml) and the combined organic layers were washed with water (2×50 ml) and brine (50 ml), dried over magnesium sulphate and concentrated in vacuo. The residue was purified using mass directed preparative HPLC (Method C) to give Example 546 as a yellow solid (0.010 g) and Example 547 as a yellow solid (0.041 g).

Example 546: LC/MS R_(t) 2.57 min, m/z 520 [MH⁺]

Example 547: LC/MS R_(t) 2.12 min, m/z 504 [MH⁺]

Example 586 8-Methyl-4-[(3-methyl-5-isoxazolyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide hydrochloride

To a stirred suspension of sodium hydride (0.008 g; 60% dispersion in mineral oil) in dry N,N-dimethylformamide (1 ml) was added [(3-methyl-5-isoxazolyl)methyl]amine (available from Aldrich) (0.020 g) and the mixture heated at 80° C. for 30 min. A suspension of Intermediate 33 (0.020 g) in dry N,N-dimethylformamide (0.5 ml) was added and the mixture heated at 80° C. for 3 h. The mixture was quenched by the dropwise addition of ethanol (0.1 ml). The mixture was loaded onto a 2 g SCX cartridge, washed with methanol, and the product eluted with 10% ‘880’ ammonia in methanol. The solvent was removed in vacuo and the residue purified by mass directed preparative HPLC (Method C) to give the title compound as a pale yellow solid (0.009 g)

LC/MS R_(t) 2.23 min, m/z 361 [MH⁺]

Example 544 6-({3-[(Dimethylamino)carbonyl]phenyl}thio)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide

A stirred mixture of Intermediate 45 (50 g), Intermediate 28 (40 g), and potassium carbonate (40 g) in 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (500 ml) was purged of air (by evacuation of the vessel and refilling with nitrogen three times) and left under nitrogen. Copper (I) iodide (5 g) was added and the mixture was warmed at 90° C. for 23 h. The mixture was cooled to 20° C. and poured into water (2.5 L). The precipitated solid was filtered off, washed with water and sucked partially dry. The damp solid was dissolved in chloroform (4 L) and washed with IN sodium hydroxide solution (1 L), followed by water (2×1 L) and brine (1 L). The organic phase was dried over sodium sulphate and the solvent evaporated to leave a sticky solid. The solid was crystallised from hot ethanol (650 ml) to give the title compound as a solid (45.1 g).

LC/MS R_(t) 2.60 min m/z 487 [MH⁺].

Similarly prepared were the following:

Example Isolation LCMS Number Starting Method LCMS R_(t) (a) R¹NH— R³S— Material (b) MH⁺ (min) 562

Intermediate 45 (I) 417 2.27 573 HCl

Intermediate 35 (II) 435 2.56 574

Intermediate 36 (III) 487 2.86 (a) Salt form: HCl = hydrochoride (b) Isolation method: (I) Aqueous work-up followed by trituration with ether and filtration. (II) Mass directed preparative HPLC (Method C). (III) Trituration with ether and filtration.

Example 544 6-({3-[(Dimethylamino)carbonyl]phenyl}thio)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide (alternative synthesis)

Intermediate 45 (5.0 g), Intermediate 28 (2.89 g), copper iodide (0.506 g) and potassium carbonate (2.94 g) were added to 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU, 25 ml) and the resulting stirred slurry was heated to 100° C. under nitrogen. The mixture was stirred at 100° C. for 7 h, allowed to cooled to room temperature and stirred overnight. DMPU (20 ml) and water (80 ml) containing pyridine (0.43 ml) were added and the slurry was heated to 100° C. The resulting solution was seeded with crystals of Example 544 and stirred for 1 h at 100° C. The suspension was cooled gradually over 6 h, allowing the product to crystallise. The product was isolated by filtration, washed with water (2×50 ml) and dried at 40° C. in vacuo to give the title compound as a pale yellow solid (3.9 g).

LC/MS R_(t) 2.58 min m/z 487 [MH⁺].

Example 478 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide (alternative synthesis)

To a solution of Example 544 (29 g) in N,N-dimethylformamide (290 ml) cooled in a water bath was added oxone (87 g) in portions over 10 min. The mixture was stirred for 2 h, then poured into a cold (5° C.) solution of sodium metabisulphite (45 g) in water (2 L). After stirring for 35 min the mixture was extracted with chloroform (2 L+3×800 ml). The combined chloroform extracts were washed with water (3×600 ml), and the aqueous washes were extracted with chloroform (600 ml). The combined organic phases were dried over sodium sulphate and the solvent evaporated to leave a solid which was dried in vacuo at 40° C. for 3 days providing the title compound (27.8 g).

LC/MS R_(t) 2.62 min m/z 519 [MH⁺].

The solid was crystallised from hot ethanol containing 20% water (5 L) to give the title compound (20.2 g).

LC/MS R_(t) 2.62 min m/z 519 [MH⁺].

Example 478 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide (alternative procedure)

To a solution of Example 544 (3.5 g) in glacial acetic acid (18 ml) and water (3.5 ml ) was added oxone (5.76 g) portionwise over 15 min. The mixture was stirred for 1.5 h at 20° C. and excess oxone quenched with a solution of sodium sulphite (0.545 g) in water (3.5 ml). The mixture was diluted with glacial acetic acid (11 ml) and water (21 ml), heated to 90°, treated dropwise over 30 min with 2M aqueous sodium hydroxide (20 ml), and cooled to 25° C. over 30 min. The resulting precipitate was collected by filtration, washed with water (25 ml×3) and dried in vacuo to give the title compound as a pale yellow solid (3.0 g).

LC/MS R_(t) 2.54 min m/z 519 [MH⁺].

Example 588 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfinyl)-3-quinolinecarboxamide formate salt

To a suspension of Example 577 (0.04 g) in methanol (10 ml) was added sodium periodate (0.023 g) in water (0.2 ml). The mixture was stirred at room temperature for 4 days and the solvents evaporated in vacuo. The residue was purified using mass directed preparative HPLC (Method A) to give the title compound as a yellow solid (0.017 g).

LC/MS R_(t) 2.0 min, m/z 382 [MH⁺]

Example 307 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide hydrochloride (alternative synthesis)

To a solution of Example 577 (0.04 g) in N,N-dimethylformamide (1 ml) was added oxone (0.337 g). The mixture was stirred at room temperature for 18 h, and quenched by addition of 10% sodium sulphite solution (15 ml). The mixture was extracted with ethyl acetate (50 ml), and the organic layer dried (Na₂SO₄) and evaporated in vacuo. The residue was purified using mass directed preparative HPLC (Method C) to give the title compound as a yellow solid (0.018 g).

LC/MS R_(t) 2.2 min, m/z 398 [MH⁺]

Example 688 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-7-(methylthio)-3-quinolinecarboxamide

A stirred mixture of Intermediate 104 (0.50 g), sodium methanethiolate (0.35 g), potassium carbonate (0.43 g) and copper (I) iodide (0.025 g) in dry N,N-dimethylformamide (3 ml) was heated at 100° under nitrogen for 18 h. The mixture was cooled, poured into water (50 ml) and stirred for 15 min. The solid material was filtered off, dried in vacuo at 80° for 2 h, and boiled in ethanol:water 15:1 (50 ml) for 30 min. The insoluble material was filtered off, and the filtrate evaporated to dryness to give the title compound as a pale yellow solid (0.163 g).

LC/MS R_(t) 2.40 min m/z 366 [MH⁺]

Example 548 4-(2,3-Dihydro-1-benzofuran-4-ylamino)-8-methyl-7-(methylsulfonyl)-3-quinolinecarboxamide hydrochloride

Example 548 was prepared from Example 688 by a similar method to Example 129, but without the addition of anisole to the reaction mixture, using 10:1 N,N-dimethylformamide: water as solvent, and purifying by mass directed preparative HPLC (method C).

LC/MS R_(t) 2.50 min m/z 398 [MH⁺] 

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein: R¹ is C₁₋₆ alkyl; C₃₋₇cycloalkyl or C₃₋₇cycloalkyl(C₁₋₄alkyl)- wherein the C₃₋₇cycloalkyl is optionally substituted by one or more substituents selected from ═O and OH; C₄₋₇cycloalkyl fused to an aryl ring; Aryl or aryl(C₁₋₆alkyl)- wherein the aryl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkylCONR⁶—, C₁₋₆alkylCO—, halogen, —CF₃, —(CH₂)_(m)OH, —OCF₃, C₁₋₆alkoxy-, C₁₋₆alkoxy(C₁₋₄alkyl)-, C₁₋₆alkoxyC₂₋₆alkoxy-, C₁₋₆alkoxycarbonyl, —CN, R⁴R⁵NCO, R⁷R⁸N—, R⁹R¹⁰NCONR¹¹—, HO(CH₂)₂₋₆O—, R¹²R¹³NSO₂(CH₂)_(m)—, (4-morpholinyl)C₂₋₆alkoxy, —NR¹⁴SO₂C₁₋₆alkyl, aryloxy, heteroaryl(optionally substituted by C₁₋₆alkyl), CO₂H, R²¹R²²N(C₁₋₄alkyl)-, C₁₋₆alkoxyCONR²³(CH₂)_(m)—, aryl(optionally substituted by C₁₋₆alkyl); Aryl fused to a C₄₋₇cycloalkyl ring, wherein the cycloalkyl ring is optionally substituted by one or more ═O; Aryl fused to a heterocyclyl ring, wherein the heterocyclyl ring is optionally substituted by one or more substituents selected from ═O, —COC₁₋₄alkyl, C₁₋₄alkyl; Heteroaryl or heteroaryl(C₁₋₆alkyl)- wherein the heteroaryl is optionally substituted by one or more substituents selected from: C₁₋₆alkyl, aryl(C₁₋₄alkyl), C₁₋₆alkoxy, halogen, C₁₋₆alkoxyCO; or Heterocyclyl optionally fused to an aryl or heteroaryl ring; R² is hydrogen or C₁₋₆alkyl; R³⁴ is hydrogen or a group of formula:

R³ is C₁₋₆alkyl optionally substituted by one or more substituents selected from —OH,—NR¹⁶COR¹⁵, —NR¹⁷R¹⁸, —CO₂R²⁴, C₁₋₆alkoxyCONR²⁵—, —CONR²⁶R²⁷, C₁₋₆alkoxy-, C₁₋₆alkylSO₂NR³³—, or a group having one of the following formulae:

C₁₋₇cycloalkyl; Aryl or aryl(C₁₋₆alkyl)- wherein the aryl is optionally substituted by one or more substituents selected from C₁₋₆alkyl-, halogen-, C₁₋₆alkoxy-, —CO₂R²⁸, —CH₂CO₂H, —OH, aryl(optionally substituted by a C₁₋₆alkoxy group), heteroaryl, —CONR²⁹R³⁰, C₃₋₇cycloalkoxy, C³⁻⁷cycloalkyl(C₁₋₆alkoxy)-, —CF₃; Heteroaryl or heteroaryl(C₁₋₆alkyl)- wherein the heteroaryl is optionally substituted by one or more C₁₋₆alkyl or —CONR²⁹R³⁰ groups; or Heterocyclyl linked to the S(═O)_(n) moiety through a carbon atom which is optionally substituted by one of more substituents selected from C₁₋₆alkyl-, C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO—, optionally substituted by one or more C₁₋₄alkyl-groups), C₁₋₆alkoxyCO—, arylCO—, R³¹R³²NCO—, C₁₋₆alkylSO₂—, arylSO₂, -heteroarylSO₂ (optionally substituted by one or more C₁₋₄alkyl or C₁₋₄alkylCONH— groups; m is 0-6; n is 0, 1 or2; R¹⁹ is hydrogen, C₁₋₆alkyl; R²⁰ is hydrogen, C₁₋₆alkyl, halogen or C₁₋₆alkoxy; R⁴⁻¹⁸, R²¹⁻²⁵, R²⁸ and R³¹⁻³³ all independently represent H, C₁₋₆ alkyl; R²⁶ and R²⁷ independently represent H, C₁₋₆ alkyl, C₃₋₇cycloalkyl or heterocyclyl; R²⁹ and R³⁰ independently represent H, C₁₋₆alkyl optionally substituted by OH; R⁷ and R⁸ together with the nitrogen atom to which they are attached may form a heterocyclyl ring; R⁹ and R¹⁰ together with the nitrogen atom to which they are attached may form a heterocyclyl ring; R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached may form aheterocyclyl ring such as morpholine; R²¹ and R²² together with the nitrogen atom to which they are attached may form a heterocyclyl ring; R²⁶ and R²⁷ together with the nitrogen atom to which they are attached may form a heterocyclyl ring; R²⁹ and R³⁰ together with the nitrogen atom to which they are attached may form a heterocyclyl ring such as morpholine; R³¹ and R³² together with the nitrogen atom to which they are attached may form a heterocyclyl ring.
 2. A compound according to claim 1 wherein R¹ is selected from Aryl optionally substituted by one or more substituents selected from C₁₋₆alkyl, halogen, C₁₋₆alkoxy-, —CN, —(CH₂)_(m)(OH), and C₁₋₆alkylCO—; Aryl fused to a heterocyclyl ring,and Heteroaryl optionally substituted by one or more substituents selected from: C₁₋₆alkyl, halogen, and C₁₋₆alkoxy groups.
 3. A compound according to claim 1 wherein R¹ is selected from benzothiazolyl, benzimidazolyl, indazolyl, pyridyl and pyrazolyl.
 4. A compound according to claim 1 wherein R¹ is selectedfrom


5. A compound according to claim 1 wherein R¹ is selected from Aryl optionally substituted by one or more substituents selected from: methyl, fluorine, chlorine, —CN, —OMe, —OH, COMe; and Heteroaryl optionally substituted by one or more methyl, ethyl, flourine, chlorine or methoxy groups.
 6. A compound according to claim 1 wherein R¹ is selected from 3-(methyloxy)phenyl, 3-methylphenyl, 3-cyanophenyl, 3-fluorophenyl, 3-chlorophenyl, 4-fluoro-3-(methyloxy)phenyl, 3-acetylphenyl, 4-hydroxy-3-(methyloxy)phenyl, 2-fluoro-3-chlorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 1-methyl-1H-benzimidazolyl-6-yl, 1-methyl-1H-indazol-6-yl, 5-(methyloxy)-3-pyridinyl, 3-pyridinyl, 1-ethyl-1H-pyrazol-5-yl, 5-methyl-3-pyridinyl, 1,3-benzothiazol-6-yl, 5-fluoro-3-pyridinyl, and 5-chloro-3-pyridinyl.
 7. A compound according to claim 1 wherein R² is hydrogen.
 8. A compound according to claim 1 wherein R³ is selected from: C₁₋₆ alkyl which is optionally substituted by one or more substituents selected from —NR¹⁶COR¹⁵ and —CONR²⁶R²⁷; C₃₋₇cycloalkyl; Aryl optionally substituted by one or more substituents selected from C₁₋₆alkyl-, C₁₋₆alkoxy-, and CONR²⁹R³⁰;and Heterocyclyl which is optionally substituted by one or more substituents selected from C₁₋₆alkylCO—, C₃₋₇cycloalkylCO—, heteroarylCO—.
 9. A compound according to claim 1 wherein R³ is selected from methyl, ethyl, n-propyl, tert-butyl, isopropyl, MeCONH(CH₂)₂—, Me₂NCO(CH₂)₂—; Cyclopentyl; Aryl optionally substituted by one or more methoxy, methyl, —CONMe₂ groups; and Heterocyclyl which is optionally substituted by one of more substituents selected from MeCO—, cyclopropylCO, 2-furylCO—.
 10. A compound according to claim 8 wherein R³ is selected from 4-(methyloxy)phenyl, phenyl, 3-[(dimethylamino)carbonyl]phenyl, 4-methylphenyl, 3,4-bis(methyloxy)phenyl, 3,4,5-tris(methyloxy)phenyl, 3-(ethyloxy)phenyl.
 11. A compound according to claim 1 wherein R³ is a piperidinyl group substituted by one or more substituents selected from MeCO—, cyclopropylCO, and 2-furylCO—.
 12. A compound according to claim 1 wherein R³ is 1-acetyl-4-piperidinyl, 1-(2-furanylcarbonyl)-4-piperidinyl, or 1-(cyclopropylcarbonyl)-4-piperidinyl.
 13. A compound according to claim 1 wherein R²⁰ is hydrogen, methyl, ethyl, fluorine or chlorine.
 14. A compound according to claim 1 wherein n is
 2. 15. A compound selected from 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-{[3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-chlorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-(1,3-benzothiazol-6-ylamino)-6-(phenylsulfonyl-3-quinolinecarboxamide, 4-[(1-methyl-1H-benzimidazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-{[3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide, 6-(cyclopentylsulfonyl)-4-[(3-fluorophenyl)amino]-3-quinolinecarboxamide, 4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-{[2-(acetylamino)ethyl]sulfonyl}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)thio]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-{[2-(acetylamino)ethyl]thio}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 4-[(1-methyl-1H-indazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-{[4-hydroxy-3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-[(3-acetylphenyl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(phenylsulfonyl)-3-quinolinecarboxamide, 7-methyl-4-{[3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-[(3-acetylphenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-(2,3-dihydro-1,4-benzodioxin-5-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-[(3-chlorophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-(1,3-benzothiazol-6-ylamino)-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-[(3-fluorophenyl)amino]-8-methyl-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide, 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide, 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-[(4-methylphenyl)sulfonyl]-3-quinolinecarboxamide, 4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(phenylsulfonyl)-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-6-(methylsulfonyl)-4-(3-pyridinylamino)-3-quinolinecarboxamide 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-fluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-{[5-(methyloxy)-3-pyridinyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-[(5-methyl-3-pyridinyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(3-cyanophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(3-fluorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, methyl 3-[(3-(aminocarbonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-quinolinyl)sulfonyl]benzoate, 6-{[3,4-bis(methyloxy)phenyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[3,4,5-tris(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide hydrochloride, 6-{[3,4-bis(methyloxy)phenyl]sulfonyl}-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-{[3-(ethyloxy)phenyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-{[2-(acetylamino)ethyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide, 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-[(1-methyl-1H -benzimidazol-6-yl)amino]-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide, 6-[(1-acetyl-4-piperidinyl)sulfonyl]-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide, 6-{[1-(cyclopropylcarbonyl)-4piperidinyl]sulfonyl}-8-methyl-4-{[3-(methyloxy) phenyl]amino}3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide, 6-{[1-(cyclopropylcarbonyl)-4-piperidinyl]sulfonyl}-4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-3-quinolinecarboxamide, 6-[(1-acetyl-4-piperidinyl)sulfonyl]-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-({2-[(methylsulfonyl) amino]ethyl}sulfonyl)-3-quinolinecarboxamide, 6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-4-[(1-methyl-1H -benzimidazol-6-yl)amino]-3-quinolinecarboxamide, 6-{[3-(dimethylamino)-3-oxopropyl]sulfonyl}-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-8-methyl-3-quinolinecarboxamide, 4-[(2,3-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-chloro-2-fluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3,5-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 6-({5-[(dimethylamino)carbonyl]-3-pyridinyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride, 8-methyl-6-[(1-methylethyl)sulfonyl]-4-(3-pyridinylamino)-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)sulfonyl]-8-methyl-4-(3-pyridinylamino)-3-quinolinecarboxamide, 4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)sulfonyl]-4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-3-quinolinecarboxamide, 4-(3,4-dihydro-2H-chromen-5-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfinyl)-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-3-quinolinecarboxamide, 8-ethyl-4-{[4-fluoro-3-(methyloxy)phenyl]amino}-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-ethyl-4-[(3-fluorophenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-8-ethyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-ethyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-ethyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-ethyl-6-(methylsulfonyl)-4-(3-pyridinylamino)-3-quinolinecarboxamide 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-fluoro-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-(ethylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-(propylsulfonyl)-3-quinolinecarboxamide, 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide, 8-chloro-4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide, 6-(ethylsulfonyl)-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide, 8-chloro-4-[(5-fluoro-3-pyridinyl)amino]-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide, 8-chloro-6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-6-(ethylsulfonyl)-8-methyl-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-8-methyl-6-(propylsulfonyl)-3-quinolinecarboxamide, 4-[(5-chloro-3-pyridinyl)amino]-6-[(1,1-dimethylethyl)sulfonyl]-8-methyl-3-quinolinecarboxamide,and or a pharmaceutically acceptable salt thereof.
 16. A compound according to claim 15 selected from 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-[(1-methyl-1H-indazol-6-yl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 8-methyl-4-[(5-methyl-3-pyridinyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(3,5-difluorophenyl)amino]-8-methyl-6-(methylsulfonyl)-3-quinolinecarboxamide, 4-[(1-ethyl-1H-pyrazol-5-yl)amino]-8-methyl-6-[(1-methylethyl)sulfonyl]-3-quinolinecarboxamide, 6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-8-methyl-3-quinolinecarboxamide, 8-chloro-6-[(1,1-dimethylethyl)sulfonyl]-4-[(5-fluoro-3-pyridinyl)amino]-3-quinolinecarboxamide,and pharmaceutically acceptable salts therof.
 17. A compound according to claim 15 selected from 8-methyl-4-{[3-(methyloxy)phenyl]amino}-6-{[4-(methyloxy)phenyl]sulfonyl}-3-quinolinecarboxamide, 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride, 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide, 4-[(3-cyanophenyl)amino]-6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-6-{[1-(2-furanylcarbonyl)-4-piperidinyl]sulfonyl}-8-methyl-3-quinolinecarboxamide, 4-(2,3-dihydro-1-benzofuran-4-ylamino)-8-methyl-6-({2-[(methylsulfonyl)amino]ethyl}sulfonyl)-3-quinolinecarboxamide, 6-({5-[(dimethylamino)carbonyl]-3-pyridinyl}sulfonyl)-8-methyl-4-{[3-(methyloxy)phenyl]amino}-3-quinolinecarboxamide hydrochloride, and a pharmaceutically acceptable salt thereof.
 18. A pharmaceutical formulation comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
 19. A combination comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt and one or more other therapeutic ingredients.
 20. A process for preparing a compound of formula (I) as claimed in claim 1 which process comprises: (i) treating a compound of formula II:

wherein R^(34,) R^(19,) and R²⁰ are as defined in claim 1, and X represents a halogen atom, with an amine of formula R¹R²NH, wherein R¹ and R² are as defined in claim 1, to make a compound of formula (I).
 21. The process of claim 20, further comprising the step of deprotecting the compound of formula (I) to form another compound of formula (I).
 22. The process of claim 20, further comprising the step of converting the compound of formula (I) into a further compound of formula (I).
 23. The process of claim 20, further comprising the step of converting the compound of formula (I) into a salt thereof. 